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In Multiple Sclerosis (MS), the insulating membrane that ensheaths axons 
termed myelin, is lost by a process known as demyelination. Initial regeneration of 
myelin, termed remyelination, restores neuronal function. However, remyelination 
failure with disease leads to a loss of cognitive, sensory and motor functions. There 
are no currently approved therapies aimed at inducing remyelination, highlighting 
the need to investigate new targets that can promote this process. Astrocytes are the 
most abundant glial cell type in the central nervous system (CNS). They are known to 
support myelin formation in development and its maintenance during adulthood, yet 
their roles during remyelination are controversial and remain poorly understood.  
The work from this thesis explores the changes in astrocytes at the cellular 
and molecular level during remyelination. Using two different in vivo models of toxin-
induced demyelination, I have found that astrocytes during remyelination undergo a 
series of changes in numbers, reactivity (assessed by GFAP, vimentin, nestin and 
NFIA), and morphology, which indicate a temporal regulation of reactivity. 
Interestingly, I observed that astrocytes increase in reactivity at the time at which the 
myelin-forming cells, termed oligodendrocytes, differentiate to remyelinate axons. 
These findings suggest that astrocytes are important for regulating remyelination. To 
explore this, unbiased RNA-sequencing of astrocyte translating mRNA, isolated using 
translational ribosome affinity purification (TRAP), was used to identify changes in 
their gene expression.  I found that astrocytes upregulate genes indicative of 
neuroprotective functions early after demyelination, characterised by the 
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upregulation of the Nrf2 pathway. Subsequently, at the time of oligodendrocyte 
differentiation, astrocytes downregulate Nrf2 signalling and activate cholesterol 
biosynthesis, which is essential during myelination. Here, I hypothesised whether 
Nrf2 is an critical regulator of astrocyte functions that are important for 
remyelination. Hence, I used a transgenic mouse model in which Nrf2 is 
overexpressed in reactive astrocytes. The results suggested that upon sustained Nrf2 
overexpression, cholesterol biosynthesis in astrocytes is impaired and consequently 
remyelination is poor. 
 This study identifies a mechanism by which astrocytes regulate their 
functions after demyelination to control the timing of remyelination. These findings 












Myelin is the insulation surrounding nerves that ensures their health and 
function and is needed for intellect, sensation, and movement. After damage of 
myelin, regeneration of myelin can take place to restore nerve function. Nonetheless, 
this process is impaired in some neurodegenerative diseases like Multiple Sclerosis. 
There are no approved therapies than can encourage the regeneration of myelin to 
stop the progression of these diseases, highlighting the need to find new ways in 
which myelin regeneration can be supported. 
 Astrocytes are the most abundant type of cell in the brain. Although during 
development, they are known to support the formation of myelin, their roles after 
damage are poorly understood. This PhD project has focused on investigating the 
functions of astrocytes in promoting the regeneration of myelin. To do so, I have used 
mouse models in which efficient regeneration of myelin takes place after inducing 
damage with a toxin. Using these models, I found that astrocytes undergo dynamic 
changes in numbers and activation and that these precede the onset of myelin 
regeneration. These findings suggested that astrocytes may be necessary for 
initiating and controlling this process. To understand this, I used an approach named 
RNA-sequencing, that enables reading a type of genetic material (RNA) which is 
converted to protein, the central molecules within a cell that regulate specific 
functions. By using this methodology, I discovered that early after myelin damage, 
astrocytes adopted roles suggestive of protection, characterised by an increase in as 
activation of a pathway called Nrf2. Before the onset of myelin regeneration, 
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astrocytes decreased the levels of activity of the Nrf2 pathway and increased the 
production of fats. Myelin is a fatty structure, and astrocytes are the main producers 
of fats in the adult brain. I then asked whether Nrf2 activity could be important in 
controlling the functions of astrocytes during myelin regeneration. To do so, I used a 
mouse model where astrocytes constant high activity of Nrf2 and explored the 
effects on myelin regeneration. I observed that in this model, astrocytes decreased 
the production of fats, and consequently, myelin regeneration was poor. These 
findings could help us understand how myelin fails in Multiple Sclerosis since this 
involves high levels of Nrf2 activity in brain lesions that regenerate poorly. This study 
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1. CHAPTER: INTRODUCTION 
1.1. Myelin and Remyelination 
1.1.1. Myelination 
Myelin is a high-lipid content membrane specialisation of oligodendrocytes in 
the central nervous system (CNS) and of Schwann cells in the peripheral nervous 
system (PNS) that wraps axons. In contrast to Schwann cells, oligodendrocytes can 
form several myelin sheaths along axons [1, 2]. Myelin forms regular segments along 
the axons, called internodes, separated by myelin-free regions termed nodes of 
Ranvier. At the nodes of Ranvier, clusters of voltage-dependent sodium (Na+) 
channels on the axonal membrane enables efficient and fast propagation of action 
potentials along myelinated fibres [3, 4]. This efficient saltatory conduction enables 
sensory, motor and higher-order cognitive functions. More recently, it has been 
demonstrated that myelin is crucial for providing trophic and metabolic support to 
axons through the transport of metabolites such as lactate, which is transformed into 
adenosine triphosphate (ATP) via the Krebs cycle [5, 6]. 
Developmental myelination is controlled spatially and temporally by extrinsic 
and intrinsic signals [7]. In the CNS, neural stem cells and radial glial cells give rise to 
oligodendrocytes precursor cells (OPCs), which differentiate into pre-myelinating 
oligodendrocytes and finally into myelinating mature oligodendrocytes. 
Oligodendrocyte development is regulated by complex transcriptional programming. 
In the brain, OPCs, characterised by expression of the chondroitin sulfate 
proteoglycan (NG2) [8], arise from neuroepithelium of ventricular zones [9]. Neural 
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stem cell progenitors mature into OPCs by the upregulation of several transcription 
factors including oligodendrocyte transcription factor (Olig)1/2, homeodomain 
factor (Nkx)2.2/6, achaete-scute complex homolog (Mash)1, myelin transcription 
factor (MyT)1 and Sry-type HMG box (Sox)8/9/10 [9, 10]. Then, pre-myelinating 
oligodendrocytes downregulate Olig1, sonic hedgehog (Shh), Mash1, MyT1 and 
Sox8/9 [9-11]. Terminal oligodendrocyte differentiation is regulated by the 
expression of myelin regulatory factor (Myrf), osterix (Sp)7 and Chromodomain 
Helicase DNA Binding Protein (Chd)7 [11]. Mature oligodendrocytes then upregulate 
genes to form myelin sheaths, including myelin-associated glycoprotein (MAG), 
myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and 
proteolipid protein (PLP)[9, 12]. 
Oligodendrocyte specification starts during late gestation in rodents [7], and 
developmental myelination initiates after birth and is complete around the third 
postnatal week [13]. In humans and primates, this process is delayed, with robust 
myelination occurring in the first year after birth. Myelination is not completed until 
sexual maturation in non-human primates and the third decade in humans [14]. It 
has also been demonstrated that myelin changes take place during adulthood due to 
learning [15]. 
Oligodendrocytes are highly dynamic cells that have the fascinating capacity 
to extend their membrane around 6,500-fold of their surface area in order to 
myelinate [5, 8]. Interestingly, in some areas, one oligodendrocyte can myelinate up 
to 80 axons [7]. Myelination is a highly metabolically demanding process that 
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Demyelination is the process by which damage of myelin takes place. 
Different types of insult inducing demyelination include inflammation, viral infection, 
acquired metabolic defects, and hypoxic-ischemia [16]. Demyelination results in 
nude axons that can atrophy and degenerate due to the lack of metabolic support 
and protection from insult and inflammation.   
Remyelination is the regenerative process, whereby oligodendrocytes form 
new myelin sheaths after demyelination, restoring neuronal function [17-19]. During 
remyelination, OPCs migrate into demyelinated lesions, proliferate, and then 
differentiate into oligodendrocytes to form new myelin sheaths [20] (Figure 1.1). 
Recent findings suggest that remyelination may also be mediated by surviving 
mature oligodendrocytes already present in the lesion that re-ensheath axons [21, 
22].  However, these last findings are still under debate, and the presence of mature 
oligodendrocytes could reflect areas that have not been fully demyelinated [22]. 
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Figure 1.1. Main phases of remyelination. Following a demyelinating insult, OPCs migrate to 
the demyelinated lesion and proliferate, then differentiate into myelin-producing cells, and 
remyelinate. OPCs: Oligodendrocyte precursor cells. 
 
Although remyelination and developmental myelination share common 
processes [23], yet they are not identical. Myelin internodes formed during 
remyelination are thinner and shorter to the ones formed during myelination [17]. 
This difference may reflect a change in the environment, such as the immune 
response, or intrinsic changes within the oligodendrocyte lineage with ageing or 
following damage [17]. The importance of myelin and remyelination is exemplified 







1.1.3. Multiple Sclerosis 
Multiple Sclerosis (MS) is the most common inflammatory neurodegenerative 
disease affecting young adults. There are three different clinical presentations of MS. 
Relapse remitting MS (RRMS) has the highest prevalence, characterised by transient 
episodes in which new demyelinating plaques are formed reflected by disability, 
followed by recovery phases [24]. Over half of the patients presenting with RRMS will 
develop secondary progressive MS (SPMS), characterised by continuous 
neurodegeneration and worsening of the clinical symptoms [25, 26]. Lastly, in 
primary progressive MS (PPMS), patients present slow and continuous neurological 
degeneration from diagnosis, without recovery phases [25]. Furthermore, MS is a 
heterogeneous disease in which different lesion types exist within patients; including 
active (characterised by a loss of myelin, active remyelination, immune cell 
infiltration), chronic active (presence of ongoing damage and remyelination in the 
rim of the lesion, and phagocytes containing myelin debris), chronic inactive (no 
remyelination, axonal degeneration and glial scar), and fully remyelinated lesions 
[27, 28].  
There are 2.2 million people (30.1 cases per 100,000 population) with MS 
worldwide, with an increase of 10.4% cases since 1990. The highest prevalence is 
found in North America (164.6 cases per 100,000 population) followed by Western 
Europe (127 cases per 100,000 population) and the lowest in Sub-Saharan Africa (2.8 
cases per 100,000 population) and Oceania (2 cases per 100,000 population) [29]. 
The Scottish population has one of the highest rates of MS, with 8.76 in 100,000 new 
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cases per year [30]. Observational studies associate high prevalence with latitude, 
increasing the prevalence of MS by 1.03 times per degree of latitude [29].  
There are more women than men with MS, with a general ratio of 2:1 (2.3:1 
in favour of women in Scotland) [29, 30]. Hormones may be a factor that increases 
the risk of MS. Sex steroids have been suggested as modulator of the inflammatory 
response. Reproductive hormones increased during pregnancy, like oestrogen, 
progesterone, glucocorticoids and prolactin can increase the number of T-regulatory 
cells (T-reg), which are supportive for remyelination [31], and decrease MS pathology 
[32, 33]. In vitro, hormones have an effect on oligodendrocyte responses, where 
oestrogen promotes oligodendrocyte proliferation, whereas oestrogen or 
progesterone mediates differentiation [34]. Nonetheless, the effects of hormone 
therapy in humans is controversial, where often confounding factors lead to weak 
evidence of effect [35-37]. 
Genetic factors have also been suggested to contribute to MS. The genetic 
risk to develop MS increases from 1 in 1,000 in the normal population to 1 in 4 in 
identical twins [38]. The major histocompatibility class (MHC) II human leukocyte 
antigen (HLA) haplotype DRB1*15:01 gene is the highest genetic risk factor for MS 
[38]. HLA DRB1 encodes for a peptide expressed in antigen-presenting cells (APC), 
mainly monocytes. It is responsible for regulating activation of cluster of 
differentiation (CD)4+ T cells, associated with the immunopathogenesis of MS [39]. 
Nonetheless, genomic studies have identified over 50 non-HLA genetic factors that 
influence the risk to develop MS [40]. 
22 
 
Migrant studies have reinforced the importance of an environmental 
component as a factor for the causation of MS [41]. Three main environmental 
factors have been described, including vitamin D deficiency, Epstein Barr virus 
infection and cigarette smoking. These all have been shown to have 
immunomodulatory effects, causing demyelination [42, 43]. 
 
1.1.3.1. Theories for remyelination failure in MS 
De novo (new lesions) and repeated lesions can form in RRMS and progressive 
MS (PMS) patients, the latter more common in progressive forms of MS [44]. Both 
types of lesions can remyelinate, but this is rarely completed as assessed by imaging 
analysis [45-47]. Nonetheless, in progressive MS, remyelination often fails, which is 
considered to contribute to irreversible axonal dysfunction and loss, which in turn 
leads to severe disability [16, 47].  
OPC deficiency has been proposed as one mechanism that could explain 
remyelination failure. OPCs are the most proliferative cells in the adult brain in 
mammals [8]. These cells are essential for the turnover and maintenance of myelin 
in the CNS [8, 48, 49]. After demyelination, other glial cells like astrocytes and 
microglia release factors, e.g. fibroblast growth factor 2 (FGF-2) or transglutaminase-
2 (TG2), that stimulate OPC proliferation [50-52]. Evidence points to OPC 
proliferation as being required for CNS remyelination [53]. Non-dividing OPCs can be 
present in demyelinated areas [54], where a lack of growth factors may not allow 
23 
 
them to survive or differentiate to finally remyelinate [55]. A second hypothesis for 
remyelination failure is impairment in OPC migration to reach the demyelinating 
plaques. For example, OPC migration is inhibited during development by Sema3A, a 
secreted factor of the semaphorin family, which acts on the receptor neuropilin-1 
[56], and chronic active MS lesions contain higher levels of Sema3A compared to 
active lesions [57].  
Another possible explanation for remyelination impairment is the failure of 
oligodendrocyte differentiation. Over 70% of MS chronic lesions have pre-
myelinating oligodendrocytes indicating a block in remyelination [58]. Some factors 
have been identified, which can prevent oligodendrocytes from reaching a complete, 
mature state. The leucine-rich repeat and immunoglobulin-like domain-containing 
Nogo receptor-interaction protein 1 (LINGO-1), expressed by both oligodendrocytes 
and axons, is a potent inhibitor of oligodendrocyte differentiation [59, 60]. Blocking 
LINGO-1 leads to increased oligodendrocyte differentiation during developmental 
myelination [60] and enhanced remyelination, axon regeneration and functional 
recovery in a chronic demyelinating model, experimental autoimmune 
encephalomyelitis (EAE) [61-64]. Moreover, a tight and transient regulation of Wnt 
signalling controls OPC differentiation during myelination and remyelination [65]. 
Wnt dysregulation and sustained activation leads to hypomyelination in 
development and is associated with remyelination failure in MS[66]. Other identified 
inhibitors of oligodendrocyte differentiation in remyelination have consisted of 
hyaluronan accumulation [67], bone morphogenic protein (BMP) signalling [68] and 
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activation of notch receptors [69]. Recent studies have suggested that 
oligodendrocyte heterogeneity could be a reason for limited remyelination, where a 
switch to a population with less myelinating capacity and immune characteristics has 
been suggested to predominate in patients with MS [70, 71].  
Remyelination failure may also result from impaired functioning of 
supporting cells. For instance, the clearance of myelin debris by phagocytes, such as 
microglia/macrophage, is required for remyelination [72-74]. Continuous 
demyelination impairs microglial/macrophage functions [75], by exhausting their 
capacity to phagocytose, leading to accumulation of myelin debris and preventing 
oligodendrocyte differentiation [74, 76]. Models of ageing have shown that in this 
context, demyelination severity is not affected in age. However, microglia and 
macrophages accumulate myelin fragments and cholesterol crystals, which leads to 
senescence and immune dysfunction, affecting remyelination efficiency [74, 75]. 
Impaired remyelination in age can be due to intrinsic factors of cells of the 
oligodendrocyte lineage [77]. Aged oligodendrocyte progenitors present a delay in 
colonising demyelinated areas, and decreased expression of the transcription factor 
MyT1 (important for differentiation) leading to reduced remyelination capacity [78]. 
Epigenetic control of gene expression is altered with ageing, in which an 





1.1.3.2. Therapeutics for Multiple Sclerosis 
There are 16 FDA (Food and drug administration) approved therapies to treat 
MS, which act by dampening inflammation and slowing neurodegeneration [80, 81]. 
Available therapies have immunomodulatory effects and are only effective during 
the relapse-remitting phase. β-interferons and glatiramer acetate were the first 
treatments used to treat MS [82]. β-interferons block blood-brain barrier (BBB) 
leakage to prevent peripheral immune cell infiltration, whereas glatiramer acetate 
prevents T-cell activation. These treatments, although having a low risk for side 
effects, only reduce relapses by a 30% [83]. More effective drugs have since been 
developed, which reduce relapses by around 70%, like dimethyl fumarate, 
mavenclad, alemtuzumab, ocrelizumab and natalizumab [83]. Nonetheless, risk of 
side effects is generally correlated to the efficacy of the therapy at preventing 
relapses.  
Some treatments effective at reducing relapses are now being tested for their 
capacity to reduce progression. Ocrelizumab is being assessed for PMS [25], targeting 
CD20 to deplete B-cells [80], significantly reducing relapses compared to β-interferon 
[84], and moderately reducing progression compared to placebo [80]. Compared to 
alemtuzumab, which is also highly effective at reducing relapses, it has very mild risk 
of developing side effects [85]. Another therapy, dimethyl fumarate (DMF), is now 
being tested in PMS, and is highly effective at preventing relapses, and has a low risk 
of side effects [86]. DMF acts by dampening oxidative stress due to activation of the 
nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway [87] expressed primarily by 
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astrocytes [88, 89], and has immunomodulatory effects on macrophages and T-cells 
[90, 91]. It has been suggested that DMF might prevent demyelination [92], and 
promote oligodendrocyte differentiation [89]; however, its role in promoting 
remyelination has not been assessed. Indeed, there are no currently approved 
therapies that are aimed at enhancing remyelination. However, there are potential 
pro-remyelination therapeutic candidates in clinical trial and pre-clinical phases 
(Table 1.1). In future, a combination of therapeutics that target inflammation and 
remyelination should be considered. Furthermore, further work is required to 
understand how efficient remyelination occurs in order to identify suitable pro-
remyelination therapies, including elucidating the indirect contribution of other glial 
cells. 
Table 1.1| Potential clinical remyelinating/neuroprotective candidates and ongoing trials 
Treatment MS type Target Brief description Phase 
Pre-clinical trials 




of CD+4 T cells into 
inducible regulatory T 
cells (iTreg). Promotes 
oligodendrocyte 
precursor differentiation 
[93, 94]  
Not yet 
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Promotes survival and 
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Astrocytes are CNS-resident cells characterised by a star-shaped cell body, and 
are the most abundant neuroglial cell type in the brain. Astrocytes form a mesh in 
the CNS contacting the vasculature, neurons and oligodendrocytes. This is a highly 
heterogeneous population defined by diverse morphologies and region-specific 
functions. Astrocytes are specialised in different homeostatic and metabolic 
functions in order to meet the needs of their neighbouring cells both in white and 
grey matter [105].  
These cells play essential roles during development and adulthood. For 
instance, they are crucial to support developmental myelination but also myelin 
turnover during the life span. Moreover, they have an essential role in supporting 
synaptogenesis, and in the regulation of synapses [106-108]. Astrocytes are active 
players in the control of synaptic transmission since they are in contact with the pre-
synaptic and the post-synaptic terminals, forming the tripartite synapses [109]. 
Their end-feet surround the cerebral vasculature and are critical components 
involved in the formation and control of the BBB [110]. Astrocytes supply nutrients 
to the brain, as they are in direct contact with the basal lamina [111]. For instance, 
they can take up glucose from the blood vessels to feed neurons or act as storage for 
glycogen [111]. Furthermore, astrocytes control cerebral blood flow via secretion of 
vasoactive molecules [112, 113]. Astrocytes can also be involved in ion and pH 
homeostasis via water and ion channels [114].  
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These cells also have neuroprotective functions, providing antioxidant 
support and regulating immune responses after insult [105, 115]. In addition, 
demyelination affects astrocyte homeostasis and activation, which in turn induces 
changes in OPCs. Astrocytes activated by injury can release factors that promote the 
rapid proliferation and differentiation of OPCs. Hence, this type of glia has been a 
focus of study in the context of white matter re/myelination and MS. 
 
1.2.1. Astrocytes in development 
Various markers are used to identify astrocytes such as the expression of 
transcription factors, upregulation of intermediate filaments and detection of other 
specific proteins. Nonetheless, their study has been challenging due to the lack of 
specific markers, most prominent during development [115]. The glial fibrillary acidic 
protein (GFAP) is an intermediate filament, which has been the most popular marker 
used to detect astrocytes. However, GFAP only labels a small subset of astrocytes in 
physiological conditions (around 30%), and it is expressed only at low levels in grey 
matter [116]. Another limitation of the use of GFAP is that some neuronal progenitors 
and radial glia also express it [117]. Other markers used to detect astrocytes consist 
of S100 calcium-binding protein-β (s100β), aquaporin 4 (Aqp4), and the glutamate 
transporters, glutamate aspartate transporter-1 (GLAST) and glutamate transporter 
soluble carrier family 1, member 2 (GLT-1). However, these markers can also be 
expressed, although at lower levels, in other cells such as OPCs (s100β, GLT-1 and 
GLAST) and ependymal cells (Aqp4) [118]. Aldehyde Dehydrogenase 1 Family 
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Member L1 (Aldh1l1) has been accepted as the most specific pan-astrocytic marker 
[119], and although there is a lack of antibodies that successfully detect this protein, 
reporter lines for Aldh1l1 can be used to overcome this limitation. Moreover, 
recently, Sun et al. (2017) identified the transcription factor Sox9 as a specific nuclear 
pan-astrocytic marker in the adult brain outside neurogenic regions [120]. 
Macroglia, consisting of astrocytes and oligodendrocytes, and neurons share 
origins from the neuroepithelial cell.  In the ventricular zone (VZ), neural precursors 
differentiate into radial glia which then turn into neurons and macroglia. 
Neurogenesis and gliogenesis take place during a tightly control period during 
development, in which neurogenesis precedes the gliogenesis phase [121]. Nuclear 
factor I A (NFIA) and Sox9 are master regulators of gliogenesis, and their upregulation 
controls the switch from neurogenesis to gliogenesis [122, 123]. Then, the 
upregulation of the transcription factor Zinc finger- and BTB domain-containing 
protein 20 (Zbtb20) defines the astrocytic fate, just before oligodendrocyte 
generation [124]. In the mouse, astrogenesis begins between embryonic days (E)16-
18 in the brain and E12.5 in the spinal cord [121].  
After the formation of astrocytes, they populate the brain, migrating with the 
support of radial glia. Astrocytes then reach different areas where they adopt specific 
functions to fulfil the needs of the respective brain region. The maturation of 
astrocytes to obtain specialised physiological functions involves several changes in 
morphology, connectivity and electrophysiological properties [121, 125]. Different 
neural precursors with specific molecular profiles in different regions could give rise 
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to distinct astrocyte populations [126]. The main types of astrocytes described 
consist of fibrous astrocytes located in white matter, protoplasmic in grey matter, 
Müller glia in the retina, Bergmann and velate glia in the cerebellum, ependymal 
astrocytes, marginal and perivascular astrocytes [127, 128]. 
 
1.2.2. Astrocytes in developmental CNS myelination 
Fibrous astrocytes are characterised by their small cell bodies and elongated 
shape aligning with myelinated axons [129]. Compared to grey matter astrocytes, 
they express higher levels of GFAP. The roles of astrocytes in white matter have been 
less studied, but evidence suggests they are supportive during developmental 
myelination and adulthood. 
During myelination, astrocytes support the formation of the myelin sheath by 
oligodendrocytes, which is a highly metabolically demanding process (Figure 1.2). 
Cultured oligodendrocytes purified from developing rat optic nerve in the presence 
of astrocytes were able to differentiate and extend their processes along the axon, a 
process that was not observed in the absence of astrocytes [130]. Moreover, mice 
deficient in GFAP have dysmyelination, non-myelinated axons and disrupted BBB 
integrity [131]. 
Astrocytes also secrete factors that promote oligodendrocyte differentiation. 
Conditioned media from astrocytes increases OPC differentiation measured by an 
increase in the expression of MBP [132]. This effect was mediated through pro-
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differentiating factors like ciliary neurotrophic factor (CNTF) and tissue inhibitor 
metalloproteinase-1 (TIMP-1) [132-135]. The energy demands of oligodendrocytes 
also depends on astrocyte-derived lipids. Astrocytes contribute to lipid biosynthesis 
and supply these to oligodendrocytes during myelination in development, a 
mechanism that has been suggested to be mediated through horizontal transfer 
[136]. Nonetheless, further studies are needed to confirm the mechanism 
underpinning this process.  In addition, astrocytes and oligodendrocytes can 
communicate through chemokine signalling. Astrocytic release of chemokine (C-X-C 
motif) ligand 1 (CXCL1) acts on the C-X-C chemokine receptor type 2 (CXCR2) on 
oligodendroglial cells to promote differentiation and myelin formation in vivo [137]. 
Moreover, immunofluorescence and ultrastructural analysis shows that most of the 
nodes of Ranvier are in contact with astrocytic processes [138]. The contact of 
astrocytes with nodes of Ranvier is essential for nodal formation and maintenance 
[139]. 
For myelin development and stabilisation, the coupling of astrocytes to 
oligodendrocytes occurs through two types of heterodimeric gap-junction 
connections, regulating ion and water homeostasis, and energy supply [140-142]. 
These consist of connexin 30 (Cx30) and connexin 43 (Cx43) present in astrocytes, 
coupled to connexin 32 (Cx32) and connexin 47 (Cx47) in oligodendrocytes, 
respectively [142]. Lack of Cx47 and Cx30 prevents oligodendrocyte-astrocyte 
coupling, which causes myelin abnormalities, consisting of myelin vacuoles and 
thinner myelin sheaths, reduced number of oligodendrocytes, and severe gliosis in 
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white matter areas, which reduces survival in these mice. Importantly, these animals 
can still form astrocyte-astrocyte connections through Cx32 and oligodendrocyte-
oligodendrocyte coupling through Cx43 [143], highlighting that astrocyte to 
oligodendrocyte connectivity is crucial for myelin development and preservation.    
Failure and dysfunction of these connections can be observed in human 
myelin disorders. One such example is the autosomal 
recessive hypomyelinating disorder Pelizaeus-Merzbacher-like disease, in which a 
mutation in the GJC2 gene that encodes for Cx47 [144] impairs Cx43/Cx47 coupling 
[145]. There is further evidence for the role of astrocytes during myelination and its 
maintenance from leukodystrophies in which astrocyte pathology leads to myelin 
disruptions [146]. Alexander’s disease is a neurodegenerative disease characterised 
by severe myelin alterations caused by a mutation in the gene encoding for GFAP 
[147]. Furthermore, the leukodystrophy Niemann-Pick type C (NPC) is caused by a 
mutation in the gene NPC-1 (NPC intracellular cholesterol transported-1) that is 
predominantly expressed in astrocytes and causes failure in cholesterol storage and 
metabolism [148]. Mutations in this gene causes premature death in humans and 
animal models, with neuropathological features including demyelination and axonal 
loss [149]. In mice lacking NPC-1, the specific expression of this protein in astrocytes 
was sufficient to at least partially restore myelination, although ultrastructural 
analyses were not performed [150]. 
Another example in which astrocyte dysfunction leads to myelin pathology is 
the rare genetic disease Pyruvate carboxylase [148, 151, 152]. Pyruvate carboxylase 
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is an enzyme mostly found in the mitochondria of astrocytes in the CNS, and it is 
essential for controlling processes like glucogenesis, lipogenesis and insulin secretion 
[151]. Patients affected with pyruvate carboxylase deficiency present generalised 
myelin defects in the CNS due to a failure in myelin formation [152, 153].   
Astrocytes are also crucial for controlling myelin development after perinatal 
CNS insult. In a mouse model of premature hypoxic-ischemic brain injury, 
transplantation of immature human induced pluripotent stem cells (iPSC)-derived 
astrocytes rescued hypomyelination of the corpus callosum and promoted 
behavioural recovery [132]. Moreover, conditional ablation of astrocytic signal 
transducer and activator of transcription 3 (STAT3), aggravated myelin injury. STAT3 
signalling in astrocytes is essential for restricting transforming growth factor beta-1 
(TGFβ1) production by microglia, which in turn regulates oligodendrocyte 
differentiation, and is critical for providing neuroprotection [154].  
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Figure 1.2. Astrocytes are important players during myelin formation in development. 
Astrocytes mediate myelination through the release of factors like C-X-C motif ligand 1, 
CXCL1, tissue inhibitor of metalloproteinase 1 (TIMP1), and ciliary neurotrophic factor 
(CNTF), transfer of cholesterol, and via direct coupling through connexins (Cx) necessary for 
potassium (K+), water and metabolite transport (taken from Molina-González et al. 2019). 
Despite the existing evidence for the implication of astrocytes in myelination, 
there are still open questions that need to be addressed in order to fully understand 
the role of astrocytes in myelin formation. Do astrocytes in different areas of white 
matter have different roles in myelination? [155] Does the direction of ion and water 
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flow through gap-junctions matter for myelin formation and maintenance? [156] Can 
transplantation of cells restore astrocyte dysfunction in human neurodevelopmental 
disorders? [157]. 
 
1.2.3. Astrocytes in myelin damage and remyelination in the 
adult CNS  
Astrocytes continue to contribute to myelin homeostasis and remodelling 
during adulthood. In physiological conditions, astrocyte processes are in contact with 
myelinated fibres [158]. Evidence shows that within areas of disrupted myelin in 
normal adult animals, astrocyte processes accumulate lysosomes which contain lipid 
droplets or membrane-like debris [158]. These findings would suggest that 
oligodendrocyte-astrocyte contacts are required for myelin turnover and 
maintenance. Furthermore, reduction of exocytosis in astrocytes is associated with 
myelin paranodal loop detachment, increased nodal gap length, and thinning of 
myelin in the optic nerve. Hence, pointing to the importance of astrocytes in 
maintaining myelin in homeostasis [139]. 
Astrocytes also play a role after demyelination. Evidence is often 
controversial showing either supportive or detrimental functions that may be 





1.2.3.1. Astrocytes phenotype regulation 
After insult, astrocytes change their activation by a complex process known 
as reactive astrogliosis. This process consists of a series of changes in transcription, 
function, increase in proliferation, and alteration in morphology including 
hypertrophy and upregulation of intermediate filaments (such as GFAP, synemin, 
vimentin and nestin) [116, 159, 160].  
Additionally, astrocytes adopt diverse phenotypes depending on the severity 
of the insult. The simplistic phenotype characterisation macrophages as ‘M1’ (pro-
inflammatory) and ‘M2’ (pro-repair) has been adapted to astrocytes [161]; in an 
ischemic mouse model, astrocytes polarised towards an ‘A2 phenotype’, defined to 
be a repair phenotype due to the upregulation of neurotrophic factors and beneficial 
cytokines. Contrarily, in the same study, they showed that astrocytes in a 
lipopolysaccharide (LPS) model, adopted pro-inflammatory functions, which were 
defined as ‘A1 phenotype’ [161]. 
Microglia are also crucial for regulating astrocyte phenotypes after insult. LPS 
promotes the expression and secretion of inflammatory molecules by microglia 
[interleukin (IL)-1α, tumour necrosis factor (TNF)-α, and complement complex-1q 
(C1q)], which in turn regulates an ‘A1 phenotype’ and expression of complement-3 
(C3) by astrocytes, also seen in human neuropathological tissue like MS [162]. 
Opposite to this, microglia were shown to induce a protective phenotype in 
astrocytes by the downregulation of the P2Y purinoceptor 1 (P2YR1), which 
39 
 
facilitated the formation of the scar and reduced neuronal damage in a model of 
traumatic brain injury [163]. In addition, pro-inflammatory microglia were shown to 
mediate astrocyte death by necroptosis in a model of spinal cord injury, which was 
required for repair [164]. This process may be a protective mechanism to prevent 
damage due to excessive astrogliosis [165].  
Astrocyte phenotypic regulation is highly complex and is likely regulated in a 
context-dependent manner. For instance, opposed to the concept of A1 being a 
detrimental phenotype, in a model of prion disease, the inhibition of A1 astrocyte 
formation accelerated the disease course and increased its severity, and lead to a 
mixed A1/A2 astrocyte phenotype. After demyelination, astrocytes beneficial or 
detrimental roles may depend on the severity of the demyelinated lesion, the level 
of inflammation and their interaction with other cells. Regenerative and damaging 
functions of astrocytes are described and discussed in the following sections. 
 
1.2.3.2. Regenerative and protective functions of astrocytes 
Due to the implication of the requirement for astrocytes in myelin formation 
in development and maintenance in adulthood, it can be considered that astrocytes 
are also crucial for promoting remyelination after insults (Figure 1.3.A). One of the 
first evidence for the direct effect of astrocytes on remyelination in vivo was in a 
model of spinal cord focal demyelination, where astrocytes were transplanted into 
the demyelinating area [166]. In this study, the transplantation of astrocytes 
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promoted remyelination by host oligodendrocytes [166]. These effects may have 
been mediated by the secretion of supportive factors that promoted remyelination. 
For example, in an in vivo model of viral induced-demyelination, astrocytes were 
shown to express CNTF during the remyelinating phase [167], shown to support 
oligodendrocyte differentiation. In the cuprizone model, in which demyelination is 
achieved by providing cuprizone to the mouse diet astrocytes secrete the 
glycoprotein osteopontin during remyelination, which promotes myelin generation 
in an oligodendrocyte-neuron co-culture model [168]. 
Moreover, astrocytes may regulate remyelination through the control of 
cholesterol metabolism. In instances of poor remyelination (EAE, and in MS optic 
chiasm), astrocytes were shown to downregulate genes for cholesterol biosynthesis 
[169]. In adulthood, astrocytes are the primary cells producing and delivering 
cholesterol, via apolipoprotein E (ApoE)[170]. The treatment of EAE mice with CS-
6253, a compound that increases cholesterol efflux to extracellular ApoE, increased 
expression of cholesterol synthesis genes and consequently decreased the severity 
of disability [169]. Furthermore, dietary cholesterol promoted remyelination in two 
models of demyelination [171]. This effect could be in part due to cholesterol 
influencing astrocyte phenotype to support remyelination through modulating the 
secretion of factors to oligodendrocytes like FGF-2 [171]. However, the outcome of 
manipulating different targets in the lipid metabolism pathway in astrocytes may 
depend on disease progression and timing of administration. For instance, depletion 
of the fatty acid binding protein 7 (FABP-7), a chaperon for long fatty acids that 
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regulates lipid metabolism, in EAE showed that, although there was increased 
inflammation and earlier presentation of symptoms, it attenuated disease severity 
late in the disease course [172]. 
Myelin debris inhibits oligodendrocyte differentiation and remyelination 
[173, 174]. Astrocytes can regulate microglia attraction, through the release of 
CXCL10 [72, 175, 176], an interaction shown to be required for clearing of myelin 
debris and remyelination in the cuprizone model [72]. Moreover, the phagocytosis 
of myelin debris by microglia can be regulated by astrocytes through angiopoietin-
like 4 (ANGPL4), an inhibitor of lipoprotein-lipase. ANGPL4 is expressed by astrocytes 
in MS lesions, and a reduction in astrocytes in vitro induced myelin clearance by 
microglia/macrophages, which was then suggested to be required to enable 
remyelination [177].  
Astrocyte expression of GFAP may also influence their function in 
remyelination. In the cuprizone model, mice overexpressing GFAP had reduced 
neuronal damage and demyelination potentially due to decreased activation 
of nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB) in astrocytes 
[175]. Accordingly, in the same model, astrocyte depletion was achieved by injecting 
ganciclovir into a GFAP-thymidine kinase transgenic, which causes non-inflammatory 
apoptosis of GFAP+ cells [72]. This model of ablation causes 60-70% of GFAP+ 
astrocytes to die [72]. Importantly, in this model, when depletion of astrocytes was 
performed at 4 weeks after cuprizone-induced demyelination, it was sufficient to 
impair remyelination [72]. This could suggest that different populations of astrocytes 
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may have different roles during remyelination, where the 30-40% of remaining 
astrocytes were not supportive of repair, as indicated by decreased numbers of 
proliferating oligodendrocytes and mature oligodendrocytes and impaired 
remyelination [72]. 
 
1.2.3.3. Damaging functions of astrocytes 
After demyelination, astrocytes have also been shown to inhibit 
remyelination (Figure 1.3.B). Blakemore and colleagues (2003) observed that OPCs 
transplanted into demyelinated lesions remyelinated axons more often in astrocyte-
free regions, suggesting that astrocytes inhibit remyelination [178]. However, 
demyelination was achieved by injecting the DNA-intercalating agent ethidium 
bromide, which creates a lesion free of OPCs and astrocytes, and a day later X-
irradiation was performed to confirm the full ablation of astrocytes [178]. Therefore, 
this type of demyelination is severe and could have promoted an inflammatory 
environment in the surrounding tissue that could have influenced astrocyte 
phenotype in a manner not favourable for repair. In this study, they also explored 
the effect of transplanting astrocytes into the X-irradiated ethidium bromide lesion, 
on remyelination [178]. They observed that although minimal, some remyelinated 
axons were present alongside transplanted astrocytes. Hence, the authors suggested 
that the impairment in remyelination could have been mediated due to other 
mechanisms that could indirectly have affected astrocytes responses [178]. 
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This could also explain the difference between Franklin et al. (1991), in which acute 
demyelination permitted transplanted astrocytes to promote remyelination [166]. 
Supporting the postulate that chronic and severe demyelination could influence 
astrocyte responses, the ablation of astrocytes after chronic 
cuprizone administration, which prevents remyelination, increased the number 
of cells of the oligodendrocyte-lineage [176]. Nonetheless, an increase in the number 
of oligodendrocytes is not necessarily reflective of repair as no evidence of new 
myelin formation was shown to confirm remyelination.   
Astrocytes could potentially impair remyelination through the production 
of factors that prevent beneficial responses from the oligodendrocyte lineage. For 
instance, fibronectin is an extracellular matrix component, which is expressed by 
astrocytes and has been correlated with disease severity in EAE [172]. Reactive 
astrocytes also express high levels of endothelin-1 (ET-1), an endogenous inhibitor of 
remyelination that is highly expressed after demyelination [179]. ET-1 induces 
Jagged1 in astrocytes and activates Notch in OPCs after LPC-induced demyelination. 
Blocking ET-1 inhibited expression of Notch by OPCs in demyelinating lesions, and 
enhanced remyelination [179]. 
Astrocytes respond to signals in their environment, coming from other cells 
that can promote further damage. For instance, astrocyte-microglia communication 
is critical for regulating the severity of oligodendrocyte and myelin damage. 
Supporting this, Rothhammer and colleagues (2018) showed that microglia are 
essential in regulating astrocyte signalling and EAE pathogenesis [180]. Transforming 
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grow factor (TGF)-α derived from microglia was shown to act on the epithermal 
growth factor receptor (ErbB1) on astrocytes and reduce EAE pathogenesis. In 
contrast, microglial-derived vascular endothelial growth factor(VEGF)β triggered 
vascular endothelial growth factor receptor (VEGFR)-1 signalling in astrocytes and 
worsened EAE [180]. Moreover, oligodendrocyte death in vitro mediated by LPS-
treated microglia was shown to require the presence of astrocytes, as 
oligodendrocytes did not die in their absence [181]. Astrocytes could also confer a 
pro-inflammatory state in microglia. Astrocytes in MS release advanced glycation 
end-products, whose receptors are on macrophages/microglia, which may induce 
nuclear factor (NF)-κB activation and proinflammatory cytokine release, potentially 
promoting MS pathology [182]. 
Astrocytes are essential for regulating immune cell functions after myelin 
insult. Mayo et al. (2014) observed the effect of depleting astrocytes at different 
stages in EAE [183]. Depleting astrocytes in the acute phase resulted in worsening of 
the clinical score, whereas it was improved when they were depleted in the 
progressive stage [183]. Transcriptomic analysis of astrocytes in the progressive 
phase revealed that B4GALT6 (Beta-1,4-Galactosyltransferase 6 gene), the gene 
encoding for Lactosylceramide (LacCer), was highly upregulated [183]. Importantly, 
the B4GALT6/LacCer pathway in astrocytes regulates the expression of C-C motif 
chemokine ligand 2 (CCL2), which controls the recruitment of inflammatory 
monocytes into the CNS, and granulocyte-macrophage colony-stimulating factor 
(GM-CSF), which modulates microglial activation [183], suggesting a role in crosstalk 
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with myeloid cells. B4GALT6/LacCer was also found to be more highly expressed in 
MS lesions compared to normal-appearing white matter (NAWM) and controls [183]. 
Astrocytes are critical in regulating the BBB, and as such, they have a crucial 
role in controlling the entrance of peripheral immune cells into the CNS. Astrocyte 
detachment from the vasculature leads to BBB dysfunction, which coincides with 
areas of T-cell infiltration and inflammation in cortex and white matter [184]. 
Moreover, astrocytes regulate the entrance of peripheral immune cells into the brain 
and spinal cord through the release of chemoattractant molecules [185]. Interleukin 
(IL)-17 expression in astrocytes is critical for the recruitment of leukocytes [186]. 
Moreover, knocking out CCL2 in astrocytes in the EAE model decreased T-cell and 
macrophage infiltration in spinal cord white matter, which decreased microglia 
activation and axonal degeneration [185].   
Transcriptomic analysis of astrocytes in EAE revealed that they upregulate 
genes indicative of inflammation [169]. Astrocytes can act as APCs for T-cell 
activation [187], and express adhesion molecules like the vascular cell adhesion 
molecule (VCAM)-1 that facilitate the entrance of lymphocytes through the BBB 
[188]. Astrocytes also regulate the activity of T-cells through the upregulation of 
CD39, which is an enzyme increased in inflammation and has a role in converting ATP 
into the immunosuppressive factor adenosine [189].  Moreover, knocking out NF-κB 
in GFAP+ astrocytes resulted in a reduction of infiltrated T-cells into the spinal cord 
during the acute and chronic phases of EAE independent of BBB disruption, which led 
to a reduction of myelin pathology and improved clinical outcomes [190]. Astrocytes 
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may influence remyelination by regulating inflammation through phagocytic 
capacity. It has been proposed that astrocytes could act as APCs and release 
cytokines to recruit immune cells after phagocytosis [191-193]. That raises the 
question as to whether astrocyte phagocytosis of myelin debris could be an early 
pathological mechanism in myelin disorders [192]. 
Figure 1.3. Astrocytes play both supportive and damaging functions after demyelination. 
A. Astrocytes upregulate glial fibrillary acidic protein (GFAP) and transforming growth factor 
receptor (TGFR)-β2 during myelin repair. To support remyelination, they transfer cholesterol 
(via ApoE) and secrete regenerative factors like fibroblast growth factor (FGF)-2, ciliary 
neurotrophic factor (CNTF), and osteopontin. B. Astrocytes express high levels of GFAP, 
increase chitinase 3 like 1 (CIH3L1), and nuclear factor kappa-light-chain enhancer of 
activated B cells (NF-κB) signalling during myelin damage. Astrocytes can promote 
demyelination and impair remyelination via the secretion of inhibitory factors like 
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endothelin-1 (ET-1), transforming growth factor beta-1 (TGFβ1), bone morphogenic protein-
4 (BMP-4), and extracellular matrix components. They mediate the recruitment of peripheral 
immune cells (lymphocytes and macrophages) by the secretion of chemokines and 
expression of vascular cell adhesion protein 1 (VCAM1) (taken from Molina-González et al. 
2019). 
1.2.3.4. Astrocytes in Multiple Sclerosis 
It has long been believed that MS is a disease in which reactive T-cells mediate 
demyelination. However, in some instances, demyelination can be observed in the 
absence of peripheral immune cells. For instance, after immunomodulatory therapy 
that prevent peripheral cell infiltration and activation, new demyelination can still 
take place. Hence, glial cells have been recently investigated as potential mediators 
of MS pathology.  
A hallmark of MS has been defined as the demyelinated plaque accompanied 
by reactive glial scar formation. After inflammation and demyelination, highly 
proliferating astrocytes adopt a hypertrophic morphology and start overlapping their 
processes in an atypical form, resulting in glial scarring [194]. Both beneficial and 
detrimental properties have been defined. For example, the glial scar is required for 
axonal regrowth in a model of severe spinal cord injury via the secretion of repair 
supporting molecules [195]. More recently, it was observed that in remyelinating 
lesions of rat EAE, astrocytes presenting characteristics of the glial scar coincided 
with the expression of factors previously shown to have pro-differentiating effects 
on oligodendrocytes [196]. Nonetheless, although the suggested benefit in limiting 
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inflammation in demyelinated lesions [191, 194, 197], it may also limit the migration 
of oligodendroglial cells, thereby impeding repair [198]. 
Several studies have supported the view that astrocytes may have supportive 
functions in promoting remyelination in MS. Gene expression analysis of astrocytes 
in MS NAWM showed that they adopted a neuroprotective role, indicated by 
upregulation of genes involved in the control of iron homeostasis and neurotrophic 
support [199]. The regulation of iron metabolism by astrocytes has been shown to 
regulate remyelination; conditional deletion of the iron efflux transporter ferroportin 
(fpn) in astrocytes (using a Cre-driver targeting GLAST+ astrocytes) in a model of toxin 
induced-demyelination caused remyelination failure and decreased OPC 
proliferation [51]. Astrocytes have also been shown to regulate microglia phenotype 
in MS and other myelin disorders and iron transport regulation by astrocytes could 
be important for regulating microglia functions. A depletion of fpn in astrocytes 
decreases microglial secretion of TNFα and IL-1β during remyelination [51]. 
Furthermore, treating cultured astrocytes with TNFα and IL-1β increases mRNA 
encoding FGF2, insulin growth factor (IGF)-1 and TGFβ, factors supportive of 
oligodendrocyte differentiation [51]. 
In NAWM of MS patients, astrocytes upregulate genes that regulate oxidative 
responses [199]. Astrocytes have antioxidant roles, mediated through the activation 
of Nrf2 [200, 201]. Nrf2 activation has been observed to be neuroprotective in some 
neurological disorders [202]. In the cuprizone model, conditional activation of Nrf2 
driven by the GFAP promoter prevented oligodendrocyte loss and demyelination 
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[92]. Nrf2 activation may need to be tightly regulated to have protective effects, as 
sustained levels may be detrimental and causative of cancer [202]. In addition, its 
expression in MS brain seems to vary in the different cell types, being highly 
expressed in degenerating cells [203], potentially as an attempt to prevent oxidative 
injury. 
Astrocyte-oligodendrocyte connections are lost in chronic MS and EAE [204]. 
This would indicate a loss of connection that would support the maintenance of 
myelin and remyelination. Masaki et al. (2013) aimed to investigate the link between 
Cx pathology in acute and chronic MS, Neuromyelitis Optica (NMO), and NMO 
spectrum disorder (NMOSD), in which lesions were classified as demyelinating, 
chronic active, and chronic inactive [205]. They observed a loss of Cx43 in 
demyelinating areas of NMO, NMOSD and MS, which consequently lead to a 
Cx43/Cx47 (astrocyte to oligodendrocyte) connection loss [205]. Loss of Cx43 was 
associated with actively progressive disease and oligodendrocyte pathology and 
degenerating astrocytes [205]. The frequency of loss of Cx43 was higher in patients 
with a rapidly progressive disease that had died after two years of onset [205]. Hence, 
astrocyte-oligodendrocyte connexin loss could be associated with the severity of the 
disease due to the failure to maintain myelin integrity.   
After a demyelinating insult, astrocytes can modulate the extracellular matrix 
and prevent remyelination (Figure 1.3.B.). In MS, astrocytes upregulate the 
expression of extracellular matrix components such as fibronectin, chondroitin 
sulfate proteoglycans, and hyaluronic acid, which inhibit oligodendrocyte 
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differentiation and impair remyelination [67, 206-209]. Astrocytes also secrete 
factors that promote inflammation and demyelination. BMP are a family of proteins 
that have a role in regulating inflammatory processes and have been studied in the 
context of demyelination. BMP4 overexpression increases astrocyte density, but 
decreases oligodendrocyte numbers in development [210], and is highly expressed 
by astrocytes during cuprizone-demyelination [211]. Noggin, a BMP4 antagonist, 
promotes oligodendrocyte differentiation and remyelination in the cuprizone model 
[211]. Importantly, BMP4 expression is upregulated in chronic-inactive MS lesions, 
which have no repair capacity, in reactive astrocytes, negatively correlating with 
remyelination potential [212]. 
Gene expression analysis of astrocytes in MS revealed that the functions of 
astrocytes could be lesion-dependent (Figure 1.3.A). Expression of TGFβ1 in 
astrocytes correlates with the development of astrogliosis, and its expression is 
associated with inhibited oligodendrocyte differentiation in the periplaques of the 
spinal cord in MS [213]. On the contrary, astrocytes in remyelinated MS lesions 
express the TGFβ-receptor2 (TGFβ-R2), but this is downregulated in chronic active 
MS lesions, thereby, associating its expression with a protective phenotype [214]. 
Astrocyte activation and morphology varies in MS, depending on the lesion 
type and the disease stage (Figure 1.3). Hence, studies have proposed the presence 
of different markers generally expressed by astrocytes as potential biomarkers for 
MS. For instance, CHI3L1 could be used as an indicator for PMS [215], but its function 
remains controversial. Astrocytes express CHI3L1 at the rim of chronic active lesions, 
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but it is downregulated in all the other lesion types [214]. Moreover, GFAP levels in 
the cerebrospinal fluid (CSF) have been associated with highly active inflammation in 
relapse-remitting MS (RRMS) and clinically isolated syndrome (CIS), in which GFAP 
levels are correlated with the levels of chronic inflammation load [216]. Moreover, 















1.3. Aims of thesis 
Astrocytes have been shown to have critical roles in the development and 
maintenance of myelin, yet their contribution to remyelination, and the molecular 
mechanisms underpinning this potential role, are not clear. Indeed, no 
transcriptomic analysis of astrocytes during remyelination have been conducted. My 
PhD project aims to characterise astrocyte responses and perform unbiased 
transcriptomic analysis of astrocytes during efficient remyelination in order to reveal 
their potential regenerative functions and identify novel therapeutic strategies to 
promote remyelination in disease. 
Hypothesis; Astrocytes are dynamic cells that are supportive of remyelination. 
Aims; 
1. Characterise astrocyte responses during remyelination. 
2. Identify the molecular mechanisms underpinning the role of astrocytes by RNA 
sequencing. 






2. CHAPTER: METHODS 
2.1. Animals and ethics 
Animal experiments were of moderate severity, approved by and performed 
under United Kingdom Home Office project licences issued under the Animals 
(Scientific Procedures) Act 1968. Animals were housed in groups of 5 in a 12:12h light: 
dark cycle with free access to food and water. A minimum of three animals were used 
per condition in each experiment unless otherwise stated. 
C57Bl/6J were purchased from Jackson Laboratories. Animals were used at 
the age of 2-3 months or 9-12 months for the ageing study. Tg(Aldh1l1-
EGFP/Rpl10a)JD130 (ASRIBO) mice were re-derived by Prof Giles Hardingham’s lab, 
The University of Edinburgh. This BAC-TRAP line expresses an eGFP-tag on the large 
ribosomal subunit protein L10a, targeted to the translational start site of the Aldh1l1 
gene. ASRIBO mice were used at the age of 2-3 months or 9-12 months for ageing 
study. GFAP-Nrf2.2 mice were provided by Prof Jeffrey Johnson, University of 
Wisconsin. The hGFAP-Nrf2 transgene was constructed as previously described 
[218] and transgenic mice were generated by pronuclear microinjection using 
fertilised eggs of the FVB/N strain. Mice were then bred in-house onto a C57/Bl6 
background by Dr Jill Fowler, The University of Edinburgh. These mice overexpress 
Nrf2 in astrocytes, which is driven by the GFAP promoter. GFAP-Nrf2.2 mice were 





2.2.1. DNA extraction 
DNA for genotyping was extracted from ear tissue which was incubated in 100 
μl of 50 mM NaOH and centrifuged for 90 seconds (sec) at 10,000 rpm. Samples were 
incubated at 100ºC for 7 minutes (min) then placed on ice for 10 min, and frozen until 
use. 
 
2.2.2. Polymerase chain reaction (PCR) 
GoTaq®Green Master Mix (Promega) for PCR was used according to the 
manufacturer’s instructions. Briefly, 1μl of DNA template was mixed with 1X 
GoTaq®Green Master Mix, 0.25 μM of forward primer, 0.25 μM of reverse primer 
(Table 2.1 & 2.2) and nuclease-free water to a volume of 25 μl. PCR reactions used 
the following cycle parameters; 5 min at 95 ºC for initial denaturation, 35 cycles of 
30 sec at 95 ºC for denaturation, 30 sec at 54 ºC for annealing and 30 sec at 72 ºC for 
extension, 5 min at 72 ºC for final extension and samples then held at 4 ºC.  PCR 
products were run on a 2% agarose gel in Tris-borate-EDTA (TBE).  
Table 2.1 | GFAP-Nrf2 genotyping primer sequence: 
Gene Forward Reverse 
Nrf2 5'-GCCTGAGAGCTGTAGGCC C–3 
' 
5'-GGAATGGAAAATAGCTCCTGCC-3' 
Gfap 5'-CTTCATAAAGCCCTCGCATC-3' 5'-TCTTGCCTCCAAAGGATGTC-3' 
* Sequence obtained from Vargas et al. 2008 [218]. 
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Table 2.2 | ASRIBO genotyping primer sequence: 









* Sequence obtained from The Jackson Laboratory 
 
2.3.  In vivo stereotaxic demyelination 
Mice were anaesthetised with isoflurane and demyelinating lesions induced by 
stereotaxically injecting 0.5 mg/ml of lysolecithin (LPC) (egg-yolk, Sigma Aldrich 
L4129) diluted in sterile phosphate-buffered saline (PBS) into the corpus callosum 
with a Hamilton syringe (Figure 3.1.A). Sham lesions were induced by injecting sterile 
PBS. Coordinates for injection corresponded; 0.5 mm mediolateral from middle line, 
1.2 mm rostral to bregma, and 1.4 mm depth to brain surface at bregma. Mice were 
sacrificed for immunofluorescence by intracardially perfusing with 4% 
paraformaldehyde (PFA) at 3, 7, 10, 14, and 21 days post-injection (DPI), or by carbon 
dioxide (CO2) asphyxiation at 3, 7, 10 DPI for translational ribosome affinity 





2.4. Cuprizone model 
Cuprizone demyelination on mice was performed and provided by Tanja 
Kuhlmann, University of Münster provided tissue. Briefly, 8 weeks mice were fed with 
0.2% (w/w) cuprizone diet for 5 weeks, and then switched to a normal diet until 10 
weeks (Figure 3.6.A). Mice were sacrificed under deep anaesthesia by intracardially 
perfusing with PBS at 3, 5, 7 and 10 weeks. Brains were then fixed overnight with 4% 
PFA and then paraffin-embedded. Cuprizone sections quantified were within bregma 




2.5.1. Tissue processing for OCT embedding 
Mouse brain tissue was post-fixed overnight with 4% PFA, and cryoprotected 
in sucrose (15% and then 30%), before OCT (VWR, 361603E) embedding on dry ice. 
Sections were cut at 10 μm thickness on a cryostat. Sections were cut from bregma 






Paraffin-embedded sections were pre-heated at 60°C in a hybridisation oven 
for 20 min. Slices were then immersed thrice for 5 min in Histo-clear II, twice for 5 
min in Ethanol Absolute, and 5 min in each 95% Ethanol, 5 min in 70% Ethanol and 
distilled water. 
2.5.3. Staining  
Heat inactivated antigen retrieval (HIER) was achieved by microwaving the 
sections at medium power in 10 mM citrate buffer (pH 6.0) and heating for 20 min at 
60°C, followed by three washes of PBS for 5 min. Slices were blocked in 5% heat-
inactivated horse serum and 0.3 % Triton-X in PBS for 1 hour (h) at room temperature 
and then primary antibodies were applied, diluted in blocking solution and left 
overnight at 4°C in a humid chamber. Following three washes with PBS for 5 min, 
secondary antibodies diluted in blocking solution were applied for 2h at room 
temperature in a humid chamber. Hoechst (Sigma-Aldrich) was applied, followed by 
three washes in PBS, and slices were mounted onto glass slides and coverslipped with 
Fluoromount G (Cambridge Biosciences, 0100-01).  






Table 2.3 | Antibodies for immunostaining: 
Antibody Dilution Provider – Catalog number 
Rat anti-myelin basic protein (MBP) 1:100 Bio-Rad antibodies - 
MCA409S 
Chicken anti-glial fibrillary acidic protein (GFAP) 1:500 BioLegend – PCK-591P 
Rabbit anti- glial fibrillary acidic protein (GFAP) 1:500 Dako – Z0334 
Rabbit anti-Sox9 1:500 Sigma-Aldrich – AB5535 
Mouse anti-nestin 1:100 Abcam – ab6142 
Mouse anti-vimentin, clone LN-6 1:100 Sigma-Aldrich – MAB1681 
Rabbit anti-nuclear factor IA (NFIA) 1:250 Abcam – ab228897 
Rabbit anti-Ki67 1:100 Sigma-Aldrich – AB9260 
Chicken anti-neurofilament H (NF-H) 1:100 Covance – PCK-592P05 
Mouse anti-neurofilament H (NF-H) 1:1000 EnCor – MCA-9B12 
Mouse anti-myelin associated glycoprotein 
(MAG), clone 513 
1:100 Sigma-Aldrich – MAB1567 
Mouse anti-myelin oligodendrocyte 
glycoprotein (MOG) 
1:100 Sigma-Aldrich – MAB5680 
Mouse anti-APC (CC-1) 1:100 Abcam – ab16794 
Rabbit anti-Olig2 1:100 Sigma-Aldrich – AB9610 
Rabbit anti-Heme oxygenase 1 (Hmox1) 1:100 Enzo – ADI-SPA-895-D 
Goat anti-NQO1 1:100 Abcam – ab2346 
Rabbit-HMGCS1 1:500 Invitrogen – PA5-29488 
Rabbit-FDPS 1:100 Invotrogen – PA5-28228 
Secondary antibodies; Alexa Fluor®-conjugated 
antibody 
1:500 Life Technologies 
 
2.6. Image acquisition and analysis 
Z-stacks of images were obtained using an Olympus 3i Spinning Disk confocal 
microscope (30x silicone objective) using SlideBook 6 software. For astrocyte counts, 
TIFF files from max projections were imported to Image J, and the images were 
converted to 8-bit fluorescence RGB tiff and thresholded. For nuclear counts, 
watershed segmentation on binary images was used to separate objects and then 
images were analysed. Two fields of view were quantified per section within the right 
hemisphere of the corpus callosum, then the mean was calculated and converted to 
mm2. For the analysis of myelin, the mean grey value was analysed in two regions of 
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interest within the right hemisphere of the corpus callosum, and from this, the mean 
background grey value of two regions of interest outside the corpus callosum were 
subtracted; the results were plotted as myelin protein intensity.  For counting 
astrocytes positive for Hmgcs1, Fdps, Hmox1 and Nqo1, Imaris 9.0.0 software was 
used. TIFF files were converted to Imaris files using ImarisFileConverter 9.0.0. and 
images in z-stacks were analysed. To analyse the number of positive cells, a 
colocalisation channel was created using ImarisColoc and analysed using 
ImarisSurfaces. Two regions of interest of 450 μm x 450 μm were selected for analysis 
within the right hemisphere corpus callosum. Thresholding was done using absolute 
intensity. The size of each surface (named particle) was adjusted so that each was 
approximately the size of a cell.  
For each image analysis, two different regions of interest were measured, and 
the mean was obtained. Three sections per animal were analysed and the mean was 
obtained, which is indicated as an ‘n’.  
 
2.7. BAC-Aldh1l1-translational ribosome affinity purification  
Translational ribosome affinity purification (TRAP) protocol was performed 
according to Heiman et al. (2014)[220]. Briefly, magnetic beads (Dynabeads, 
Invitrogen) were coupled to anti-eGFP antibodies (Htz-GFP-19F7 and Htz-GFP-19C8, 
Memorial-Sloan Kettering Monoclonal Antibody Facility) and tissue lysates were 
prepared. The injured hemisphere of the corpus callosum was dissected using a brain 
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matrix and brain sections were homogenised in tissue-lysis buffer [20 mM HEPES 
RNase-free (Affymetrix), 10 mM Magnesium Chloride RNase-free (MgCl2, Applied 
Biosystems), 150 mM Potassium chloride RNase-free (KCl, Applied Biosystems), 0.5 
mM DL-Dithiothreitol (DTT, Sigma-Aldrich), 100 mg/ml cycloheximide (CHX) (Sigma 
Aldrich), 10μl/ml RNasin (Promega), and 10μl/ml Superasin (Applied Biosystems) in 
RNase free water). Lysates were centrifuged at 2,000 g for 10 min at 4°C. A 1/9 
volume of 300 mM 1,2-diheptanoyl-sn-glycero-3-phosphocholine (DHPC, Avanti 
Polar Lipids) was added to supernatants. Following a 5 min incubation, lysates were 
centrifuged at 20,000 g for 20 min at 4°C. A small fraction of the supernatant was 
saved at this point as ‘input’ sample. The rest of the supernatant was added to the 
anti-eGFP-coated-magnetic beads and incubated overnight at 4°C in rotation. Beads 
were collected with a magnet, washed 4 times in high-salt wash buffer [20 mM 
HEPES, 10 mM MgCl2, 350 mM KCl, 0.5 mM DTT, 1% Nonidet P-40 (NP-40, AG 
Scientific), and 100 μg/mL CHX] and then resuspended in 100 μl of Nanoprep Lysis 
Buffer with β-ME (Stratagene Absolutely RNA Kit).  
 
2.8. RNA extraction and bioanalysis 
Input and TRAP samples were processed for RNA extraction. RNA extraction 
was achieved by using the Agilent Nanoprep kit following the manufacturer’s 
protocol. Quality of the samples was measured by the use of an Agilent Bioanalyzer, 
using the Agilent RNA 6000 PICO assay protocol. Samples selected had an RNA 
integrity number (RIN)>7.  
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2.9. Quantitative polymerase chain reaction (qPCR) 
Complementary DNA (cDNA) for qPCR was obtained using SuperScriptTM 
VILOTM cDNA Synthesis Kit (Invitrogen). The FastStart Universal SYBR Green Master 
Mix (ROX) (Roche, 04913850001) was used, and qPCR was run on a QuantStudio 5 
Real-Time PCR System.  
 
2.10. RNA sequencing 
Samples were sent to Cambridge Genomic Services for Next-Generation 
Sequencing. For Library preparation the SMART-Seq v4 Ultra Low input RNA kit 
according to manufacturer’s protocol (Takara Bio USA). The sequencing was run on 




Bioinformatics was carried out by Dr Owen Dando from Prof Giles Hardingham’s 
Lab, The University of Edinburgh. For each sample, 75 base pair paired-end reads 
were mapped to the primary assembly of the mouse (mm10) reference genome 
contained in Ensembl release 93 [221]. Alignment was performed with STAR version 
2.5.3a [222]. Tables of per-gene read counts were generated from the mapped reads 
with featureCounts version 1.5.2 [223]. Differential expression analysis was then 
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performed using DESeq2 (R package version 1.18.1) [224]. Sample heatmaps and PCA 
plots were produced using variance-stabilized per-gene read counts.  
In order to account for variable amounts of background mRNA contamination 
in these TRAP-seq samples the presence of a set of cell-type-specific genes which 
should not be expressed in astrocytes were quantified, including microglial-specific 
genes (Sfpi1 and Aif1), oligodendrocyte-specific genes (Sox10 and Mbp) and 
neuronal-specific genes (Syp and Rbfox3). For each cell-type-specific gene, its 
expression in FPKM (fragments per kilobase per million mapped reads) in each 
sample was divided by its maximum FPKM in any sample, giving, for each gene, a per-
sample measure of background contamination (with a value between 0 and 1). Per-
gene contamination values for the six genes correlated well across samples. 
An average was taken over the six genes to give a per-sample contamination 
measure, C, with a value between 0 and 1. For every other gene, the correlation of 
its gene expression with C over all samples was calculated, giving a per-gene 
measure, R, of the likelihood of a gene’s apparent presence in the data as being due 
to background mRNA contamination. 
To determine how likely it was to get high values of R by chance, a fake gene 
expression data set containing the FPKM values from our data was created with the 
values scrambled between samples for each gene (in which case, this fake gene 
expression should not be correlated with C). From this fake data, the R value for each 
scrambled gene was created, deriving a null distribution of R values. In the real data, 
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a Z-score for each gene indicating how far its own R value was from the mean of this 
null distribution in units of standard deviations of the null distribution was calculated. 
Hence, any gene whose Z-score that was greater than 2 excluded from the gene 
ontology enrichment and gene set analyses, thus removing significant GO terms and 
GSA gene sets whose presence was likely due to non-astrocytic background mRNA 
expression. 
 
2.12. Pathway analysis 
Pathway analysis was performed using Ingenuity Pathway Analysis software 
(QIAGEN). The list of genes and their FPKM for the control, sham (3 DPI), and 
demyelinating conditions (3, 7 and 10 DPI)  with a cut off of 5 FPKM, were analysed 
in IPA to identify canonical pathways, top biological functions, top upstream 
regulators and top toxicity functions. Parameters included ‘species=mouse’ and 
‘confidence=experimentally observed’. 
Gene ontology and pathway networks were explored using the plugging 
ClueGO v.2.5.4 for Cytoscape v.3.7.1 software. The top 200 significantly upregulated 
genes at each time point (3, 7 and 10 DPI) were used for the analysis. Mus Musculus 
annotation was used. Ontologies/Pathways selected corresponded to GO-Biological 
processes, KEGG pathways and WikiPathways. Statistical significance was analysed 
by two-sided hypergeometric test, and Bonferroni step down correction. Grouping 
was based on highest significance and GO-term fusion. 
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2.13. Cluster analysis 
Cluster analysis performed using Graphia Professional (KAJEKA) in three-
dimensional (3D) layout, using the top 5000 highly expressed genes in control and 
comparing FPKM values to 3, 7 and 10 DPI. A 0.8 Pearson correlation threshold was 
applied. Pearson correlation measures the association between two different 
variables. In this study, Pearson correlation related to the similarity between nodes, 
which represent genes [225]. Markov clustering algorithm (MCL) with inflation 
value of 2.0 was applied. MCL clustering, groups genes according to similarities in 
their expression pattern and forms clusters. Inflation is a factor which defines how 
clean and robust the clusters are (1.7 to 2.2 correspond to optimal values) [225]. 
Clusters were set to contain ≥4 nodes. Graphs of different clusters were plotted 
against the mean centred FPKM, where the mean is centred to 0, meaning that the 
average of the FPKM values for each cluster is calculated and then the average is 
subtracted to the average of each group (CT, 3, 7 and 10 DPI). The graphs were 
scaled by the software from 1 to -1. 
 
2.14. Statistical analysis 
Samples were blinded prior to quantification. Statistical analysis was performed 
by the use of GraphPad Prism 7 software. Shapiro-Wilk were applied to analyse the 
data for Gaussian distribution, and then statistical analysis was performed using the 
parametric tests (student’s t-test or ANOVA) when normal distributed, and the non-
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parametric test (Kolmogorov-Smirnoff test or Kruskal-Wallis test) when not normally 
distributed. When two independent variables were compared (eg. treatment and time) a 
two-way ANOVA was applied. Data was represented as mean ± standard error of 
means (s.e.m.). P values <0.05 were considered statistically significant and are 














3. CHAPTER: CHARACTERISATION OF ASTROCYTE RESPONSES 
DURING REMYELINATION 
3.1. Introduction 
Fibrous astrocytes are crucial for developmental myelination and homeostasis of 
white matter during adulthood [129]. After an insult, astrocytes become reactive. In 
acute situations, temporary astrocyte reactivity counteracts damage and limits 
inflammation to restore homeostasis. In contrast, in chronic injury, continuous 
astrogliosis can promote further damage, thereby limiting repair [226]. 
The opposite functional regulation of astrocytes after demyelination comes from 
studies in MS and experimental models of demyelination. These have shown that 
reactive astrocytes can have several detrimental functions, and thus impair 
remyelination. Astrocytes can secrete unfavourable factors that inhibit the 
differentiation of OPC into new myelin forming-oligodendrocytes. As astrocytes also 
are in contact with the BBB, they control the entrance of peripheral immune, which 
can aggravate myelin damage [184, 185]. Reactive astrogliosis can lead to the 
formation of glial scar, a significant component of chronic inactive MS lesions [27], 
and impair the migration of oligodendrocyte progenitors to the lesion [198]. 
Contrarily, astrocytes can promote remyelination by secreting factors that promote 
new myelin sheath formation by oligodendrocytes [51, 227]. They can attract 
microglia to phagocytose myelin debris, required for remyelination [72]. Moreover, 
they are essential for limiting inflammation and oxidative stress by mediating 
antioxidant functions [92, 199]. 
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These differences observed in the astrocyte responses towards oligodendrocyte 
differentiation and remyelination could result from changes in activation and 
responses over time. However, the responses of astrocytes (i.e. reactivity, numbers, 
proliferation) during the course of efficient remyelination have never been fully 
















3.2.1. Characterisation of astrocytes after LPC-demyelination 
3.2.1.1. GFAP+ astrocytes increase during oligodendrocyte differentiation 
 
To characterise astrocyte responses during remyelination, I used a model of focal 
demyelination where remyelination occurs in temporal isolation of demyelination, 
allowing characterisation of astrocyte responses during remyelination alone (Figure 
3.1.A-B). In this model, the myelin toxin lysolecithin (LPC) is stereotaxically injected 
into the white matter tract the corpus callosum. After LPC-induced demyelination, 
remyelination takes place within a well-characterised time-window, where 
proliferation and recruitment of OPCs occurs after 3-4 days post-injection (DPI), 
oligodendrocyte precursor differentiation occurs between 7-10 DPI, and 
remyelination takes place between 14-21 DPI (Figure 3.1.A-B). Hence, I first 
confirmed de- and re-myelination in this model by staining for myelin basic protein 
(MBP). 
I then assessed astrocyte reactivity during remyelination, using GFAP as a pan-
reactivity marker. I observed that in comparison to PBS-injected controls (‘sham’) and 
non-lesioned controls, demyelinated lesions showed an increase in GFAP+ reactive 
astrocytes over the course of remyelination, peaking during the phase of 
oligodendrocyte differentiation and early remyelination (7-14 DPI) (Figure 3.1. C-D). 
GFAP+ astrocytes were subsequently reduced when remyelination was completed at 
21 DPI. Moreover, early after demyelination, astrocytes adopted a hypertrophic 
morphology characteristic of a reactive state, compared to the clear separation of 
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cell bodies along the corpus callosum seen in undemyelinated and sham 




Figure 3.1. Reactive astrocyte numbers peak during oligodendrocyte differentiation and 
onset of remyelination. A. Schematic representation of the focal demyelination model, 
where the toxin LPC is injected into the corpus callosum. B. Main phases of the LPC model 
are shown by MBP staining (magenta) in the corpus callosum (indicated with dashed lines) 
in a control animal (no lesion), at 3DPI (OPC migration/proliferation phase), 7 and 10 DPI 
(oligodendrocytes precursor differentiation phase), and 14 and 21 DPI (remyelination phase). 
C. Representative images of GFAP+ astrocytes in lesions (yellow). Scale bar; 100µm. White 
box shows a magnified view of different astrocyte morphologies. Scale bar; 50 µm. D. 
Quantification of GFAP+ astrocytes in Sham animals (injected with PBS) and lesioned animals 
(injected with LPC). Error bars indicate s.e.m. of the number (n) of animals. n=3-6 animals. 
Significance was determined by using one-way ANOVA with multiple comparisons and Tukey 
posthoc test. *P<0.05, **P<0.01. OPCs; oligodendrocytes precursor cells. LPC; Lysolecithin. 
MBP; Myelin basic protein. CC; Corpus callosum. DPI; days post-injection. GFAP; Glial 
fibrillary acidic protein. 
 
3.2.1.2. Sox9+ astrocytes decrease early after LPC-demyelination 
I next assessed astrocyte numbers during remyelination using the 
transcription factor Sox9 as a pan-astrocyte marker [120]. I observed that Sox9+ cells 
decreased significantly at 3 DPI compared to the Sham and non-lesion controls 
(Figure 3.2.A-B). The number of Sox9+ cells were rapidly recovered by 7 DPI, reaching 
similar levels to those observed in control and not significantly changing during the 
rest of the remyelination process (Figure 3.2.B). To determine the proportion of 
astrocytes that become reactive during remyelination, I assessed the proportion of 
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Sox9+ astrocytes which are GFAP+ (Figure 3.2.C). This ratio was close to 1.0 at 3 DPI, 
indicating that the majority of astrocytes became reactive after demyelination 
(Figure 3.2.C). The proportion of reactive astrocytes subsequently decreased during 
early remyelination (14 DPI) and reached basal levels when remyelination was 
completed (21 DPI) (Figure 3.2.C). 
Figure 3.2. Dynamic changes in the proportion of astrocytes, which are reactive during 
remyelination. A. Representative images of all astrocytes (Sox9+; cyan) which are reactive 
(GFAP+; yellow). Cell nuclei are stained with Hoechst (Blue). Scale bar; 100 µm.  B. 
Quantification of Sox9+ astrocytes in Sham animals (injected with PBS) and lesion animals 
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(injected with LPC). Significance was determined by using the Kruskal-Wallis test with 
multiple comparisons and Dunn’s test correction. C. Quantification of the proportion of 
GFAP+Sox9+/Sox9+ cells (ratio) in Sham animals (injected with PBS) and lesion animals 
(injected with LPC). Significance was determined using one-way ANOVA with multiple 
comparisons and Tukey posthoc test.  Error bars indicate s.e.m. of the number (n) of animals. 
n=3-6 animals. *P<0.05.  
 
3.2.1.3. Vimentin+ and Nestin+ astrocytes increase during remyelination 
To confirm the changes in reactive astrocytes during remyelination, I 
investigated additional markers for reactivity: nestin and vimentin (Figure 3.3.). I 
found that vimentin+ GFAP+ astrocytes increased at the time of oligodendrocyte 
differentiation (7 DPI) with a small but not significant drop at 10 DPI, and a significant 
increase during early remyelination (14 DPI) compared to non-lesioned controls 
(Figure 3.3.A and C). Similarly, Nestin+ GFAP+ cells were gradually increased after 
demyelination, reaching a significant peak at 14 DPI compared to non-lesioned 
animals (Figure 3.3.B and D). Vimentin and nestin positive GFAP+ cells reached basal 
levels when remyelination was completed (21 DPI). No significant changes were 
observed in the sham controls for both markers. 
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Figure 3.3. Reactive astrocytes express vimentin and nestin during oligodendrocyte 
differentiation and onset of remyelination. A and B. Representative images of GFAP+ 
astrocytes (green) co-stained with vimentin (A), or nestin (B) (magenta). Scale bar; 100 µm.  
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C. Quantification of Vim+GFAP+ astrocytes in Sham animals (injected with PBS) and lesion 
animals (injected with LPC). Significance was determined using the Kruskal-Wallis test with 
multiple comparisons and Dunn’s test correction. D. Quantification of Nestin+GFAP+ 
astrocytes in Sham animals (injected with PBS) and lesion animals (injected with LPC). 
Significance was determined using one-way ANOVA with multiple comparisons and Tukey 
posthoc test.  Error bars indicate s.e.m. of the number (n) of animals. n=3-6 animals. *P<0.05. 
Vim; Vimentin. 
 
3.2.1.4. GFAP+ astrocyte proliferate early in remyelination 
Given that I observed an increase in GFAP+ astrocytes during remyelination, 
I next asked whether this reflected increased proliferation by using the proliferation 
marker Ki67. I observed that reactive astrocytes which were proliferating (GFAP+ 
Ki67+) significantly increased during the oligodendrocyte differentiation phase (7-10 
DPI) and the numbers were maintained during early remyelination (14 DPI) 
compared to the sham and non-lesioned controls (Figure 3.4). The increase in 
proliferative astrocytes coincided with the increase in reactive astrocyte 
numbers (Figure 3.1.C-D). Proliferating reactive astrocytes returned to normal levels 




Figure 3.4. GFAP+ astrocytes proliferate during oligodendrocyte differentiation and 
remyelination phases. Representative images of proliferative astrocytes identified with Ki67 
(magenta) and GFAP+ (green). Cell nuclei are stained with Hoechst (Blue). Scale bar; 100 µm. 
White boxes show magnified views of proliferative reactive astrocytes (Ki67+GFAP+). Scale 
bar; 25 µm.  B. Quantification of Ki67+GFAP+ astrocytes in Sham animals (injected with PBS) 
and lesion animals (injected with LPC). Significance was determined using one-way ANOVA 
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with multiple comparisons and Tukey posthoc test. Error bars indicate s.e.m. of the number 
(n) of animals. n=3-6 animals. *P<0.05.  
 
3.2.1.5. NFIA is increased in reactive astrocytes during remyelination 
I then investigated whether astrocytes could be derived from progenitors by 
staining for an astrocyte progenitor marker NFIA, a transcription factor expressed in 
glial progenitors that controls the formation of astrocytes in development [122]. I 
observed that NFIA expression in reactive astrocytes significantly increased at the 
onset of remyelination (10 DPI) and in early remyelination (14 DPI) when compared 
to sham and non-lesioned controls (Figure 3.5). NFIA levels returned to normal 
when remyelination was completed at 21 DPI. However, NFIA may also mark reactive 
astrocytes [228], and more definitive lineage tracing would be required to claim that 
new astrocyte differentiation was taking place. 
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Figure 3.5. Reactive astrocytes express the progenitor marker NFIA during oligodendrocyte 
differentiation and onset of remyelination. A. Representative images of GFAP+ astrocytes 
(green) co-stained with NFIA (magenta). Cell nuclei are stained with Hoechst (Blue). Scale 
bar; 100 µm.  Scale bar; 25 µm.  B. Quantification of NFIA+GFAP+ astrocytes in Sham animals 
(injected with PBS) and lesion animals (injected with LPC). Significance was determined using 
one-way ANOVA with multiple comparisons and Tukey posthoc test. Error bars indicate 




3.2.2. Characterisation of astrocytes after cuprizone-
demyelination 
3.2.2.1. GFAP+ astrocytes increase during oligodendrocyte differentiation in 
the cuprizone model 
 
To confirm whether the astrocyte responses observed during remyelination in 
the LPC-demyelination model could be observed in a distinct remyelination model, I 
used another model of toxic induced-demyelination, the cuprizone model. Cuprizone 
is a copper chelator, which affects the cytochrome oxidase activity required for 
mitochondrial oxidative phosphorylation, which in turn impairs mature 
oligodendrocyte metabolism leading to apoptosis and demyelination [229, 230]. In 
this model, cuprizone is administered in the diet of mice to achieve demyelination. 
Here, cuprizone was provided in the diet for 6 weeks, where after 3 weeks initial 
demyelination starts and after 5 weeks extensive demyelination and initial 
oligodendrocyte regenerative responses can be observed (Figure 3.6.A) [231, 232]. 
Then mice were switched to a normal diet to induce spontaneous remyelination, 
where early and late remyelination are observed at 7 and 10 weeks, respectively 
(Figure 3.6. A-B) [232]. The mouse experiments were performed by Prof. Tanja 
Kuhlmann’s lab (University of Muenster, Germany), and I obtained brain sections to 
assess the astrocyte responses. I first assessed de- and re-myelination in this model 
using MBP as a marker for myelin. I observed that maximal demyelination was 
achieved after 5 weeks of cuprizone diet. After 7 weeks of cuprizone, early 
remyelination was observed followed by nearly complete remyelination at 10 weeks. 
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I found that astrocyte reactivity (GFAP expression) increased early during the 
demyelinating phase (3 weeks, figure 3.6), and subsequently peaked when 
oligodendrocyte differentiation and initial remyelination occur (5 weeks, figure 3.6). 
GFAP expression then decreased when remyelination is complete (10 weeks, figure 
3.6). Similar to what I observed in the LPC-induced demyelination model, in the 
cuprizone model maximal astrocyte reactivity took place during oligodendrocyte 




Figure 3.6. Reactive astrocyte numbers peak early in remyelination in the cuprizone model. 
B. Schematic representation of the cuprizone-induced demyelination models, where red 
arrowheads indicate the time-points used in this study. B. Main phases of the cuprizone 
model are shown by MBP staining (magenta) in the corpus callosum (indicated with dashed 
lines) where GFAP+ astrocytes are shown in a control animal (no lesion), at 3 weeks (w) (early 
demyelination phase), 5w (demyelinating/remyelinating phase), 7w (early remyelination 
phase) and 10w (late remyelination phase). Scale bar; 100 µm. C. Quantification of GFAP+ 
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astrocytes. Error bars indicate s.e.m. of the number (n) of animals. n=3 animals. Significance 
was determined using Kruskal-Wallis with multiple comparisons and Dunn’s test correction. 
*P<0.05. 
 
3.2.2.2. Sox9+ astrocytes decrease during demyelination in the cuprizone 
model 
To assess the total number of astrocytes in the cuprizone model, I used Sox9 
as the pan astrocyte marker. Sox9+ cells significantly dropped at 3 weeks of cuprizone 
administration, compared to non-demyelination controls (Figure 3.7). The numbers 
of Sox9+ cells were subsequently recovered and did not significantly change after 5 
weeks of cuprizone diet (Figure 3.7.B). Moreover, the majority of astrocytes became 
reactive during demyelination (at 3 weeks) and the onset of remyelination (5 weeks) 
(measured by the GFAP+ Sox9+/Sox9+ cell ratio; Figure 3.7.C) and this proportion 




Figure 3.7. Dynamic changes in astrocyte number and reactivity in the cuprizone model. A. 
Representative images of astrocytes stained with Sox9 (magenta) and GFAP (green). Cell 
nuclei are stained with Hoechst (Blue). Scale bar; 100 µm. B. Quantification of Sox9+ 
astrocytes. Significance was determined using the Kruskal-Wallis test with multiple 
comparisons and Dunn’s test correction. C. Quantification of the GFAP+Sox9+/Sox9+ cell 
ratio in Sham animals (injected with PBS) and lesion animals (injected with LPC). B and C. 
Significance was determined using one-way ANOVA with multiple comparisons and Tukey 
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posthoc test. Error bars indicate s.e.m. of the number (n) of animals. n=3 animals. *P<0.05, 
**P<0.01, ***P<0.001.  
 
3.2.2.3. Vimentin+ and Nestin+ astrocytes increase during remyelination in 
the cuprizone model 
I confirmed astrocyte reactivity by staining for nestin and vimentin (Figure 
3.8). A similar pattern was observed with both markers, with a significant increase in 
GFAP+ cells that were nestin or vimentin positive at 5 weeks, compared to non-lesion 
controls (Figure 3.8). After this time-point expression of both markers was decreased, 
and although the vimentin+ GFAP+ cells were not significantly higher compared to 
control (Figure 3.8.B), they remained significantly increased for nestin+ GFAP+ 






Figure 3.8. Reactive astrocytes expressing vimentin and nestin peak during 
oligodendrocyte differentiation and onset of remyelination. A and B. Representative 
images of GFAP+ astrocytes (green) co-stained with vimentin (A), or nestin (B) (magenta). 
Scale bar; 100 µm. C. Quantification of Vim+GFAP+ astrocytes. Significance was determined 
by using the Kruskal-Wallis test with multiple comparisons and Dunn’s test correction. D. 
Quantification of Nestin+GFAP+ astrocytes. Significance was determined using one-way 
ANOVA with multiple comparisons and Tukey posthoc test.  Error bars indicate s.e.m. of the 
number (n) of animals. n=3 animals. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Vim; 
Vimentin. 
 
3.2.2.4. GFAP+ astrocyte proliferate during demyelination and early 
remyelination in the cuprizone model 
I next investigated astrocyte proliferation in the cuprizone model using the 
proliferation marker Ki67. GFAP+ Ki67+ astrocytes significantly increased during the 
demyelinating phase (3 weeks) and during oligodendrocyte differentiation and onset 
of remyelination phase (5 weeks). This coincided with the increase in the number of 
GFAP+ astrocytes. GFAP+ Ki67+ cells decreased after early remyelination (7 
weeks) and maintained during late remyelination (10 weeks). 
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Figure 3.9. Reactive astrocyte proliferation peaks during oligodendrocyte differentiation 
and early remyelination phases in the cuprizone model. A. Representative images of 
proliferative astrocytes stained with Ki67 (magenta) and GFAP (green). Scale bar; 100 µm. 
White box shows magnified view of proliferative reactive astrocyte (Ki67+GFAP+). Scale bar; 
25 µm.  B. Quantification of Ki67+GFAP+ astrocytes. Significance was determined using one-
way ANOVA with multiple comparisons and Tukey posthoc test. Error bars indicate s.e.m. of 




In this chapter, I found that astrocytes undergo significant changes in 
activation and number during remyelination. These changes were similar in two 
distinct models of demyelination, a focal lesion model using the myelin toxin LPC, 
and a widespread demyelination model using the cuprizone diet. After demyelination 
in both models, immunofluorescent analysis of GFAP showed that astrocyte 
morphology was hypertrophic, a feature characteristic of a reactive state [163, 233]. 
Astrocyte morphology was normalised when remyelination was complete, 
presenting a morphology similar to that in undemyelinated conditions (Figure 3.1 
and 3.6). Furthermore, in both models of remyelination, there was a significant 
increase in the number of GFAP+ astrocytes during the phases of oligodendrocyte 
differentiation and the onset of remyelination, which returned to normal levels when 
remyelination was completed. I also found that in both models, the majority of 
astrocytes became reactive just after demyelination, indicating early activation of 
astrocytes (Figure 3.2.C and 3.8.C).   
In concordance with my results, GFAP+ astrocytes have been shown to 
accumulate in LPC-demyelinated lesions of the spinal cord [234], and with lesion 
progression in the EAE model [196]. GFAP is the major component of the astrocyte 
cytoskeleton and is important for controlling cell division, migration and signal 
transduction [160]. GFAP upregulation is required to regulate astrocyte function in 
the cuprizone model, and its overexpression reduces oligodendrocyte apoptosis, 
demyelination and axonal damage even during chronic demyelination from long-
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term cuprizone administration [175]. In agreement with this, depletion of GFAP+ 
astrocytes was shown to impair remyelination after injury [72, 235]. In my study, an 
increase in GFAP expression in astrocytes was observed preceding oligodendrocyte 
precursor differentiation and early remyelination in both models, suggesting that 
astrocytes may have essential functions that regulate these processes.  However, 
after various CNS insults, an increase in GFAP expression has also been correlated 
with pathogenesis. For instance, in active and chronic MS plaques, GFAP is found to 
be highly expressed in astrocytes [236, 237]. Therefore, studying astrocyte functions 
in the context of efficient remyelination is crucial to understand their 
contributions during this process to then be able to assess what mechanisms fail in 
pathology.  
Astrocyte activation was confirmed by staining for vimentin 
and nestin (Figure 3.3 and 3.9), with a similar pattern in expression observed for both 
markers. However, a more gradual increase was observed in the LPC model, peaking 
at 14 DPI. In the cuprizone, a moderate increase was observed compared to control, 
peaking at 5 weeks on the cuprizone diet. Increased vimentin expression has been 
previously observed in the cuprizone model at 5 weeks, being less pronounced at 
other time-points [72]. Both of these markers are highly increased in astrocytes 
during the peak clinical stage of EAE, which subsequently decrease during recovery 
phases [238]. 
The small differences I observed in astrocyte responses between the two 
models could be due to differential severity of each model, with the LPC model being 
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acute demyelination in a small focal region. In contrast, the cuprizone model incurs 
a more globalised and continuous demyelination [239]. Differences in vimentin and 
nestin expression have been observed in comparing an acute stroke model to a more 
severe LPS model, even though a similar pattern of GFAP activation was 
observed [161]. Surprisingly, I found vimentin staining to be nuclear in astrocytes.  In 
another report using cuprizone as a model of demyelination, some vimentin+ 
astrocytes were also observed with a rounded shape [240]. Vimentin filaments bind 
to the nuclear lamina regulating nuclear shape, maintaining stiffness and providing 
support [241]. Condensed vimentin filaments around the nucleus could explain this 
round shape observed in both studies. 
To assess the total variation of astrocyte number, I used Sox9, a pan-
astrocytic marker that has been defined to be specific for detecting all astrocytes in 
the adult mouse brain, outside of neurogenic niches [120]. I detected a decrease in 
the total number of astrocytes during active demyelination in both models compared 
to non-demyelinated conditions (Figure 3.2 and 3.7), which could reflect the death 
of astrocytes as a response to injury. Astrocyte numbers were then rapidly recovered 
to reach basal levels. Given that a recent study showed that LPC could be toxic to 
astrocytes at a concentration of 100 μM, LPC could have induced the death of 
astrocytes in my study [242]. However, the same effect of decreased astrocyte 
numbers was observed in the cuprizone model, indicating it could occur independent 
of LPC, and raises the question of whether astrocyte death may be an early protective 
effect in remyelination.  Other models of injury have reported astrocyte death after 
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insult [164, 243], for instance, as a response to spinal cord injury, in which the death 
of astrocytes was mediated by pro-inflammatory microglia and was observed to be 
protective [164]. In this model and the LPC model, pro-inflammatory microglia are 
observed at the time-point in which the drop of astrocytes occurs [244], which may 
contribute to the astrocyte death and would require further study.  
Importantly, although Sox9 has been accepted as a pan-astrocytic marker in 
the adult brain, it should be taken into account that other NSCs expressing this 
marker may be migrating into the lesion to repopulate the area. Hence, the numbers 
of Sox9+ cells could be accounting for progenitor cells within the lesion and not only 
astrocytes. This would emphasize the need of investigating better markers specific 
for astrocytes that could be applied for their quantification. Aldh1l1 would be the 
best marker currently defined [143], however it lacks of good antibodies that can be 
used in mouse tissue and reporter lines have to be used to this end. 
To understand the increase in astrocyte numbers observed in both models I 
assessed astrocyte proliferation. Astrocyte proliferation took place early during 
active demyelination and initial remyelination in both the LPC and cuprizone models. 
This could explain the increase in GFAP+ astrocytes and recovery of Sox9+ cells after 
the initial decrease. Proliferation after demyelination or another CNS insult is a 
characteristic feature of astrocytes [72, 240, 245]. A study in which live imaging was 
performed in a traumatic brain injury model showed that astrocytes had minimal 
migration after lesioning, but rather proliferated to repopulate injured areas  [245].  
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Interestingly, the levels of reactivity and proliferation of reactive astrocytes 
in the cuprizone model did not return to basal levels. This was also observed in a 
previous study in the cuprizone model whereby GFAP+ astrocytes and GFAP+Ki67+ 
astrocytes decreased upon return to a normal diet, but not back to the levels of non-
demyelinated controls [72]. However, this could be explained by a slower recovery 
in this model due to widespread demyelination, in comparison to a small acute 
lesion. Nonetheless, overall, similar changes in astrocyte numbers, reactivity and 
proliferation were observed in both models used. This could due to both models 
inducing acute demyelinating models, where mainly oligodendrocyte damage causes 
demyelination and spontaneous remyelination can efficiently take place. Even 
thought the cuprizone model would has widespread damage over different brain 
areas, the area assessed in the present study (the corpus callosum) was consistent in 
both models and this could explain a similar trend of recovery. Moreover, similar 
patterns of activation have been previously observed in microglia in these two 
models of demyelination [243]. Given that astrocytes and microglia communicate to 
drive remyelination that could also explain the similar results observed in the present 
study. 
 To explore whether the increase in reactive astrocytes was a result of 
increased astrocyte differentiation, I used NFIA as a marker for astrocyte progenitors. 
I observed that NFIA expression showed a gradual increase during remyelination, 
peaking at 14 DPI LPC compared to non-lesioned controls. I noted that this pattern 
was similar to that observed for vimentin and nestin in the LPC model, which could 
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raise the question as to whether GFAP+NFIA+ cells are reactive astrocytes instead of 
astrocytes recently derived from progenitors. Supporting these findings, a recent 
study showed that in a model of stroke, astrocytes had increased levels of NFIA 
expression in damaged grey and white matter [228].  Inhibiting NFIA in astrocytes 
prevented white matter repair in this model [228]. Moreover, NFIA was required to 
produce new reactive astrocytes [228]. NFIA is located on the GFAP promoter before 
the phase of astrocyte differentiation in development, and its inhibition decreases 
GFAP expression and prevents formation of long processes [160]. It could be that 
reactive astrocytes express NFIA, and its expression is required for a change in their 
activation after demyelination. After insult, reactive astrocytes are plastic cells that 
express progenitor markers and characteristics of neural stem cells [246]. Some of 
the basic and most commonly used pan-markers for astrocytes are also expressed by 
radial glia and neural stem cells during development:  Aldh1l1, GLAST, and Glt-1[246]. 
Unlike GFAP, vimentin and nestin are predominantly expressed in the brain during 
development by radial glia, but this shifts when astrocytes are mature [160]. Often 
after injury, reports are not clear as to whether the expression of these markers 
corresponds to astrocytes or progenitor cells [238]. Hence, in the present study, I 
suggest that NFIA is expressed due to a state of reactivity in astrocytes. To confirm 
the origin of NFIA+ cells, lineage tracing of NFIA+ cells would be required.   
In conclusion, in this chapter, I observed that astrocytes present changes in 
activation during remyelination. GFAP was observed to be an early marker of 
activation, and the peak in GFAP+ astrocytes coincided with the timing of 
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oligodendrocyte differentiation and early remyelination. This suggests that astrocyte 
activation coincides with oligodendrocyte lineage cell responses and raises the 
question as to how they might support these processes after demyelination. I then 
aimed to address this question by performing RNA sequencing of astrocytes isolated 













4. CHAPTER: CHARACTERISATION OF ASTROCYTE 
TRANSCRIPTOME DURING REMYELINATION 
4.1. Introduction 
Different methods have been applied to investigate gene expression changes in 
astrocytes to have a better understanding of their roles in the context of pathology. 
RNA sequencing is the gold-standard technique currently used to investigate gene 
expression in an unbiased manner. By these means, astrocytes have been 
investigated in the context of neurodegeneration, where astrocytes lose homeostatic 
functions and upregulate inflammatory functions indicated by complement 
upregulation, engagement of pathways associated with innate immunity and 
synapse dysfunction, and downregulation of cholesterol synthesis [169, 247-249]. 
Different techniques are currently applied to isolate specific cells to extract the 
mRNA and then assess gene expression. These techniques can sort cells using 
antibodies against cell surface-specific markers, coated beads or enzymes that would 
dissociate the tissue, which includes fluorescent activated cell sorting (FACS), 
magnetic-activated cell sorting (MACS) or immunopanning [250, 251]. More recently, 
methods have been developed to tag the ribosome of specific cells and hence isolate 
the actively-translating mRNAs, which includes BAC-TRAP and RiboTag [250]. An 
advantage of these ribosome tagging techniques over other soring approaches is less 
artefact induced by manipulation from long cell purification processes such as cell 
panning, fixation, and cell isolation or the addition of enzymes to dissociate cells from 
specific tissues [251]. In BAC-TRAP and RiboTag methodology, the application of 
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Cycloheximide just after tissue dissection stops translation [252], and then the mRNA 
readout corresponds to the moment soon after the animal is terminated. 
Furthermore, these techniques enable purifying cell-type-specific ribosomes and 
the associated translating mRNA, and hence can avoid contamination of mRNA from 
other cells, for instance, due to phagocytosis [253]. Ribosome tagging methodologies 
allows us to look at the translatome compared to other sorting techniques like 
immunopanning, FACS and MACS, which give information on the transcriptome. 
Hence, TRAP and RiboTag have a more accurate readout of gene expression at a 
specific time, as not all mRNAs are translated due to elements that bind mRNAs to 
block translation [254].  
A limitation of BAC-TRAP is that transgenic lines for each cell line needs to be 
developed, in which EGFP-tagging of the ribosomal subunit RPL10 is under the 
control of a specific promoter [220]. For this reason, new techniques aiming at 
isolating the ribosome and the translating mRNAs like RiboTag have been developed 
[255]. The advantage of RiboTag versus BAC-TRAP is that one can use cell-type-
specific Cre-LoxP recombinase lines that are crossed to the RiboTag lines, where the 
RPL22 ribosome subunit is tagged with hemagglutinin (HA) [250, 255]. Moreover, 
ribosome expression and their ability of translation is heterogenic, where RPL22 
ribosome expression is more consistent than RLP10 [256]. Nonetheless, mRNA 
sequencing should be considered for hypothesis generation, as neither of these 
methodologies control for transcription efficiency and thus lacks information on the 




4.2.1. Astrocyte mRNA isolated using TRAP for RNA-sequencing 
To characterise astrocyte functions at the molecular level during remyelination, I 
purified the translating mRNAs from astrocytes at key time-points in the focal 
remyelination model (3, 7 and 10 DPI LPC), by using TRAP methodology. To do so, I 
performed LPC-induced demyelination of the corpus callosum of an Aldh1l1-
eGFP/Rpl10a reporter line (ASRIBO line) (Figure 4.1. A), in which astrocytes 
specifically express a molecule of enhanced GFP (eGFP) on the L10a large ribosomal 
subunit. Hence, this technique enables purifying only the mRNAs that are actively 
being translated to protein by using magnetic beads that have been coated with anti-
eGFP antibodies (Figure 4.1. B). This methodology successfully enabled me to obtain 
an enrichment of astrocytic genes (Aldh1l1, Gfap) (represented in figure 4.1. C by an 
increased log2 fold change), over genes enriched in other cell types like neurons 
(Eno), and oligodendrocytes (Mbp), when comparing to an input sample, which is 
collected before the immunoprecipitation step and has mRNA from all cell types. To 
perform RNA sequencing, I determined the RNA integrity (RIN) score within a scale 
of 1 (degraded RNA) to 10 (highest RNA integrity), and found my samples to have an 




Figure 4.1. Enrichment of astrocyte genes after TRAP and RNA integrity score for RNA 
sequencing. A. Schematic representation of the corpus callosum section dissected (blue 
box) for TRAP after LPC-induced demyelination in the Aldh1l1-EGFP/Rpl10a mice. B. 
Representation of the ribosome purification of Aldh1l1+ astrocytes by using a magnetic 
bead coated with anti-eGFP antibodies. C. Astrocytic gene (Aldh1l1, Gfap) enrichment in 
TRAP-isolated samples, compared to genes associated with neurons (Eno) and 





4.2.2. Cluster analysis reveals 6 main cluster of genes during 
remyelination 
Cambridge Genomics performed RNA-sequencing for ultra-low input RNA-
sequencing. Bioinformatics was performed by Dr Owen Dando (Prof Hardingham’s 
Lab, University of Edinburgh), where alignment to the mouse genome was performed 
with STAR RNA-seq aligner, quality control by FastQC and gene expression analysis 
by DESeq2 package for R (see methods section 2.11). To assess whether there were 
differences in the global expression of genes in astrocytes after demyelination, I 
performed an unbiased cluster analysis of the top 5000 most highly expressed genes 
in the control (no demyelination) using Graphia Professional software (KAJEKA), and 
compared their expression in astrocytes during remyelination (at 3, 7, and 10 DPI 
LPC). This type of analysis creates a graph structured according to the correlation of 
gene expression, in which nodes represent genes, and edges (lines) join nodes 
according to their similarity in gene expression [257]. In other words, genes that have 
similar patterns of expression are clustered together, which allows visualisation of 
gene expression on a global scale. By using this tool and collapsing nodes by MCL 
cluster (inflation 2.0) (see methods section 2.13), I observed that genes were split 
across 6 main clusters whose expression was differentially regulated during 
remyelination (figure 4.2.A). Cluster 1 included 1719 genes mostly upregulated in 
control and recovered at 7 DPI. Genes included in cluster 1 were associated with 
neuronal functions like synaptic regulation, energy functions like glycolysis and 
gluconeogenesis, and growth factor and cytokine receptor expression. Cluster 2 
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included 1673 genes whose expression peaked at 3 and 10 DPI. Genes included in 
cluster 2 indicated functions associated with oxidative stress and development. 
Interestingly, clusters 3 (520 genes), 4 (541 genes) and 5 (332 genes) 
represented genes that were most highly upregulated during remyelination, in which 
the genes were most highly expressed at 3, 7 and 10 DPI, respectively. Cluster 3 
represented genes associated with oxidative stress, apoptosis and migration. Cluster 
4 contained genes associated with metabolic processes, cholesterol biosynthesis and 
intracellular processes (changes in structure and function taking place inside the cell, 
including intracellular organelles). Cluster 5 presented genes associated with 
regulation of cell cycle and nuclear functions. Lastly, cluster 6 consisted of the smaller 
cluster with 215 genes whose expression was more pronounced in the control and at 
10 DPI (figure 4.2.B), and consisted of genes associated with mRNA metabolic 






Figure 4.2. Cluster analysis shows global regulation of genes and functional relationship of 
top 5000 expressed genes in control. Cluster analysis performed using Graphia Professional 
(KAJEKA) in 3D layout, showing difference in gene expression patterns in astrocytes during 
remyelination versus the top 5000 highly expressed genes in control, using 0.8 Pearson 
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correlation threshold and MCL cluster (inflation value 2.0). A. Each node (sphere) represents 
a gene, connected by edges (lines) according to similarity in the pattern of individual gene 
expression. A total of 6 clusters containing ≥4 nodes are represented. B. The graph 
presenting the change in expression profile for the different clusters is represented, where 
X are the different time-points, including CT (non-lesion), 3, 7, and 10 DPI and Y is the mean 
centred FPKM. 
 
4.2.3. Top significantly changed genes of astrocytes during 
remyelination 
I then explored in greater detail the genes that were significantly upregulated 
and downregulated relative to control during remyelination (at 3, 7 and 10 DPI). I 
observed that different genes were significantly upregulated and downregulated at 
each time-point (using a cut-off of 1.3-fold and adjusted p-value ≤0.05) (Figure 4.3). 
Using this threshold, 673 genes were found to be significantly upregulated, and 1380 
downregulated at 3DPI, 374 were significantly upregulated and 626 downregulated 
at 7DPI, and 833 genes were significantly upregulated and 916 downregulated at 
10DPI (Figure 3.A-C). The top 25 significantly upregulated genes at each time point 
included Timp1, S1pr3, Lgals1 and Lgals3 at 3 DPI, Hmgcs2 at 7 DPI, and Lgals3 and 
S100a11 at 10 DPI, all of which have been reported to be implicated in remyelination 
(Figure 4.3.D-F) [258-263]. The top 25 significantly downregulated genes at each time 
point included genes like Sema3a at 3DPI, which has been associated with 






Figure 4.3. Significantly upregulated and downregulated genes in astrocytes during 
remyelination. A-B. Volcano plots constructed using the adjusted P-values plotted against 
the Log2 fold-change (log10 scale) of 3 DPI (A), 7 DPI (B), and 10 DPI (C) groups compared to 
the control. The cut-off used to represent the significantly up, and downregulated genes 
consisted of a 1.3-fold change and adjusted p-value of <0.05.  D-F. Heat map showing the top 
25 significantly up and downregulated genes at 3 DPI (D), 7 DPI (E), and 10 DPI (F) groups 
compared to the control. 
 
4.2.3.1. Changes in GO terms of significantly upregulated genes 
during remyelination vs control 
The above results show that astrocytes have different gene expression at 
distinct phases of remyelination. To determine whether this was associated with 
differing functions I performed pathway analysis to explore gene ontology and 
pathway networks using the top 200 significantly upregulated genes at each time 
point. I used ClueGO (Cytoscape), where grouping was based on highest significance, 
using GO-term fusion (see methods section 2.12). Astrocytes presented different 
profiles at the different time-points investigated. At 3 DPI, upregulated genes were 
associated with functions indicative of repair (wound healing involved in 
inflammatory response, and regulation of establishment of endothelial barrier) and 
apoptosis (regulation of extrinsic apoptotic signalling pathway via death domain 
receptor) (Figure 4.4.A); the latter is consistent with the reduced astrocyte numbers 
observed at 3 DPI (Figure 3.2). At 7 DPI, astrocytes upregulated genes associated with 
pathways supportive of remyelination like cholesterol processes (cholesterol 
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metabolism, and cholesterol homeostasis), and increase in glial and neural cells 
(stem cell differentiation, glial cell migration, and regulation of neural precursor cell 
proliferation) (Figure 4.4.B). At 10 DPI, astrocytes had a transcriptional profile 
indicative of inflammatory responses (innate immune response) and repair (wound 







Figure 4.4. Astrocytes present different pathway profiles at 3, 7 and 10 days after LPC-induced demyelination. Pie chart constructed with 
clueGO (Cytoscape) showing the enriched pathways of the most significantly upregulated genes (2-fold change and adjusted p-value of 0.05) 
at 3DPI LPC (A), 7DPI LPC (B), and 10DPI LPC (C).   GO terms are grouped using functional grouping (% of genes in each GO group) and based on 
highest significance. Each term is defined with a minimum of 3 genes. 
 
 




4.2.4. Astrocyte gene expression indicates a change in their 
phenotype during remyelination 
These results show that astrocytes present supportive functions for repair at all 
the time-points explored, with an inflammatory molecular signature at 10 DPI. 
Previous work classified astrocytes into phenotypes based on damaging properties 
(termed A1) and reparative function (termed A2). These were determined using 
injection of LPS, which was associated with upregulation of inflammatory genes, and 
an ischemic stroke model (middle cerebral artery occlusion (MCAO)), which 
upregulated neurotrophic and antioxidant genes [161]. I thus investigated the 
expression of these A1- and A2-associated genes in astrocytes at 3 DPI, 7 DPI or 10 
DPI in comparison to control (using a cut-off of ≥0.5fpkm). The criteria for genes 
analysed were 1) the top 50 upregulated genes uniquely expressed in MCAO or the 
LPS model, or 2) genes that were increased more than 4-fold in the MCAO or the LPS 
model.  
I observed a trend at 3 DPI in the upregulation of genes associated with the 
A2 phenotype (p-value = 0.0523 when using the top 50 gens in the MCAO, and p-
value = 0.0026 when using genes upregulated ≥4FC in the MCAO) (Figure 4.6). A2 
genes were found within the most significantly upregulated genes at 3 DPI (Figure 
4.6.C). When this analysis was performed using genes for A1 phenotype at 3 DPI, no 
significance was observed (Figure 4.5). At 10 DPI, astrocytes showed significant 
expression of A1-associated genes (p-value = 0.0495 when using the top 50 gens in 
the LPS model, and p-value = 0.0966 when using genes upregulated ≥4 fold-changes 




(FC) in the LPS model) (Figure 4.7), and no significance was observed when assessing 
A2-associated genes (Figure 4.8). A1 genes were found within the most significantly 
upregulated genes at 10 DPI (Figure 4.7.C). No A1 or A2 phenotype was observed at 
7 DPI using these sets of genes. 
 
Figure 4.5. Astrocytes do not present a pro-inflammatory phenotype at 3 days post-LPC 
demyelination. Differential gene expression analysis between the 3 DPI LPC group compared 
to the control using the top 50 genes that are only upregulated after LPS (A) or the genes 




that were > 4-fold increased after LPS (B) in Zamanian et al. 2012 [161]. Genes expressing 
>0.5 FPKM in the 3 DPI LPC and control group were included in the analysis. The represented 
p-value was calculated using a paired t-test between the average FPKM of the 3 DPI LPC vs 
control. 





Figure 4.6. Astrocytes present an A2 phenotype at 3 days post-LPC demyelination. 
Differential gene expression analysis between the 3 DPI LPC group compared to the control 
using the top 50 genes only upregulated after MCAO (A) or the genes that were > 4-fold 




increased after MCAO (B) in Zamanian et al 2012 [161]. Genes expressed at >0.5 FPKM in the 
3 DPI LPC and control group were included in the analysis. The represented p-value was 
calculated using a paired t-test between the average FPKM of the 3 DPI LPC vs control. C. 
Expression of genes (FPKM) in astrocytes after 3 DPI LPC is plotted against the expression of 
genes in control astrocytes. Genes expressed >0.5FPKM and significantly changed (p-value 
<0.05) by 2-fold are represented in red, and the top 5 from the 50 most upregulated genes 
after MCAO in Zamainan et al. 2012 [161] are indicated on the plot.  





Figure 4.7. Astrocytes present an A1 phenotype at 10 days post-LPC demyelination. 
Differential gene expression analysis between the 10 DPI LPC group compared to the control 
using the top 50 genes only upregulated after LPS (A) or the genes that were > 4-fold 
increased after LPS (B) in Zamanian et al. 2012 [161]. Genes expressed >0.5 FPKM in the 10 




DPI LPC and control group were included in the analysis. The represented p-value was 
calculated using a paired t-test between the average FPKM of the 10 DPI LPC vs control. C. 
Expression of genes (FPKM) in astrocytes after 10 DPI LPC is plotted against the expression 
of genes in control astrocytes. Genes expressed >0.5FPKM. Genes significantly changed (p-
value <0.05) by 2-fold are represented in red, and the top 5 from the 50 most upregulated 
genes after LPS in Zamainan et al. 2012 [161] are indicated on the plot.  
 
Figure 4.8. Astrocytes do not present an A2 phenotype at 10 days post-LPC demyelination. 
Differential gene expression analysis between the 10 DPI LPC group compared to the control 
using the top 50 genes only upregulated after MCAO (A) or the genes that were > 4-fold 
increased after MCAO (B) in Zamanian et al. 2012 [161]. Genes expressed >0.5 FPKM in the 




10 DPI LPC and control group were4 included in the analysis. The represented p-value was 
calculated using a paired t-test between the average FPKM of the 10 DPI LPC vs control.  
 
4.2.5. Nrf2 signalling is increased in astrocytes early after LPC-
demyelination 
To explore astrocyte functions in further detail, IPA analysis was performed. At 
3 DPI, Nrf2-mediated oxidative stress response (p-value=1.18E-08) was a top 
upregulated pathway (Figure 4.9). The Nrf2 pathway is of relevance due to its 
neuroprotective role after degeneration and demyelination [92, 218]. Nrf2 is a 
transcription factor mediating antioxidant responses by promoting the transcription 
of antioxidant and detoxification regulators (Figure 4.9.A) [265]. Furthermore, it is 
involved in other cellular mechanisms like autophagy, stem cell quiescence and 
intermediary metabolism [265].Nrf2 is bound to Kelch-like ECH-associated protein 1 
(Keap1), which is a redox-sensitive E3 ubiquitin ligase substrate adaptor and acts as 
its negative regulator [265]. In physiological situations, Keap1 targets Nrf2 for 
ubiquitin degradation [266]. In response to insult, Nrf2 is oxidised and inactivates 
Keap1, and then translocates to the nucleus and promotes transcription of 
antioxidant and detoxification enzymes, including the heme oxidase 1 (Hmox1), 
catalase (cat), NAD(P)H dehydrogenase (quinone) (Nqo1), cystine/glutamate 
antiporter xCT (Slc7a11), sulfiredoxin 1 (Srxn1), glutamate-cysteine ligase catalytic 
subunit (Gclc), and oxidative stress-induced growth inhibitor 1 (Osgin1) (Figure 4.9.A) 
[266]. By comparing the fold change in expression of these Nrf2-target genes 




between the control and the different time-points (3, 7 and 10 DPI), I found that Nrf2 
signalling was significantly enriched at 3 DPI LPC compared to the control, whereas 
this was no longer significant at other time points (Figure 4.9.C-D). To validate this 
finding, Nrf2 activation was assessed at the protein level by co-staining GFAP+ 
astrocytes with Hmox1. Compared to undemyelinated control and sham-control, a 
significant increase in GFAP+ Hmox1+ cells was observed at 3 DPI, which 
subsequently decreased at 7 DPI and was maintained at this level at 10 DPI (Figure 
4.9. E-F). Interestingly, when Nrf2 targets were searched within the different clusters 
from the cluster analysis above (Figure 4.2), genes like Hmox2 and Srxn1 were found 
in cluster 3, and Nqo1 in cluster 2.  
 





Figure 4.9. Astrocytes significantly upregulate genes of the Nrf2 pathway at 3 days post-
LPC-induced demyelination. A. Schematic representation of the Nrf2-pathway, wherein 
homeostasis Nrf2 is bound to Keap1, and after insult (e.g. oxidative stress) Nrf2 is cleaved 




from Keap1 and translocates to the nucleus promoting the transcription of antioxidant 
genes. B. The Nrf2 pathway was found to be upregulated at 3DPI LPC in astrocytes C. 
Heatmap of Nrf2-target genes expressed by astrocytes. Significance between groups was 
measured using a paired t-test between the control versus the remyelinating time-points. 
Asterisks in genes represent significance in a sample compared to the control by DESeq2 
analysis (*p<0.05, **p<0.01, *** p<0.001). D. Plot showing the FPKM values of Nrf2-target 
genes. E. Representative images of GFAP+ astrocytes (green) co-stained with Nrf2-target 
Hmox1 (magenta) within the lesioned side in the corpus callosum. Scale bar; 25μm. F. 
Quantification of Hmox1+GFAP+ astrocytes at the different time-points investigated. 
Significance was determined by using a two-way ANOVA (condition (LPC vs sham) and time) 
with Tukey´s multiple comparisons test. Error bars indicate s.e.m. of the number (n) of 
animals. n=3 animals.*P<0.05.  
 
4.2.6. Cholesterol biosynthesis signalling is increased in 
astrocytes during oligodendrocyte differentiation  
At 7 DPI, IPA analysis showed upregulation of the cholesterol biosynthesis 
pathway (p-value=1.18E-08). Cholesterol is the major lipid component of myelin 
[267]. Whereas oligodendrocytes mainly produce it in development, it is primarily 
produced by astrocytes during adulthood [136, 268, 269]. Cholesterol biosynthesis is 
indispensable for oligodendrocyte differentiation and myelin formation [270, 271]. 
Astrocytes contribute to cholesterol production, which is then transferred to 
oligodendrocytes during myelination [136]. Cholesterol synthesis in the brain starts 
by the transformation of acetyl-CoA by the HMG-CoA-synthase-1 (Hmgcs1) to 3-




hydroxy-3-methylglutaryl-CoA (HMG-CoA), which is then transformed into 
mevalonate by the rate-limiting enzyme HMG-CoA-reductase (Hmgcr) [170, 268, 
269]. Downstream, farnesyl pyrophosphate synthase (Fdps) promotes lanosterol 
synthesis [272]. In astrocytes, final conversion of cholesterol occurs via the Bloch 
pathway in which desmosterol is transformed by lanosterol-converting enzymes 24-
dehydrocholesterol reductase (Dhcr24) (Figure 4.10.A)[269]. Here, I observed that 
the cholesterol biosynthesis signalling pathway was significantly upregulated at 7 DPI 
in astrocytes compared to control, as observed by the increase in expression of 
enzymes within this cascade selectively at this time point (Figure 4.10.B-C). 
Furthermore, I compared the expression of the astrocyte data set in the present 
study with the one obtained in a chronic EAE model by Itoh and colleagues (2018) 
[169]. In this study, the mRNA of GFAP+ astrocytes was isolated by RiboTag 
purification, and they observed that in the chronic phase of this EAE model (where 
continuous neurodegeneration and lack of recovery is observed), there was a marked 
decrease in expression of the cholesterol pathway genes compared to the expression 
observed in astrocytes during remyelination in the present study  (Figure 
4.10.B)[169]. I then validated the activation of this pathway at the protein level by 
co-staining GFAP+ astrocytes for enzymes involved in the cholesterol biosynthesis 
pathway: Hmgcs1 and Fdps. I observed a significant increase of GFAP co-localization 
with Hmgcs1+ or Fdps (measured by particles) at 7 DPI LPC, but not less so in the 
other time-points examined (Figure 4.11). Furthermore, targets of cholesterol 
biosynthesis were explored within the cluster analysis, Hmgcs1, Mvk, Mvd, were 
found within cluster 4 and Sqle and Acat2 in cluster1.  




Figure 4.10. Astrocytes significantly upregulate genes of the cholesterol biosynthesis 
pathway at 7 days post-LPC-induced demyelination. A. Schematic representation of the 
cholesterol biosynthesis pathway, in bold are represented the enzymes converting the 
cholesterol intermediate (in blue cycle). B. Heatmap of cholesterol pathway genes expressed 




by astrocytes. Gfap and Vim are pan-reactive genes included as a control. Significance 
between groups was measured using a paired t-test of the FPKM values between the control 
versus the different conditions (PBS and LPC). Asterisks in genes represent significance in a 
sample compared to the control by DESeq2 analysis (*p<0.05, **p<0.01, *** p<0.001). Data 
set from this study is compared to astrocytes from spinal cord (sc) astrocytes in EAE, from 
Itoh et al 2018 C. Plots showing the FPKM values of samples genes in the cholesterol 
biosynthesis pathway.  
 









Figure 4.11. Components of the cholesterol biosynthesis pathway are significantly 
upregulated in astrocytes at 7 days post-LPC-induced demyelination. A. The cholesterol 
biosynthesis pathway was found to be upregulated at 7DPI LPC in astrocytes. B. 
Representative images of GFAP+ astrocytes (yellow) co-stained with Hmgcs1 (magenta). 
Scale bar; 100 μm. White box shows a magnification of a Hmgcs1+ GFAP+ astrocyte, Scale 
bar; 50μm.  C-D. Quantification of Hmgcs1+ GFAP+ astrocytes (C) and Fdps+ GFAP+ 
astrocytes (D) at the different time-points investigated. Each particle represents a cell per 
mm2. Significance was determined by using a two-way ANOVA (condition (LPC vs sham) and 
time) with Tukey´s multiple comparisons test. Error bars indicate s.e.m. of the number (n) of 













The role of astrocytes after demyelination has been controversial. In chronic 
situations such as in MS, they seem to adopt detrimental functions that exacerbate 
damage preventing repair [212, 213]. Studying astrocytes in a model where efficient 
remyelination takes place spontaneously is ideal to have a better understanding of 
their regenerative functions. In this chapter of the present study, the gene expression 
of astrocytes has been characterised at key time-points during remyelination. To do 
so, TRAP-seq has been performed, which indicated that astrocytes dynamically 
change their functions during remyelination, presenting a neuroprotective 
phenotype early after demyelination (3 DPI) characterised by the upregulation of the 
Nrf2 pathway, and moving towards a pro-inflammatory profile at the onset of 
remyelination (10 DPI). At the time of oligodendrocyte differentiation (7 DPI), 
enrichment in the cholesterol biosynthesis pathway was observed, suggested to 
contribute to remyelination. These results would suggest that after an acute 
demyelinating insult, astrocytes adopt supportive and protective roles to assist 
remyelination.  
To investigate the overall gene regulation in astrocytes in remyelination, cluster 
analysis was performed looking at the 5000 most enriched genes in the control and 
observing how they changed in remyelination (Figure 4.2). By doing this analysis, I 
observed that 6 different clusters were present, from which cluster 3, 4 and 5 
included genes that were mostly upregulated at 3, 7 and 10 DPI, respectively (Figure 
4.2.B). When looking closely at the most significantly changed genes at these time-




points, different genes were observed to be significantly upregulated or 
downregulated (Figure 4.3). At 3 DPI, Timp1, S1pr3, Lgals1 and Lgals3 were within 
the top 25 most significantly upregulated genes. Timp1 is a  gene that encodes for 
the extracellular protein TIMP-1, which is required for growth factor activation and 
is a negative regulator of matrix metalloproteinases (MMPs), which together regulate 
the extracellular matrix (ECM) and BBB integrity [258]. TIMP1 expression in 
astrocytes confers neuroprotective functions [273], and studies have shown that 
astrocytic TIMP-1 is important for remyelination in EAE and myelination in 
development [227, 259, 260].  
Lgals1 and Lgals3, which encode for the lectins, galactosidase-binding, soluble 
(galectin)-1 and-3, were also significantly upregulated at 3 DPI, and Lgals3 was found 
to be still significantly upregulated at 10 DPI. Galectins have been studied due to their 
positive effects after demyelination. Lack of galectin-3 impairs spontaneous 
remyelination in the cuprizone model [261]. Furthermore, galectin-1 treatment after 
LPC-induced demyelination prevents myelin degeneration and polarises microglia to 
a pro-regenerative phenotype [262]. Nonetheless, after stab-wound injury, galectin-
1 and -3 are upregulated in a subset of reactive astrocytes and their expression is 
important for regulating astrocyte proliferation and reactivity (assessed by GFAP 
levels), where all dividing astrocytes express galectin-3 [274]. This could suggest that 
galectins are important regulators of astrocyte proliferation and increase astrocyte 
activation state in response to demyelination. However, galectin expression could be 
required to prevent further damage and promote repair, as its upregulation was 




maintained at the onset of remyelination. S1pr3, which encodes for the 
sphingosine1-phosphate (S1P) receptor subtype 3 (S1P3), was also significantly 
upregulated in astrocytes at 3 DPI, but not at the other time-points. S1P3 is primarily 
expressed by astrocytes in inflammation and is important for astrocyte proliferation, 
migration, and production of neurotrophic factors and neuroprotective chemokines 
[275-277]. S1P3 expression in astrocytes has been observed in MS in actively 
demyelinating lesions, chronic inactive plaques and their borders [277]. The S1P 
modulator fingolimod (FTY720), currently applied for RRMS [278], induces 
neurotrophic mediators and decreases production of toxic factors by astrocytes, 
which ameliorates EAE pathogenesis [279, 280]. Importantly, in the present study, 
the expression of S1P3 was transiently expressed at 3 DPI, which would be opposite 
to what occurs in the context of MS. This could suggest that a controlled regulation 
of astrocyte functions is required to prevent damage and induce repair. At 7 DPI, 
Hmgcs2 was significantly upregulated, which is the rate-limiting enzyme of the fatty 
acid β-oxidation pathway in mitochondria [281], and β-oxidation of fatty acids in 
astrocytes is required for myelin maintenance [263]. Furthermore, Cxcl5 and 
S100a11 were significantly enriched at 10 DPI. CXCL5 is a cytokine with chemotactic 
properties. After myelin phagocytosis in different human demyelinating CNS 
diseases, astrocytes release CXCL5 which has been suggested to recruit immune cells 
[192]. CXCL5 is produced by reactive spinal cord astrocytes after the application of 
IL1β where a neuroprotective phenotype is described due to the upregulation of 
genes important for axon regeneration [282]. In contrast to the upregulation of these 
beneficial factors, Sema3a, which has chemorepellent properties for OPCs after 




demyelination, was downregulated at 3DPI [20]. The upregulation and 
downregulation of these factors suggest that astrocytes may have protective and 
regenerative functions rather than detrimental roles during remyelination. 
To further assess the specific functions of astrocytes in remyelination, GO terms 
were investigated. This analysis suggested that astrocytes have specific functions at 
the different time-points studied (Figure 4.4). Firstly, at 3 DPI, GO terms indicated 
astrocyte death due to apoptosis which is consistent with my findings of a reduction 
in the total number of astrocytes (Sox9+ cells) at this time (Figure 
3.2). Furthermore, astrocytes upregulated genes that indicated wound healing and 
reestablishment of the endothelial barrier. Astrocyte end-feet surround the 
endothelial cells that form the BBB and are essential for its formation and 
maintenance, and to control the entrance of cells and nutrients [283, 284]. LPC-
induced demyelination compromises BBB integrity, which can exacerbate 
damage due to the infiltration of peripheral immune cells and lack of clearance of 
toxic products [171, 285].  Astrocytes have the ability to rapidly restore their end-
feet on the BBB after ablation [286]. After stab wound injury, astrocyte activation has 
been suggested to mediate BBB recovery [287]. In the present study, early astrocyte 
functions could support BBB repair to prevent further damage and prepare the 
environment for remyelination. Next, GO terms revealed that at 7 DPI astrocytes 
upregulated genes suggestive of precursor cell proliferation, stem cell 
differentiation, and glial migration, which could indicate the positive impact of 
astrocytes on other cells like neurons, oligodendrocyte precursors and microglia at 




the time of oligodendrocyte differentiation and onset of remyelination. As discussed 
in earlier sections, astrocytes can secrete factors that induce oligodendrocyte 
differentiation (reviewed in Molina-González et al. 2019). Astrocytes can also 
mediate the attraction of other cells like microglia so that remyelination can take 
place [72]. Lastly, GO term analysis at 10 DPI revealed functions suggestive of an 
immune response and inflammation. As described in previous chapters, astrocytes 
can adopt immune functions after demyelination, where they play crucial roles in 
mediating peripheral immune cell extravasation through the BBB and their 
activation, and also attract innate immune cells to the demyelinating areas. 
After characterising astrocyte transcriptomes and observing that they were 
adopting regenerative and inflammatory profiles, I questioned whether this was 
reflected in the A1 and A2 phenotypes previously described. In an attempt to simplify 
astrocyte phenotypes, Zamanian et al. (2012) described the astrocytic gene 
expression pattern in a stroke model as a neuroprotective phenotype. In contrast, a 
neuroinflammatory model from LPS injection represented an inflammatory and 
detrimental phenotype [161]. Supporting the repair functions observed at 3 DPI in 
the GO terms, astrocytes presented a phenotype that closely resembled 
a neuroprotective phenotype (A2) described by Zamanian and colleagues (2012). GO 
terms at 10 DPI demonstrated that later, astrocytes presented a gene expression 
profile indicative of an A1 phenotype. However, not all A2 or A1-associated genes 
were regulated in the same way at both 3 and 10 DPI. Indeed, this simplification of 
A1 and A2 astrocyte phenotypes has failed to be represented in other models of 




injury, where often mixed phenotypes are present [196, 249]. Whereas A1 astrocytes 
were first described as upregulating genes for inflammatory cytokines and 
immune function, and production of neurotoxic factors that induce neuronal 
death [162], other studies have shown opposite effects in which prevention of 
inflammatory astrocyte activation worsens pathology [288]. Indeed, in the present 
study, remyelination happens successfully even though there is the apparition of an 
inflammatory astrocyte phenotype at the onset of remyelination. A limitation that 
could be argued in the study of Zamanian and colleagues (2012) is that the gene 
expression that is associated with astrocyte phenotypes in these two different 
models was only studied at a specific and early time-point after insult (1 day after the 
insult). In both models, this pattern of gene expression could have shifted at later 
times, as astrocytes may play different roles according to the state of the injury. In 
other words, the gene expression from the MCAO model could 
have initially represented a neuroprotective phenotype due to the need for resolving 
the oxidative stress produced by dying cells, and the need for neurotrophic factors 
to promote the proliferation of other cells; however, this scenario could be 
changed at a later time-point due to the infiltration of immune cells that could 
alter astrocyte phenotype [289, 290]. 
An interesting feature of the A2 phenotype is the upregulation 
of genes suggestive of functions in response to oxidative 
stress like Hmox1 and Srxn1 which form part of the Nrf2 pathway (Figure 4.5), a 
cascade that was found to be significantly upregulated at 3 DPI in the present 




study.   Interestingly, when Nrf2 targets were searched within the different clusters 
from the cluster analysis above (Figure 4.2), genes like Hmox2 and Srxn1 were found 
in cluster 3, and Nqo1 in cluster 2. Oxidative stress is a common hallmark in the 
pathogenesis of different neurodegenerative disorders in which the death of cells 
and the continuous inflammation caused by microglia/macrophages leads into the 
accumulation of reactive oxygen and nitrogen species (ROS and RNS) [201]. The 
increase in oxidative stress induces the activation of Nrf2 signalling [291]. Nrf2 is a 
member of the Cap’n’Colar (CNC)/basic-leucine zipper subfamily of redox-sensitive 
transcription factors [265]. CNC has a subunit, the Nrf2-ECH homology 1 (Neh1), 
which is essential for the binging to its negative partner Keap1. Neh1 also enables 
Nrf2 to form a heterodimer with the small musculoaponeurotic fibrosarcoma (sMaf) 
protein, which allows binding to the antioxidant response element promoter region 
(ARE) [265] [292]. Hence, this promotes the transcription of Phase II detoxification 
(NADPH, Nqo1, Glutathione peroxidase, ferritin, Hmox1) and antioxidant enzymes 
which neutralise ROS and RNS, clear xenobiotic (external substances, which are 
generally toxic) species and reduce inflammation [200]. Astrocytes have been 
suggested as a main cell which activates Nrf2 after insult, and activation of this 
pathway has been thought to have neuroprotective functions[201]. For instance, 
specific overexpression of Nrf2 in GFAP+ astrocytes in a mouse model of amyotrophic 
lateral sclerosis (ALS), an early-onset form of motor neuron disease, led to delayed 
disease onset and extended survival [201], demonstrating that Nrf2 is efficient at 
decreasing neural degeneration. In another study, demyelination after 3 weeks of 
cuprizone diet, which induces demyelination and gliosis, was assessed in mice in 




which GFAP+ astrocytes were deficient for Keap1, leading to hyperactivation of the 
Nrf2 cascade [92]. Continuous Nrf2 activation in astrocytes prevented demyelination 
by reducing oligodendrocyte loss, axonal damage and microglia activation [92]. 
However, Nrf2 hyperactivation effects were not shown during remyelination, nor 
was demyelination assessed at the ultrastructural level. Importantly, a mechanism of 
action of DMF is thought to be through the activation of Nrf2, where astrocytes have 
been described as the primary cells expressing Nrf2 in patients with MS and psoriasis 
[88]. In the present study, early activation of Nrf2 signalling at 3 DPI could suggest 
that astrocytes have protective functions to initiate repair, by resolving oxidative 
damage and reducing inflammation caused by the demyelinating insults. 
At 7 DPI, GO terms indicated upregulation of cholesterol metabolism and 
homeostatic functions. Moreover, IPA analysis found this pathway to be significantly 
engaged at 7 DPI. Interestingly, and supporting these results, components of the 
cholesterol pathway were distributed within the clusters 1 and 4, characterised by a 
peak at 7 DPI. Astrocytes are the primary producers of different lipid species such as 
cholesterols in the adult brain due to lipid molecules being unable to cross the BBB 
[170, 269, 293]. Cholesterol is an essential and significant component of myelin [293-
295]. Astrocytes actively transfer cholesterols to neurons through the cholesterol 
transporter, apolipoprotein E (APOE). Although it has never been 
directly addressed, studies suggest that astrocytic lipid production is essential for 
myelination [136]. Cholesterol biosynthesis is also decreased in models where 
deficient remyelination fails, such as in EAE and ageing [169, 248]. Promoting 




cholesterol transfer has been shown to promote remyelination in aged mice [296] 
and dampen EAE clinical course [169]. Moreover, dietary cholesterol in different 
models of demyelination promotes remyelination [171]. In the present study, 
cholesterol upregulation was observed at the time of oligodendrocyte differentiation 
and remyelination, which suggests that astrocytic cholesterol production, might lead 
to transfer to the oligodendrocyte for myelin membrane formation. 
The different functions observed at the different time-points could be regulated 
by distinct types of astrocytes which are more abundant at each of the time-points. 
In this study, the different astrocyte populations could be described mainly as 
antioxidant (protective) at 3 DPI, a metabolically supportive population at 7 DPI and 
inflammatory at 10 DPI. Wheeler et al. (2020) recently discovered that in EAE there 
was the presence of different astrocyte clusters, from which the most expanded 
astrocyte population was characterised by an increase in inflammatory pathways and 
decreased Nrf2 signalling [297]. Future scRNA-sequencing could define whether the 
different astrocyte phenotype observed in the present study really represent 
different populations, and this could be compared with the populations observed in 
the EAE model, other injury models and MS tissue. 
In summary, in the present chapter, I conducted a transcriptomic analysis of 
astrocytes during remyelination which suggested that astrocytes play different roles 
at the different time-points of the regenerative process. Initially, astrocytes may 
mediate neuroprotective functions through the upregulation of Nrf2 signalling. 
During oligodendrocyte differentiation, astrocytes may upregulate the cholesterol 




cascade to feed oligodendrocytes so that they can form new myelin sheaths. Lastly, 
at 10 DPI, astrocytes upregulate inflammatory functions possibly to attract other cells 
like microglia and macrophages so that they can release factors that can further 
influence oligodendrocyte beneficial responses. Importantly, I observed that 
upregulation of these functions was time-regulated. Results shows that the Nrf2 
pathway is downregulated when cholesterol biosynthesis signalling is activated. 
Previous studies have shown that Nrf2 could be a negative regulator of lipid 
metabolism in the liver [298-302]. In the next section, I tested the role of Nrf2 














5. CHAPTER: SUSTAINED NRF2 ACTIVATION IN ASTROCYTES 
IMPAIRS REMYELINATION 
5.1. Introduction 
In the previous chapter, I observed that during remyelination, astrocytes activate 
Nrf2 signalling early and transiently after demyelination, and following its 
downregulation, the cholesterol biosynthesis pathway is activated.  
Previous studies carried out in the liver have shown a link between Nrf2 and 
metabolism of fatty acids, where cholesterol synthesis is negatively regulated by the 
Nrf2 cascade [298-300, 302-306]. A proposed mechanism is that Nrf2 could affect 
cholesterol synthesis by decreasing acetyl-CoA production, the initial and 
fundamental factor for cholesterol synthesis [298, 304]. Proteomics of wild-type and 
Nrf2 null mouse livers revealed that 7 of the 10 most significantly changed pathways 
in the knockouts corresponded to lipid homeostasis, which were increased in the 
Nrf2 null mice. In this study, one of the proteins that was most significantly increased 
in the Nrf2 null mice was ATP-citrate synthase, which has a crucial role in the 
formation of Acetyl CoA [307] in the presence of ATP and Coenzyme A [298].  
Other studies have explored the effect of Nrf2-signalling on lipid production in 
the liver, by treating mice with the synthetic oleanolic triterpenoid 1-[2-cyano-3,12-
dioxooleana-,9(11)-dien-28-oyl] imidazole (CDDO-Im), a potent Nrf2 inducer, and 
similar results have been observed [303, 304]. CDDO-Im prevents fatty acid synthesis 
in an Nrf2-dependent manner in vitro [308]. CDDO-Im-treatment in vivo decreases 
expression of genes in the liver encoding enzymes required for acetyl-CoA 




production: acetyl-CoA carboxylase 1 (encoded by Acaca) and 2 (Acacb), fatty acid 
synthase (Fasn), and sterol regulatory element-binding protein-1c (Srebp1c), a 
transcription factor that promotes expression of Fasn and Acaca/b [304].  
Nrf2 is a master regulator of antioxidant defence, wherein the brain it confers 
neuroprotective effects after demyelination [92], yet its roles during remyelination 
are unexplored. Lipidosin, an acyl-CoA synthetase, the precursor enzyme in the β-
oxidation pathway to form acetyl-CoA in the mitochondria [307], is increased in 
astrocytes during the remyelinating phase in the cuprizone model, and it has been 
suggested to be involved in fatty acid metabolism [309]. Nonetheless, the link 
between these two pathways has never been investigated in the brain, and 
understanding their interplay is crucial due to the critical functions they mediate 
after demyelination. Given that I observed that during efficient remyelination, Nrf2 
activation in astrocytes is downregulated when cholesterol synthesis is upregulated, 
in this chapter, I investigated the effects of sustained Nrf2 pathway activation on 










5.2.1. Nrf2 is overexpressed in the GFAP-Nrf2 mice 
 
To investigate the effects of Nrf2-overexpression in astrocytes during 
remyelination, I used a model, the GFAP-Nrf2 mice, which overexpress Nrf2 under 
the control of the Gfap promoter [218] (Figure 5.1.A).  I confirmed that in these mice, 
GFAP+ astrocytes had increased Nrf2 activation under basal conditions (non-lesion) 
when compared to wild-type (WT) mice, as indicated by expression of Nrf2 
downstream target Nqo1. (Figure 5.1.B).  
 




Figure 5.1. Nrf2 activation in reactive astrocytes in the GFAP-Nrf2 model. A. Schematic 
representation of the experimental timeline in the GFAP-Nrf2 line in which Nrf2 signalling is 
sustained during remyelination. B. Representative images of a non-lesion WT animal and a 
GFAP-Nrf2 animal, where GFAP+ astrocytes are co-stained with the Nrf2 target Nqo1, 
confirming Nrf2 activation. Scale bar; 100μm. White box shows a magnification of an Nqo1+ 
GFAP+ astrocyte. Scale bar; 50μm. 
 
5.2.2. GFAP+ astrocyte decrease during oligodendrocyte 
differentiation in the GFAP-Nrf2 mice 
 I next characterised astrocyte responses to investigate whether Nrf2 
activation affected astrocytes. To do so, I investigated GFAP levels at the peak of 
astrocyte reactivity in the wildtype mouse (WT), being 7 and 14 DPI. I observed a 
decrease in the number of reactive astrocytes (GFAP+) at 7 DPI within the lesion core 
in GFAP-Nrf2 mice when compared to WT mice (Figure 5.2.A-B). Reactive astrocytes 
were, however, recovered in number at 14 DPI, to similar levels as observed in WT 
(Figure 5.2.A-B). Therefore, the GFAP-Nrf2 mice show a delay in astrocyte reactivity.  
I also noted that astrocyte hypertrophy seemed more pronounced in the 
GFAP-Nrf2 mice, particularly at 14 DPI, where astrocytes presented a dysmorphic 
shape (Figure 5.2.A). Nonetheless, to understand the consequences of this change in 
shape on astrocyte function, further markers for reactivity (eg. Vimentin, nestin and 
NFIA) or astrocyte progenitors (delta isoform of GFAP (GFAPδ) [310], should be used 
and gene expression analysis should be performed. 





Figure 5.2. Sustained Nrf2 activation in reactive astrocytes leads to decreased numbers 
after demyelination. A. Representative images of GFAP+ astrocytes in WT and GFAP-Nrf2 
mice at different time-points during remyelination. Scale bar; 100 μm. White box shows a 
magnification of GFAP+ astrocytes. Scale bar; 50μm. B. Quantification of GFAP+ astrocytes. 
Significance was determined by the Kolmogorov-Smirnoff test against non-lesion controls, 
and at 14 DPI an unpaired t-test with Welch’s correction was performed at 7 DPI between 




WT and GFAP-Nrf2. Error bars indicate s.e.m. of the number (n) of animals. n= 3 mice per 
group per time point.   
 
5.2.3. Sox9+ astrocyte decrease during oligodendrocyte 
differentiation in the GFAP-Nrf2 mice 
As a reduction in reactive astrocyte numbers was observed in the GFAP-Nrf2 
compared to the WT mice, I next explored whether the total numbers of astrocytes 
(Sox9+) were changed (Figure 5.3). I observed a trend towards a decrease in astrocyte 
numbers at 7 DPI compared to the WT group (Figure 5.3.A-B), yet this did not reach 
significance. The decrease in the total number of astrocytes was similar to the 
decrease in the number of reactive astrocytes. The total astrocyte number was 
however similar at 14 DPI between both genotypes, although power calculations 
indicated that an increase in the sample size would be required to avoid Type I (false 
negative) and Type II (false positive) errors. 





Figure 5.3. Sustained Nrf2-overexpression in reactive astrocytes leads to decreased 
numbers of reactive astrocytes after demyelination. A. Representative images of Sox9+ 
astrocytes in WT and GFAP-Nrf2 mice at different time-points during remyelination. Scale 
bar; 50μm. B. Quantification of Sox9+ astrocytes. Significance was determined by an 
unpaired t-test with Welch’s correction, comparing 7 and 14 DPI GFAP-Nrf2 to WT. Error bars 
indicate s.e.m. of the number (n) of animals. n= 3 mice per genotype per time point. 




5.2.4. Hmgcs1 and Fdps are decreased in reactive astrocytes 
during oligodendrocyte differentiation in the GFAP-Nrf2 mice 
I next explored whether cholesterol biosynthesis was altered in astrocytes in 
GFAP-Nrf2 mice, by looking at two enzymes of the cholesterol synthesis pathway, 
Hmgcs1 and Fdps at 7 DPI, time at which an increase in cholesterol synthesis peaks 
in WT (Figure 3.20). To do so, I used ImarisSurfaces and analysed the number of 
Hmgcs1 or Fdps surfaces, in which each surface was adjusted to be the size of a cell 
(named particle) (see methods section 2.6). I observed that Hmgcs1 and Fpds were 
decreased in GFAP+ astrocytes when compared to the expression in WT animals 
(Figure 5.4). These findings could indicate an impairment of the cholesterol 
biosynthesis pathway in astrocytes when Nrf2-signalling was sustained. Nonetheless, 
a reduction in reactive astrocyte numbers could have also contributed to the 
decreased expression of these enzymes in astrocytes within the lesion. 





Figure 5.4. Sustained Nrf2-overexpression in reactive astrocytes leads to reduced levels of 
Hmgcs1 and Fdps in astrocytes. A. Representative images of GFAP+ astrocytes (yellow), co-
stained with Hmgcs1 or Fdps (magenta). Scale bar; 100μm. B. Quantification of 
Hmgcs1+GFAP+ astrocytes (B) or Fdps+GFAP+ astrocytes (C). Each particle represents a cell 
per mm2. Significance was determined using unpaired t-test with Welch’s correction. Error 
bars indicate s.e.m. of the number (n) of animals. n= 3 




5.2.5. Oligodendrocyte lineage cells are decreased in the GFAP-
Nrf2 mice 
I next assessed whether the effect of sustained Nrf2-overexpression in 
astrocytes and associated disruptions to the cholesterol biosynthesis pathway could 
have an effect on oligodendrocyte differentiation, a critical step in successful 
remyelination. To do so, I used the pan-oligodendrocyte lineage-cell marker 
oligodendrocyte transcription factor-2 (Olig2+) and labelled mature 
oligodendrocytes using the marker anti-adenomatous polyposis coli (APC) (CC1+). I 
counted the numbers of positive cells at 7 DPI (the time at which oligodendrocyte 
differentiation is initiated) and 14 DPI (the time at which initial remyelination takes 
place). I observed a trend decrease in total oligodendrocyte lineage cell numbers 
(Olig2+) in the GFAP-Nrf2 mice compared to the WT at 7 and 14 DPI (Figure 5.5.A-B). 
Similarly, when the number of mature oligodendrocytes was assessed (CC1+Olig2+), 
a trend decrease was observed at these two time-points (Figure 5.5.C). However, 
when the percentage of total oligodendrocyte lineage cells (Olig2+) which were 
mature oligodendrocytes (CC1+Olig2+) was analysed, a similar proportion was 
observed in both genotypes, which could suggest that although there was a 
reduction in the number of oligodendrocyte lineage cells in Gfap-Nrf2 mice, the cells 
that were present were able to differentiate into mature oligodendrocytes (Figure 
5.5.D). This suggests that GFAP-Nrf2 mice show a reduction in total numbers of 
oligodendrocyte lineage cells, but differentiation was not impaired, suggesting a 
reduction in proliferation/migration of OPCs to the lesion and/or induction of 
apoptosis due to elevated Nrf2 levels. Future, experiments assessing OPCs 




proliferation by co-staining with Ki67 would be required to confirm this. Moreover, 
assessing oligodendrocyte-lineage cell apoptosis by flow cytometry and Annexin-V 
expression, a marker for cell death, could also be performed. Nonetheless, an 
increase in ‘n’ numbers would be required to reach the statistical power as variability 
between the samples was observed. 




Figure 5.5. Sustained Nrf2-overexpression in reactive astrocytes does not affect 
oligodendrocyte differentiation. A. Representative images of co-staining for the pan-
oligodendrocyte lineage cell marker, Olig2 (magenta), and the mature oligodendrocyte 
marker, CC1 (green) at 7 and 14 DPI in the WT and GFAP-Nrf2 mice. Scale bar; 100 μm. B-C. 
Quantification of Olig2+ cells (B) and CC1+ cells (C) per mm2 at 7 and 14 DPI in WT and GFAP-
Nrf2 mice. Significance was determined by using an unpaired t-test with Welch’s correction 




comparing WT and GFAP-Nrf2 at 7 and 14 DPI. D. Percentage of Olig2+ cells which are CC1+ 
(green) and negative (magenta) in the WT and GFAP-Nrf2 mice at 7 and 14 DPI. Error bars 
indicate s.e.m. of the number (n) of animals. n= 3 mice per genotype per time point.   
 
5.2.6. Total number of cells are decreased early after LPC-
demyelination in the GFAP-NRf2 mice 
I next assessed whether the total number of cells that were not astrocytes 
were different between the WT and the GFAP-NRf2 mice during remyelination. To 
do so, I subtracted the total number of astrocytes (Sox9+) from the total number of 
cells (Hoechst+). There was a trend decrease in the total number of cells that were 
not astrocytes (Hoechst + Sox9-) at 3 DPI (Figure 5.6.A-B), although this did not reach 
significance. No significant differences were observed at the other time-points 
investigated (Figure 5.6.A-B). Nonetheless, an increase in ‘n’ numbers would be 
required to avoid Type I and Type II errors. This decrease in the total number of cells 
that were not astrocytes at this early time-point could reflect a decrease in microglia 
infiltration, as this is when microglia are expected to migrate to the lesion site [244]. 
Nonetheless, further characterisation with microglial markers would be required to 
confirm these findings. 





Figure 5.6. Sustained Nrf2-overexpression in reactive astrocytes leads to a trend decrease 
in the total number of cells. A. Representative image of Hoechst staining (cyan), GFAP+ 
astrocytes (yellow) and Sox9+ cells (magenta). Scale bar; 100 μm.  B. Quantification of 
Hoechst+ cells that were negative for Sox9 and GFAP. Significance was determined using an 
unpaired t-test with Welch’s correction comparing WT and GFAP-Nrf2 at 7 and 14 DPI. Error 
bars indicate s.e.m. of the number (n) of animals. n= 2-3 mice per genotype per time point.  
 




5.2.7. Nrf2 and cholesterol biosynthesis associated genes are 
dysregulated in astrocyte in ageing 
Due to the potential link between the Nrf2 and the cholesterol biosynthesis 
pathways, I next aimed to explore whether the Nrf2 and cholesterol pathways are 
altered in astrocytes in ageing, where there is decreased remyelination efficiency 
[296, 311, 312]. To explore these pathways in aged mice, I performed TRAP to isolate 
the mRNA of astrocytes and quantify the expression of target genes by qPCR. Nrf2-
signalling was reported to be increased in ageing in a region and cell-dependent 
manner [202]. Hence, I first assessed the basal levels of Nrf2 signalling in astrocytes 
in aged animals (9-12 months of age) compared to young mice (2-3 months) under 
basal conditions (non-demyelinated animals), by assessing mRNA expression of 
Hmox1 and Cat. I found that the log2 fold-change in expression of these two genes 
in astrocytes was increased in aged mice versus young mice by around 0.7 (Figure 
5.7.A). I then performed demyelination and looked at mRNA expression of these two 
genes at 7 DPI in aged animals, when Nrf2-signalling is normally shut down in young 
mice. No difference in mRNA expression levels was observed between lesion and 
control (non-demyelinated) in aged animals (Figure 5.7.B), suggesting that Nrf2 levels 
were sustained after demyelination. I then investigated expression of cholesterol 
biosynthesis-associated genes Hmgcs1 an Fdps at 7 DPI in aged mice, and compared 
expression to that at 7 DPI in younger animals, and found a decrease in expression 
(log2 fold-change) in aged mice (Figure 5.7.C). These findings could indicate that in 
ageing, the Nrf2 activation levels in astrocytes are increased, sustained following 
demyelination, and associated with dysregulated cholesterol biosynthesis. These 




results reinforce the concept of a crosstalk between the Nrf2 and cholesterol 
biosynthesis pathways and the importance in their correct regulation in astrocytes 
to ensure that remyelination can take place. 
Figure 5.7. Dysregulation of Nrf2 and cholesterol biosynthesis associated genes in 
astrocytes in ageing. A. Log2-Fold-change in expression of the Nrf2 target genes Hmox1 and 
Cat in non-lesioned old mice (9-12 months old) compared to young mice (2-3 months old). 
B. Hmox1 and Cat relative mRNA expression at 7 DPI in old mice. C. Log2-Fold-change in 
expression of the cholesterol biosynthesis associated genes Hmgcs1 and Fdps at 7 DPI in old 
mice compared to young mice. n= 3 mice per group. 
 




5.2.8. Remyelination is reduced in the GFAP-Nrf2 mice 
The data from the GFAP-Nrf2 model suggested a reduction of the cholesterol 
synthesis pathway, and there was a decrease in overall oligodendrocyte lineage cell 
numbers. I next explored consequences for remyelination. When LPC-induced 
demyelination was performed in these mice, I observed a trend in decreased 
remyelination at 14 DPI in the GFAP-Nrf2 mice compared to WT, as indicated by a 
decrease in MBP staining (Figure 5.8.A-B). As ‘n’ numbers were low, further 
experiments would be needed. Calculation of sample size for statistical power 
showed that ‘n’ numbers at 7 and 14 DPI should be increased to avoid Type I and 
Type II  errors. 





Figure 5.8. Sustained Nrf2-overexpression in reactive astrocytes leads to impaired 
remyelination. A. Representative images of MBP staining (magenta) in the corpus callosum 
(indicated with dashed lines) at the main time-points explored in the WT and GFAP-Nrf2 
mice.  B. Quantification of MBP staining intensity in the WT vs the GFAP-Nrf2 mice. 
Significance was determined by the Kolmogorov-Smirnoff test compared to non-lesion 
controls, and an unpaired t-test with Welch’s correction was performed at 7 DPI between 
WT and GFAP-Nrf2. No statistical quantification was performed at 3 and 14 DPI due 
insufficient “n” numbers.  Error bars indicate s.e.m. of the number (n) of animals. n= 2-6 mice 
per group per time point.  





In this chapter, the effects of sustained Nrf2 activation in astrocytes on astrocyte 
behaviour, the cholesterol biosynthesis pathway, and oligodendrocyte-lineage cell 
responses during remyelination were investigated. Although some findings are 
preliminary as an increase in ‘n’ numbers would be required, my data thus far 
suggests that when Nrf2 activation is maintained in reactive astrocytes following 
demyelination, oligodendrocyte lineage cell responses and remyelination are 
impaired (Figure 3.21). This may be due to a reduction in cholesterol biosynthesis 
activation in astrocytes (Figure 5.4). Accordingly, I observed that in aged animals, 
which are known to remyelinate poorly, basal Nrf2 pathway activation is high and 
maintained following demyelination, and this is associated with decreased 
expression of cholesterol synthesis-associated genes compared to young mice at 7 
DPI (Figure 5.7). Sustained Nrf2 activation in astrocytes seemed not to impair 
differentiation of oligodendrocytes, although overall oligodendrocyte lineage cell 
numbers were decreased (Figure 5.5), which was then associated with reduced 
remyelination. 
Furthermore, given the importance of cholesterol in myelin membrane 
formation, dysregulated cholesterol biosynthesis in astrocytes could have impaired 
the capacity of oligodendrocytes to form myelin. Moreover, sustained Nrf2 activation 
in astrocytes affected the total number of cells present in the lesion early after 
demyelination (Figure 5.6). This decrease in numbers could reflection a decrease in 
OPCs present that would then differentiate to myelin-forming oligodendrocytes, 




and/or microglia that would clear myelin debris, which in turn could also be a reason 
for impaired remyelination.  
In the present study, RNA sequencing suggested an early and transient 
engagement of the Nrf2 pathway in astrocytes after demyelination, which was then 
confirmed at the protein level (Figure 4.9). Similar observations were previously 
made in the cuprizone model, in which early activation of Nrf2 is present in 
astrocytes, peaking at 3 days of cuprizone diet [92]. After insult, there is high 
generation of oxidative stress and cytotoxic molecules, which induce cell death [201, 
313]. Neurons and oligodendrocyte are more vulnerable to oxidative stress 
compared to astrocytes and microglia, which may be explained by the difference in 
expression of intrinsic players regulating antioxidant responses [291]. Nrf2 signalling 
is an intrinsic mechanism that mediates cellular defence, by the upregulation of 
antioxidant and cytoprotective genes that are involved in detoxification, antioxidant 
function, redox balance and metabolism regulation [265].Treatment-induced-Nrf2 
activation in astrocytes in vitro promotes cell defence functions and protects them 
against cytotoxic stimuli like hydrogen peroxide (H2O2) and platelet-activating factor 
(PAF) [313]. In addition, specific Nrf2 expression in astrocytes protects neurons from 
H2O2 toxicity and glutamate toxicity in a mixed culture system [314], indicating that 
Nrf2 activation in astrocytes is protective for neighbouring cells.  
Early induction of Nrf2 after demyelination is required to control inflammation, 
as a lack of this signal early in demyelinating models aggravates inflammation, and 
thus demyelination. For instance, Nrf2-deficient mice have higher numbers of 




apoptotic cells after 1 and 3 weeks of cuprizone treatment, and reduced numbers of 
oligodendrocytes and astrocytes, likely due to cell death [315]. Moreover, after 3 
weeks of cuprizone diet, there was more severe demyelination, increased axonal 
damage and higher numbers of microglia when compared to WT animals [315]. 
Similarly, Nrf2 induction in astrocytes, by Gfap-specific deletion of Keap1, prevents 
oligodendrocyte and myelin loss and decreases microglia activation after 3 weeks of 
cuprizone administration [92]. In EAE, mice lacking Nrf2 present an early onset of 
clinical symptoms and worse clinical scores than WT mice [316]. At 14 days of EAE 
induction, which is the onset of pathology, Nrf2 null mice exhibited severe 
demyelination, higher peripheral immune cell infiltration and microglial activation 
compared to WT mice with EAE [316]. However, in this study, the normality of myelin 
was not evaluated before EAE induction in the transgenic mice. These findings, 
alongside my results, indicate that early and transient activation of Nrf2 signalling is 
required after demyelination to control and prevent further damage.  
Fumarate esters (FAE), consisting of monomethyl fumarate (MMF) and DMF, 
have been shown to have immunomodulatory effects, decrease inflammatory cell 
infiltration and confer neuroprotection [90, 317, 318]. Moreover, a principal 
mechanism by which FAE are thought to act is by preventing oxidative stress and 
promoting cytoprotection via Nrf2 signalling activation [87, 319, 320]. Interestingly, 
in tissue obtained from brain autopsies of MS patients that had been treated with 
DMF, Nrf2 activation is mainly observed in astrocytes [88]. DMF promotes neuronal 
recovery after experimental demyelination. This was assessed by treating mice with 




DMF for 7 days after cuprizone-induced demyelination and upon return to normal 
diet, isolating brain slices from these mice, and performing electrophysiological 
analysis [320]. Nonetheless, DMF is only effective in RRMS forms, potentially due to 
its neuroprotective effects [203, 318]. Accordingly, rats treated with DMF early after 
EAE do not show any recovery in EAE clinical score after treatment [321]. In this 
study, DMF was only provided three days after EAE induction, suggesting that earlier 
intervention could have been required to confer neuroprotection. 
Moreover, treatment with DMF and MMF does not prevent demyelination 
and axonal damage within 6 weeks of cuprizone demyelination, nor does it confer 
any protective effect on oligodendrocytes [322]. DMF also does not improve white 
matter pathology outcomes after ischemic insult [323]. Future studies would be 
required to assess the direct effects of DMF on remyelination, by investigating the 
effect on oligodendrocytes or investigating myelin at the ultrastructural level. 
The studies investigating the neuroprotective effects of Nrf2 have only been 
performed during demyelination, and DMF, which acts in part via activating Nrf2 in 
astrocytes, has not been shown to improve white matter pathology. Moreover, the 
specific effects of Nrf2 overexpression in astrocytes during remyelination have never 
been explored. In the present study, a reduction in remyelination was observed at 14 
DPI in lesioned mice with sustained Nrf2 expression in astrocytes compared to WT 
animals, a time at which early remyelination is expected in this model (Figure 3.21.C). 
Similarly, overexpression of Nrf2 in astrocytes did not recover white matter integrity 
of the corpus callosum in an ischemic mouse model [324].  




In addition, I observed a reduction in the overall number of cells within 
demyelinated lesions, including astrocytes and oligodendrocytes (Figure 4.11, 23 & 
25). Although Nrf2 activation (induced genetically or with drugs) confers 
neuroprotective effects, Nrf2 expression is already present in cells within MS lesions. 
High levels of Nrf2 are expressed by degenerating oligodendrocytes and astrocytes 
in actively demyelinating lesions of RRMS patients [203]. Similarly, in another study, 
Nrf2 signalling was found to be highly upregulated in astrocytes in chronic inactive 
MS lesions (which have reduced remyelination potential) and to a lesser extent in 
active lesions [297, 325]. Nrf2 activation can mediate activation of the integrated 
stress response (ISR) [326], which if transiently activated is associated with a pro-
survival response and restoration of homeostasis. In contrast, a prolonged ISR 
activation promotes cell death  [327]. This could have taken place in my model, in 
which continued overexpression of Nrf2 could have induced a negative feedback 
loop, further increasing ISR mechanisms resulting in cell death, which could then 
explain the reduced numbers of cells found within the lesions of GFAP-Nrf2 mice.  
I found that at 3 DPI, there was a decrease in the total number of cells that were 
not astrocytes (Figure 5.6). Nrf2 overexpression reduces microglia numbers and 
activation during the demyelinating stage of different demyelination models [92, 
315, 316]. In the LPC-induced demyelination model, pro-inflammatory microglia 
numbers peak at 3 DPI [244, 328]. My findings could thus indicate a reduction of the 
numbers of microglia early after demyelination. Moreover, microglia are required to 
phagocytose myelin debris after demyelination [72, 262, 296, 329], and their 




reduction could be a further explanation as to why remyelination is impaired 
consequently to Nrf2 overexpression in astrocytes. This could be explored by co-
staining with the transmembrane protein-119 (TMEM119), which specifically labels 
microglia, and the activating-macrophage lineage marker cluster of differentiation-
68 (CD68), which labels phagocytic macrophages, and explore whether upon 
astrocytic Nrf2-overexpression, these cells contain fragments of myelin, detected by 
damaged MBP (dMBP) staining. 
I also found that Nrf2 overexpression in astrocytes following demyelination was 
associated with a dysmorphic morphology in reactive astrocytes, characterised by 
blunt processes, which were not as elongated as during normal hypertrophy (Figure 
4.11). This feature, along with reduced astrocyte numbers, is also observed in 
astrocytopathies (leukodystrophies caused by astrocyte pathology) like vanishing 
white matter disease (VWM) [146]. Interestingly, VWM is also characterised by a 
reduction in the number of oligodendrocytes, thinner and reduced myelin sheaths 
[146]. These are striking results, where a similar pathology as VWM is observed upon 
Nrf2 overexpression in astrocytes after demyelination. To further confirm the 
similarity in pathology, staining with delta isoform of GFAP (GFAPδ), which is highly 
expressed in VWM astrocytes, could be performed which indicates a defect in final 
maturation of astrocytes, which in turn affects oligodendrocyte responses  [310]. 
Furthermore, impaired remyelination consequent to overexpression of Nrf2 in 
astrocytes could be mediated, at least in part, due to a decrease in cholesterol 
synthesis (Figure 5.4, 26). As I have previously described, Nrf2 negatively regulates 




cholesterol synthesis in the liver [298-300, 302-306]. The present data have shown 
that proteins and genes associated with cholesterol synthesis are downregulated in 
two different models in which remyelination is impaired, and which are characterised 
by increased Nrf2 levels (ageing and transgenically sustained Nrf2 expression). 
Cholesterol is required to drive myelination and remyelination [272], and inhibiting 
cholesterol production in astrocytes during developmental myelination leads to 
hypomyelination [136]. The data from this last chapter indicates that in the brain, a 
similar mechanism of Nrf2-cholesterol crosstalk may be taking place as observed in 
the liver. Upon Nrf2 overexpression in astrocytes, I found cholesterol synthesis 
associated proteins to be lower in expression, oligodendrocyte lineage cells 












6. CHAPTER: THESIS DISCUSSION 
 
This thesis describes how astrocytes change to mediate repair in a model of efficient 
remyelination, the LPC-demyelination model. RNA sequencing revealed that 
astrocytes are dynamic and change their molecular profile throughout this process. 
To characterise astrocytes in two models of remyelination (LPC and cuprizone) 
different markers have been applied. Nonetheless, better markers could be applied 
in future studies for a more accurate characterisation. Aldh1l1 is the most specific 
marker for astrocytes in the adult brain but there is a lack of good antibodies for 
immunohistochemical characterisation. Comparing different RNA sequencing 
datasets could be performed in future studies to find highly expressed markers that 
are definitive for astrocytes. Bioinformatic analysis of single cell and bulk RNA 
sequencing could help to define different astrocyte subpopulations, which could be 
validated through lineage tracing of subpopulation specific promoter activity to 
confirm that these markers are stable and specific in adulthood. This also would 
provide information on astrocyte functions in these different subpopulations. For 
instance, in the present study it was observed that astrocytes mainly present 
antioxidant, metabolic and inflammatory profiles at the different time-points 
investigated which could have represented a change in function or a change in the 
dominance of different astrocyte populations. Investigating this further in diseases 
such as MS could reveal that some subpopulations are mainly prevalent in disease 
which would reveal specific target for therapeutic intervention.  




Current approved treatments for MS only modulate the inflammatory component, 
and there are no therapies available that repair the lesions, leaving the disease with 
no cure. The present study focused on the Nrf2 and cholesterol signalling in 
astrocytes and their crosstalk to mediate remyelination. New therapies for MS could 
combine drugs that are aimed at targeting these pathways such as DMF for Nrf2 and 
Biotin for cholesterol synthesis [102]. Drugs could be directed to astrocytes via 
nanocapsules targeting receptors specific for astrocytic markers, for example the 
newly discovered astrocyte cell surface antigen (ACSA)-2 [330]. Nonetheless, 
specificity of this marker in WM has never been investigated and would need to be 
validated. Current drugs may have off-target effects throughout the body if given 
orally or via infusions, highlighting the need to design better ways to deliver MS 
drugs. For instance, drugs aimed at increasing cholesterol metabolism should be 
targeted to the CNS and animal studies should check cholesterol production in the 
liver. One promising drug delivery strategy is intranasal delivery, due to the direct 
transport to the CNS [331]. Moreover, this could address the issue of systematically-
administered drugs poorly reaching the CNS, for example DMF reaches the CNS at 










The work of this thesis describes astrocyte responses at the cellular and 
molecular level during remyelination. I found that after demyelination, astrocytes 
undergo a series of significant changes in number, proliferation and activation. 
Astrocytic expression of reactive markers (GFAP, Nestin, Vimentin and NFIA) was 
found to be temporally regulated during remyelination. Interestingly, GFAP+ 
astrocyte numbers increased early and peaked at the time of oligodendrocyte 
differentiation and early remyelination in two different models of toxin-induced 
demyelination, the LPC and cuprizone models. This increase in astrocyte reactivity 
during oligodendrocyte regenerative responses led to the next question as to how 
they might support these processes after demyelination. To address this question, I 
performed RNA sequencing of TRAP isolated astrocytic mRNA at key time-points 
during remyelination which consisted of the phase of OPC proliferation (3 DPI), 
oligodendrocyte differentiation (7 DPI), and the onset of remyelination (10 DPI). 
Gene expression and pathway analysis suggested a dynamic change of astrocyte 
functions during remyelination. Gene expression indicated that astrocytes presented 
a change from a neuroprotective profile at 3 DPI, to a pro-inflammatory profile at 10 
DPI. This neuroprotective phenotype was characterised by an early and transient 
activation of Nrf2-signalling. Upon the downregulation of the Nrf2 pathway, 
astrocytes upregulated the cholesterol biosynthesis pathway at the time of 
oligodendrocyte differentiation (7 DPI), a pathway suggested to be important for 
myelination and remyelination. Due to previous data from liver studies indicating 




that Nrf2 is a negative regulator of cholesterol synthesis, I next aimed to investigate 
this crosstalk in the context of remyelination. I used a mouse model in which Nrf2 is 
overexpressed in reactive astrocytes (GFAP+). Although the results obtained are still 
preliminary, they indicated that Nrf2-overexpression in astrocytes during 
remyelination decreased expression of genes and proteins involved in cholesterol 
synthesis. Remyelination was impaired in association with reduced numbers of 
oligodendrocyte lineage cells, although oligodendrocyte differentiation was not 
impaired, which could indicate that cholesterol is important for final maturation to 
myelin-producing oligodendrocytes. The link between Nrf2 signalling and cholesterol 
biosynthesis was also observed in aged mice, in which increased basal levels of Nrf2 
pathway activation were observed in comparison to young animals. After 
demyelination of aged mice, decreased expression of enzymes involved in 
cholesterol synthesis was documented at 7 DPI compared to young mice. In addition, 
Nrf2 overexpression in astrocytes reduced the total number of cells in the lesion early 
after demyelination. This could indicate that Nrf2 is a master regulator of astrocytic 
functions during remyelination, and its dysregulation causes impairment in their 
cholesterol synthesis, responses from other cells, and in turn, remyelination (Figure 
6.1).  





Figure 6.1. Nrf2 activation may interplay with cholesterol biosynthesis required for 
remyelination. Schematic representation of astrocyte responses during remyelination. 
Astrocytes increase in reactivity (as determined by increased GFAP, vimentin, nestin and 
NFIA levels) at the onset of oligodendrocyte differentiation and remyelination in the LPC and 
cuprizone models. Early after demyelination, astrocytes increase Nrf2 expression, which is 
downregulated during oligodendrocyte differentiation and at the onset of remyelination, 
when cholesterol biosynthesis is activated. Nrf2 may control cholesterol biosynthesis as 
sustained Nrf2 activation in astrocytes dysregulated expression of cholesterol biosynthesis-
associated genes/proteins and consequently impaired oligodendrocyte lineage cell 










6.2. Limitation of thesis 
The present study describes the cellular and molecular changes in astrocytes 
during remyelination and defines a mechanism by which their regenerative functions 
may be regulated. Nonetheless, there are experimental limitations that could be 
overcome in future studies.  
During activation, astrocytes express markers also associated with progenitors 
and neural stem cells (NSCs) [246]. Hence, although different markers were used in 
conjunction with astrocytic markers, their expression could be associated with other 
cells in the lesion. Sox9 was used as a pan-astrocytic marker. However, NSCs can also 
express Sox9 in neurogenic areas, and after lesioning some of the Sox9+ nuclei could 
have represented NSCs migrating to the lesion. In an attempt to overcome this 
limitation, I used the ASRIBO line, in which only astrocytes express green fluorescent 
protein due to expression of the astrocyte-specific gene Aldh1l1. Nonetheless, 
fluorescence in this line was not sufficiently strong for quantification, and anti-GFP 
antibodies could have been used to amplify this signal. Future experiments could be 
done to address this and confirm that the markers used in this study were primarily 
associated with astrocytes after demyelination. 
In the RNA sequencing experiments, qPCR validation is not shown as variability 
was found within the groups, and further repetitions were required. This could have 
been of importance, especially to validate the expression of the genes explicitly 
upregulated from demyelination rather than from injection alone (sham controls). 
However, I overcame this by using protein validation by immunofluorescence. 




Further ‘n’ numbers would be required for the experiments described in the last 
chapter to achieve statistical power. Moreover, although I used an Nrf2-target gene 
product as validation of overexpression of Nrf2 in the GFAP-Nrf2 mice, Nrf2 
overexpression itself was not confirmed nor was pathway activation after lesioning 
measured. 
In the present study, I assessed the expression of two enzymes essential for 
cholesterol synthesis as a proxy for this pathway. To further validate cholesterol 
production by astrocytes, other approaches could be applied. Different mass 
spectrometry variances have been used to detect and quantify lipids in the serum 
and liver [301, 334]. Mass spectrometry characterises, identifies and quantifies 
molecules according to their molecular weight and fragmentation profile, which 
identifies ionic properties [335]. To obtain cholesterol esters and its intermediates 
from astrocytes, they would need first to be isolated from the lesion using FACS or 
MACS; however, the risk would be obtaining enough protein from the isolated cells 
within the lesion, and would likely require pooling several animals to obtain a single 
quantification.  
In the last chapter, my preliminary data suggests that GFAP-Nrf2 mice show a 
failure in remyelination. Further analysis at the ultrastructural level is underway and 
is required to confirm this finding, and detect any other abnormality in myelin 
integrity. Moreover, the experiments performed in aged animals would require 
further characterisation and validation at the protein level to support the qPCR data. 




6.3. Future directions 
In the first results chapter, I showed a different temporal pattern of expression 
of reactive markers by astrocytes during remyelination. Briefly, GFAP and vimentin 
were increased, starting from 7 DPI, whereas NFIA and Nestin showed a gradual 
increase in expression peaking at 14 DPI. Moreover, not all GFAP+ astrocytes were 
positive for the other reactive markers used, representing heterogeneity of 
astrocytes in the lesion. Future studies could investigate whether different types of 
astrocytes exist after demyelination and if these have different functions, or whether 
this difference in expression of markers reflects different maturation states. Single-
cell (sc) RNA-sequencing analysis could be performed to study this. Importantly, the 
data could be compared with the GFAP-Nrf2 model and see whether the different 
populations are changed or explore whether there is a maturation effect. This could 
then be compared to subpopulations in MS tissue and see whether there are 
changes. Jäkel and colleagues recently performed scRNA-sequencing from white 
matter of MS patients and from control (healthy) patients [71]. In this study, although 
the focus was characterising oligodendrocyte populations, they discovered two 
different astrocyte clusters in white matter that were differently distributed between 
MS and controls [71]. Following up on this study, I could further explore the reactive 
markers used in the present study, and investigate their expression in different MS 
lesions to compare whether in pathology there is a higher expression of those 
markers in different astrocyte subpopulations, and in which lesions they are most 
highly expressed. In addition, it could be interesting to explore in this data set 




whether there is a defect in the Nrf2 and cholesterol synthesis pathways in different 
astrocyte populations found in MS lesions.  
Following up on the Nrf2 and cholesterol signalling interplay, it would be 
interesting to stimulate cholesterol signalling in the Nrf2-overexpressing mice to 
explore whether this can rescue effects on remyelination. To do so, cholesterol 
biosynthesis could be stimulated with a cholesterol efflux enhancer CS-6253, 
previously used in the EAE model, to which enhanced cholesterol synthesis in 
astrocytes [169]. Then cholesterol biosynthesis pathway activation could be 
confirmed at 7 DPI as I have done, and remyelination could be assessed at 14 DPI by 
MBP staining and at the ultrastructural level. This would determine whether the 
impairment in remyelination caused by Nrf2-overexpression can be overcome by 
stimulating cholesterol synthesis. Alternatively, if stimulating cholesterol synthesis is 
not sufficient to promote remyelination, Nrf2-overexpression could be inhibited by 
retinoic acid treatment. Nrf2 protein has seven Nrf2-ECH homology (Neh) domains, 
Neh1-7, which enable regulating different functions [265]. The Neh7 domain binds 
to the retinoid X receptor α to repress its transcriptional activation [336]. Thus 
treatment with retinoic acid (all-trans retinoic acid (ATRA)) to inhibit Nrf2 signalling 
could be used to explore whether the defects observed in GFAP-Nrf2 mice can be 
rescued [337, 338]. 
In the present study, I observed that a reduction in the total number of cells that 
were not astrocytes occurred early after demyelination at 3 DPI. For future studies, 
it would be interesting to explore whether these cells reduced in the lesion were 




microglia. Astrocytes respond to microglia after demyelination. Oxidative stress is a 
hallmark of MS [339], and microglia are the main inducers of oxidative stress 
pathways during demyelination [340]. In the LPC model, pro-inflammatory microglia, 
characterised by the expression of inducible nitric oxide synthetase (iNOS) which 
produces reactive nitrogen species (RNS), are most abundant at 3 DPI [244, 328]. 
Astrocytes may overcome the oxidative stress produced by microglia at this time 
through the activation of the Nrf2 cascade [202]. Overexpression of Nrf2-signalling 
activation after demyelination may inhibit microglia migration and activation after 
demyelination. A reduced number of microglia in the lesion could lead to impaired 
myelin debris clearance [72], and the production of regenerative factors for 
remyelination [328]. This could explain why the lesions characterised by higher Nrf2 
expression in astrocytes are generally the ones with less remyelinating capacity in 
MS lesions [88]. Investigating this could enable finding new therapeutic targets that 
balance Nrf2-pathway activation in astrocytes so that the downstream cascade of 












A1: Pro-inflammatory astrocytes 
A2: Pro-repair astrocytes 
Acaca: Acetyl-CoA carboxylase 1 gene 
Acacb: Acetyl-CoA carboxylase 2 gene 
Acat2: Acetyl-CoA Acetyltransferase 2 gene 
Aldh1l1: Aldehyde dehydrogenase 1 family membrane L1 
ALS: Amyotrophic lateral sclerosis 
ANGPL4: Angiopoietin-like 4 
APC: Antigen-presenting cells 
ApoE: Apolipoprotein E 
Aqp4: Aquaporin 4 
ASRIBO: Tg(Aldh1l1-EGFP/Rpl10a)JD130 
ATP: Adenosine triphosphate 
ATRA: All-trans retinoic acid 
B4GALT6: Beta-1,4-Galactosyltransferase 6 
BBB: Block blood-brain barrier 
BMP: Bone morphogenic protein 
C1q: Complement complex-1q 
C3: Complement complex-3 
CC: Corpus callosum 




CC1: Anti-adenomatous polyposis coli (APC) 
CI: Confidence interval 
CCL: C-C motif chemokine ligand  
CD: Cluster of differentiation  
CDDO-Im: Oleanolic triterpenoid 1-[2-cyano-3,12-dioxooleana-,9(11)-dien-28-oyl] 
imidazole 
Chd7: Chromodomain Helicase DNA Binding Protein 7 
CHX: Cycloheximide 
CIH3L1: Chitinase 3 like 1 
CIS: Clinically isolated syndrome 
CNS: Central nervous system 
CNTF: Ciliary neurotrophic factor 
CO2: Carbon dioxide 
CSF: Cerebrospinal fluid 
Cx: Connexin 
CXCL: Chemokine (C-X-C motif) ligand 
CXCR: C-X-C chemokine receptor type 
DHPC: 1,2-diheptanoyl-sn-glycero-3-phosphocholine 
Dhcr24: 24-dehydrocholesterol reductase 
dMBP: Damage MBP 
DMF: Dimethyl fumarate 
DPI: Days post-injection 





EAE: Experimental autoimmune encephalomyelitis 
eGFP: Enhanced green fluorescent protein 
ErbB1: Epithermal growth factor receptor 
ET-1: Endothelin-1 
FABP-7: Fatty acid-binding protein 7 
FACS: Fluorescent activated cell sorting 
FAE: Fumarate esters 
Fasn: Fatty acid synthase 
FC: Fold-change 
FDA: Food and drug administration 
Fpn: Ferroportin 
Fdps: Farnesyl diphosphate synthase 
FGF: Fibroblast growth factor 
FPKM: Fragments per kilobase of transcript per million mapped reads 
Gclc: Glutamate-cysteine ligase catalytic subunit 
GFAP: Glial fibrillary acidic protein 
GFP: Green fluorescent protein 
GLAST: Glutamate aspartate transporter-1 
GLT-1: Glutamate transporter soluble carrier family 1, member 2 
GM-CSF: Granulocyte-macrophage colony-stimulating factor 
GO: Gene ontology 




CCL: C-C motif chemokine ligand 
CXCL: Chemokine (C-X-C motif) ligand 
H2O2: Hydrogen peroxide 
HA: Hemagglutinin 
HIER: Heat inactivated antigen retrieval 
HLA: Human leukocyte antigen 
HMG-CoA: 3-hydroxy-3-methylglutaryl-coenzyme A 
Hmgcr: Hydroxymethylglutaryl-CoA reductase 
Hmgcs: Hydroxymethylglutaryl-CoA synthase  
Hmox: Hemeoxygenase  
IGF: Insulin growth factor 
IL: Interleukin 
iNOS: Inducible nitric oxide synthetase 
iPSC: Induced pluripotent stem cells 
IPA: Ingenuity pathway analysis 
iTreg: inducible regulatory T-cell 
ISR: Integrated stress response 
KCl: Potassium chloride 
Keap1: Kelch-like ECH-associated protein 1 
KOR: Kappa opioid receptor 
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LINGO-1: Leucine-rich repeat and immunoglobulin-like domain-containing nogo 
receptor-interaction protein 1 
Lgasl: Galectin gene  
LPC: Lysolecithin 
LPS: Lipopolysaccharide 
M1: Pro-inflammatory microglia/macrophages 
M2: Pro-repair microglia/macrophages 
MACS: Magnetic-activated cell sorting 
MAG: Myelin associated glycoprotein 
Mash1: Achaete-scute complex homolog 1 
MBP: Myelin basic protein 
MCAO: Middle cerebral artery occlusion 
MCL: Markov clustering algorithm 
MgCl2: Magnesium Chloride 
MHCII: Major histocompatibility class II 
MMF: Monomethyl fumarate 
MOG: Myelin oligodendrocyte glycoprotein  
MS: Multiple sclerosis 
Mvd: Mevalonate diphosphate decarboxylase 
Mvk: Mevalonate kinase gene 
Myrf: Myelin regulatory factor 
MyT1:  Myelin transcription factor 1 





NaOH: Sodium hydroxide 
NAWM: Normal appearing white matter 
Neh: Nrf2-ECH homology domain 
Nes: Nestin 
NF-H: Neurofilament 
NFIA: Nuclear factor IA 
NF-κB: Nuclear factor kappa-light-chain enhancer of activated B cells 
NG2: Chondroitin sulfate proteoglycan 
Nkx: Homeodomain factor  
NMO: Neuromyelitis Optica 
NMOSD: NMO spectrum disorder 
NP40: Nonidet P-40 
NPC: Niemann-Pick type C 
NPC1: NPC intracellular cholesterol transported-1 
Nqo1: NAD(P)H quinone dehydrogenase1 
NSC: Neural stem cells 
mRNA: Messenger ribonucleic acid 
Nrf2: Nuclear factor (erythroid-derived 2)-like 2 
OCT: Optical cutting temperature compound 
Olig: Oligodendrocyte transcription factor  
OPCs: Oligodendrocytes precursor cells 




Osgin1: Oxidative stress-induced growth inhibitor 1 
P2YR1: P2Y purinoceptor 1 
PAF: Platelet-activating factor 
PBS: Phosphate buffered saline 
PCR: Polymerase chain reaction 
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PLP: Proteolipid protein 
PMS: Progressive multiple sclerosis 
PPMS: Primary progressive multiple sclerosis 
PTP: Permeability transition pore 
qPCR: Quantitative polymerase chain reaction 
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RIN: RNA integrity number 
ROS: Reactive oxygen species 
RNS: Reactive nitrogen species 
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scRNA-seq: Single-cell RNA-sequencing 
s.e.m: Standard error of the mean 
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Sqle: Squalene monooxygenase gene 
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ARTICLE
Deletion of a Csf1r enhancer selectively impacts
CSF1R expression and development of tissue
macrophage populations
Rocío Rojo 1,2, Anna Raper 1, Derya D. Ozdemir1, Lucas Lefevre 1, Kathleen Grabert 1,3,
Evi Wollscheid-Lengeling1, Barry Bradford 1, Melanie Caruso 1, Iveta Gazova 1, Alejandra Sánchez1,
Zofia M. Lisowski 1, Joana Alves 1, Irene Molina-Gonzalez 4, Hayk Davtyan 5, Rebecca J. Lodge6,
James D. Glover1, Robert Wallace7, David A.D. Munro8, Eyal David9, Ido Amit 9, Véronique E. Miron4,
Josef Priller8, Stephen J. Jenkins 6, Giles E. Hardingham8,10, Mathew Blurton-Jones 5, Neil A. Mabbott 1,
Kim M. Summers 11, Peter Hohenstein1,12, David A. Hume11,14 & Clare Pridans 6,13,14
The proliferation, differentiation and survival of mononuclear phagocytes depend on signals
from the receptor for macrophage colony-stimulating factor, CSF1R. The mammalian Csf1r
locus contains a highly conserved super-enhancer, the fms-intronic regulatory element (FIRE).
Here we show that genomic deletion of FIRE in mice selectively impacts CSF1R expression
and tissue macrophage development in specific tissues. Deletion of FIRE ablates macrophage
development from murine embryonic stem cells. Csf1rΔFIRE/ΔFIRE mice lack macrophages in
the embryo, brain microglia and resident macrophages in the skin, kidney, heart and peri-
toneum. The homeostasis of other macrophage populations and monocytes is unaffected, but
monocytes and their progenitors in bone marrow lack surface CSF1R. Finally, Csf1rΔFIRE/ΔFIRE
mice are healthy and fertile without the growth, neurological or developmental abnormalities
reported in Csf1r−/− rodents. Csf1rΔFIRE/ΔFIRE mice thus provide a model to explore the
homeostatic, physiological and immunological functions of tissue-specific macrophage
populations in adult animals.
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The proliferation, differentiation, and survival of vertebratemacrophages is controlled by signals from the macrophagecolony-stimulating factor (CSF1) receptor (CSF1R), enco-
ded by the c-fms protooncogene1, now known as Csf1r. The
function of the receptor and its two ligands, CSF1 and interleukin
34 (IL34), in macrophage differentiation is conserved in all
amniotes (i.e. reptiles, birds, and humans)2,3. Deletion of the
Csf1r locus in the mouse or rat germ line produces a global
deficiency in most tissue macrophage populations4,5. Mutant
animals are osteopetrotic (associated with loss of osteoclasts) and
exhibit severe postnatal growth retardation and multiple pleio-
tropic impacts on development. Tissue macrophages remain
dependent upon CSF1R in adult mice and can be depleted by
treatment with an inhibitory anti-CSF1R antibody6 or treatment
with orally available inhibitors of CSF1R kinase activity7. In
humans, dominant-negative mutations in the tyrosine kinase
domain are associated with an adult-onset neurodegenerative
disease8.
The expression of Csf1r mRNA is restricted to myeloid cells.
During embryonic development, Csf1r mRNA is expressed in the
earliest macrophages identifiable in the yolk sac and transcription
of this gene in pluripotent bone marrow (BM) progenitors is the
hallmark of commitment to the monocyte–macrophage lineage.
Accordingly, the molecular basis for myeloid-restricted tran-
scription regulation of Csf1r has been studied in considerable
detail (reviewed in ref. 9). The second intron, downstream of the
first coding exon, contains a conserved 337bp sequence known as
the fms-intronic regulatory element (FIRE), identified as a super-
enhancer in genome-wide analysis of chromatin in mouse mac-
rophages. The mouse FIRE sequence contains binding sites for
numerous macrophage-expressed transcription factors9. The
combination of a 3.5 kb Csf1r promoter and intron 2, containing
FIRE, is sufficient to direct reproducible transgenic reporter gene
expression in progenitors, monocytes, granulocytes, classical
dendritic cells, and tissue macrophages that also express Csf1r
mRNA10,11. Removal of FIRE from the reporter construct abol-
ishes expression10. The same Csf1r construct was used to drive
conditional Cre-recombinase in lineage-trace studies that dis-
sected the role of the yolk sac in macrophage development12. In
mammals, the FIRE sequence is more highly conserved than any
of the exons of the Csf1r gene13. A FIRE sequence is present in the
same relative intronic location of the Csf1r locus in all reptile and
bird species, and a core element required for enhancer activity14
is perfectly conserved13. The chicken CSF1R promoter and FIRE
sequences are also sufficient to direct macrophage-specific
expression in chicken transgenic lines and to highlight the
appearance of the earliest phagocyte populations in the yolk sac15.
There have been relatively few studies of the function of
macrophage-specific enhancers in their genomic context. A
highly conserved upstream regulatory element that is present in
the Spi1 locus (which encodes the macrophage-specific tran-
scription factor PU.1) is required for regulated expression in
myeloid cells. Deletion of this element in the germline produces a
failure of myeloid differentiation and development of acute
myeloid leukemia16. Deletion of a super-enhancer within the
locus of the orphan nuclear receptor transcription factor (Nr4a1)
reveals its functional specificity, as only the LY6Clo monocytes are
lost, whilst the sensitivity of other monocyte and macrophage
subsets to pro-inflammatory stimuli is preserved17.
We aimed to determine the function of FIRE by deleting it
from the mouse germ line. If FIRE is essential for Csf1r tran-
scription, genomic deletion should partly or completely pheno-
copy the loss of tissue macrophages observed in Csf1r−/− mice.
Here we report that deletion of FIRE has an organ-specific effect
on Csf1r expression and macrophage differentiation. Despite the
lack of brain microglia and resident macrophages in skin, heart,
kidney, and peritoneum, Csf1rΔFIRE/ΔFIRE mice are healthy and
fertile. Aside from highlighting the likely function of other reg-
ulatory elements in the Csf1r locus, these mice provide a model to
explore tissue-specific macrophage transcriptional regulation and
function.
Results
In vitro validation of CRISPRs targeting the FIRE sequence.
Guide RNAs (gRNAs) designed to delete FIRE (Fig. 1a) were first
validated in the RAW 264.7 macrophage cell line and in E14
mouse embryonic stem cells (ESC). The macrophage cell line
expresses Csf1r mRNA and was used in all of the transfection
studies that previously led to the characterization of the role of
FIRE14. Both cell types were co-transfected with pairs of Cas9-2A-
EGFP constructs each expressing single gRNAs (US1+DS1 or
DS2), and pools of EGFP+ cells were screened via PCR to detect
the deletion of FIRE mediated by the CRISPR/Cas9 system. Both
pairs of gRNAs produced deletions in E14 ESC and RAW 264.7
cells (Supplementary Fig. 1a). The deletion of FIRE and the ab-
sence of mismatches in the remaining Csf1r sequence in E14 ESC
were confirmed by Sanger sequencing (Supplementary Fig. 1b). In
RAW 264.7 macrophage cells, individual Csf1rΔFIRE/ΔFIRE clones
carried slightly different deletions of the FIRE sequence (Supple-
mentary Fig. 1c). RAW 264.7 cells are not CSF1R-dependent and
most of the cellular CSF1R protein is retained in the Golgi
apparatus. We therefore analyzed cell-associated CSF1R by flow
cytometry in permeabilized cells. The deletion of FIRE completely
ablates detectable intracellular CSF1R (Fig. 1b). There is no impact
of the FIRE mutation on cell morphology (Fig. 1c) or phagocytic
capacity of cells (Fig. 1d). Neither the frequency nor the median
fluorescence intensity (MFI) of the macrophage surface marker
F4/80 distinguishes between Csf1r+/+ and Csf1rΔFIRE/ΔFIRE clones
(Fig. 1e). We conclude that FIRE is required specifically for the
expression of CSF1R in the RAW 264.7 macrophage cell line.
E14 mouse ESC can be cultured in the absence of feeders and
form embryoid bodies (EB)18 with the potential to generate cells
belonging to all the primary embryonic germ layers (i.e.
endoderm, mesoderm, and ectoderm). Macrophage differentia-
tion from EB was induced by supplementing culture medium
with murine IL3 (mIL3) and recombinant human CSF1
(rhCSF1). Csf1rΔFIRE/ΔFIRE mouse ESC generated using the
gRNA pair US1+DS2 are able to produce EB that are
indistinguishable from the controls (Fig. 1f, Day 0). By day 7,
they give rise to cells that attach to culture plates, indicating that
the deletion of FIRE does not affect responsiveness to IL3. By
2 weeks post-differentiation, a lawn of ESC-derived macrophages
are produced from the Csf1r+/+ EB, whereas the number of
macrophages from Csf1rΔFIRE/ΔFIRE clones was ≈200-fold lower
(Fig. 1f). Overall, these in vitro results indicate that FIRE is
required for expression of Csf1r and/or macrophage
differentiation in EB.
Generation of Csf1rΔFIRE/ΔFIRE mice. To produce
Csf1rΔFIRE/ΔFIRE mice, vectors encoding the FIRE gRNAs US1 and
DS2 and Cas9 were microinjected into C57BL/6J/CBA F1 mouse
oocytes. One male founder with the expected 418 bp deletion was
crossed with Csf1r+/+ C57BL/6J females and the progeny were
interbred. The frequencies of Csf1r+/+, Csf1r+/ΔFIRE and
Csf1rΔFIRE/ΔFIRE mice at weaning are 26%, 55%, and 19%,
respectively (n= 501). Unlike Csf1r−/− mice or the Csf1op/op
mouse4 there is no postnatal growth retardation, failure of tooth
eruption or evidence of osteopetrosis in Csf1rΔFIRE/ΔFIRE
mice (Fig. 2a–c). The proximal growth plates of control and
Csf1rΔFIRE/ΔFIRE mice are indistinguishable and normal numbers
of osteoclasts are present (Fig. 2d, e). Brain abnormalities
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in Csf1r−/− mice include reduced brain size, severely enlarged
ventricles, hollow olfactory bulbs, deficient myelination and
failure of commissure closing in the corpus callosum19. The
Csf1rΔFIRE/ΔFIRE brains are not macroscopically distinguishable
from controls and Luxol fast blue staining reveals no differences in
myelination (Fig. 2f, g).
Csf1op/op, Csf1r−/− mice and adult mice treated with anti-
CSF1R antibody lack lamina propria and Peyer’s patch macro-
phages in the small intestine. These mice also show associated
changes in villus architecture, increased goblet cell numbers
detected with periodic acid-schiff (PAS) staining, reduced
proliferation in the crypts and defects in differentiation of Paneth
cells6,20,21. Csf1r mRNA is not expressed in intestinal epithelial
cells and the impacts of anti-CSF1R treatment are attributable to
the loss of macrophages surrounding the crypts21. There are no
detectable alterations in intestinal epithelia that distinguish
between Csf1r+/+ and Csf1rΔFIRE/ΔFIRE mice (Fig. 2h and
Supplementary Fig. 2).
The development of normal sexual maturity is compromised in
both male and female Csf1op/op mice22,23 and in Csf1r−/− rats5.
By contrast, the Csf1rΔFIRE/ΔFIRE mice reach sexual maturity and
are fertile.
The impact of FIRE deletion in blood and BM. Two subsets of
blood monocytes can be distinguished based upon the expression
of LY6C. The differentiation of the LY6Clo subset depends upon
CSF1R signaling6,24. Csf1rΔFIRE/ΔFIRE mice have normal cell
populations in peripheral blood (Fig. 3a) and F4/80, LY6C, and
CD11b expression is unchanged compared to littermates
(Fig. 3b–d). However, the expression of CSF1R detected with
anti-CD115 antibody is abolished (Fig. 3c). Furthermore, the
binding of labeled CSF1 (pCSF1-FcAF647)11 is undetectable in the









































































































Fig. 1 FIRE deletion reduced CSF1R expression and prevented macrophage differentiation. a Schematic of Csf1r gene and location of gRNAs (US1, DS1, DS2),
targeting FIRE. Protospacer adjacent motifs (PAM) are located to the right of each gRNA. Black boxes= coding exons, white boxes= untranslated regions,
lines connecting exons= intronic sequences, yellow and green arrows= trophoblast/osteoclast promoter and macrophage transcription start sites,
respectively. b Flow cytometry analysis of total CSF1R in fixed and permeabilized RAW 264.7 cell clones. Histograms are representative of three clones per
genotype, from two repeat experiments in duplicate. MFI median fluorescence intensity, black line=+/+, gray line=Δ/Δ, dotted line= isotype control.
P≤ 0.0001 (****). c CRISPR-treated Csf1r+/+ and Csf1rΔFIRE/ΔFIRE RAW 264.7 cells cultured in vitro. Scale bar= 50 µm. d A phagocytosis assay was
performed with RAW 264.7 cells and pHrodo® Red E. coli BioParticles® followed by flow cytometry analysis. n= 4 clones per genotype from two repeat
experiments. MFI median fluorescence intensity. e Flow cytometry analysis of surface F4/80 in RAW 264.7 cell clones. Histograms are representative of
three clones per genotype from two repeat experiments in duplicate. f Csf1r+/+ and Csf1rΔFIRE/ΔFIRE E14 ESC clones were differentiated into macrophages
with mIL3 and rhCSF1. Scale bars= 200 µm (Day 0, embryoid bodies) and 50 µm (Days 7 and 14). n= 3 clones per genotype, P= 0.005 (**). All source
data are provided within a Source Data excel file. Graphs show mean+ SEM and P values were determined by two-tailed t-tests
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for F4/80+ blood monocytes (Fig. 3d). Notably, the level of both
CSF1R and CSF1 binding is reduced by around 50% in the het-
erozygotes (Fig. 3c, d), which is consistent with a lack of dosage
compensation at the mRNA level also reported in Csf1r-deficient
mice and rats4,5.
Unlike Csf1r and Csf1 mutant mice4, Csf1rΔFIRE/ΔFIRE mice are
not osteoclast-deficient and osteopetrotic. Total BM cellularity
remains unchanged by the FIRE mutation (Supplementary Fig. 3a).
Aside from progenitors, BM contains multiple specialized macro-
phage populations that regulate bone homeostasis and hematopoietic
differentiation (reviewed in ref. 25). BM cell populations were
analyzed by flow cytometry as described in Supplementary Fig. 3b.
Two populations of F4/80+ cells are detected in control mice that
differed in the level of CSF1R. The proportion of F4/80+ cells is
unchanged in Csf1rΔFIRE/ΔFIRE mice, but CSF1R expression and
CSF1 binding is abolished in both F4/80+ populations (Supplemen-
tary Fig. 3c and d). As in the blood, the level of CSF1R is reduced
around 50% in heterozygotes. BM contains a population of
monocyte–dendritic cell progenitors (MDP) that express KIT,
FLT3, and CSF1R, and committed proliferative LY6C+ progenitors
derived from the MDP that lack both KIT and FLT326. Although











































































Csf1r +/+ Csf1r +/+ Csf1r +/+
Csf1r +/+
Csf1r ΔFIRE/ΔFIRE Csf1r ΔFIRE/ΔFIRE
Csf1r ΔFIRE/ΔFIRE
Csf1r ΔFIRE/ΔFIRE
Fig. 2 FIRE-deficient mice displayed none of the gross phenotypes found in Csf1r−/−-mice. a Mice were weighed between 2 and 11 weeks of age. n= 7, 20,
9 (females) and 5, 16, 7 (males) for +/+, +/Δ, and Δ/Δ, respectively. b Representative images of tooth eruption in adult mice. c Femurs from 4-week-old
male and female mice were scanned by Micro-CT. Scale bars= 1 mm. n= 5 mice per genotype. BV/TV bone volume over total volume (bone density), Tb.
Th trabecular thickness, Tb.N trabecular number. d Hematoxylin and eosin (H&E) staining of sections of bone. Images are representative of six mice per
genotype; ep epiphyseal plate, bt bony trabeculae, bm bone marrow. Scale bar= 250 µm. e Femurs from the same cohort of mice above were stained for
tartrate-resistant acid phosphatase (TRAP). Arrows point to TRAP+ osteoclasts. Scale bar= 100 µm. f Luxol Fast Blue staining of paraffin-embedded
formalin-fixed adult brains. Images are representative of three mice per genotype. Scale bar= 2.5 mm. g H&E staining of olfactory bulbs from adult mice.
Images are representative of six mice per genotype. EPL external plexiform layer, GL glomerular layer, IGC internal granular cell layer of the olfactory bulbs,
MCL mitral cell layer. Scale bar= 1 mm. h H&E staining of sections of duodenum from adult mice. Yellow arrows point to Paneth cells. Images are
representative of six mice per genotype. Scale bar= 100 µm. All source data are provided within a Source Data excel file. Graphs show mean+ SEM
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reduction in the number of cells expressing LY6C, KIT, or FLT3
(Supplementary Fig. 3e). In view of the apparent loss of CSF1R
protein, we examined whether BM frommutant mice is responsive to
CSF1. BM-derived macrophages (BMDM) are generated from
Csf1rΔFIRE/ΔFIRE BM, but with greatly reduced yield compared to
controls (Supplementary Fig. 3f). The macrophages derived from
Csf1rΔFIRE/ΔFIRE BM still express F4/80 and CD11b but have lower
levels of surface CSF1R detected with pCSF1-FcAF647 relative to
controls (Supplementary Fig. 3g). Hence, the production/survival of
these few BMDM relies on some mechanism that compensates for
the absence of FIRE.
Macrophage populations in Csf1rΔFIRE/ΔFIRE mice. We per-
formed flow cytometry and/or immunohistochemistry analyses
on major organs as shown in Fig. 4, Supplementary Figs. 4 and 5.
Liver macrophages (Kupffer cells, KC) are CSF1R-dependent4,6,
CSF1-responsive27, and the main site of clearance of labeled
CSF111. The number, location, or morphology of KC and the
liver-to-body weight ratio of Csf1rΔFIRE/ΔFIRE mice are similar to
littermate controls (Supplementary Fig. 4a, b). Flow cytometry
analysis confirmed the unchanged numbers of KC and dendritic
cell subsets (cDC2 as defined previously11) (Fig. 4a) and retention























































































































































































































FSC-A FSC-A Zombie violet
Fig. 3 FIRE deletion reduced functional CSF1R expression in blood. a Cell populations in whole blood of 11–13-week-old Csf1rΔFIRE/ΔFIRE mice (Δ/Δ) and
controls (+/+) were quantified using an automated hematology analyzer. n= 5 mice per genotype. WBC white blood cells, RBC red blood cells, PLT
platelets, Nφ neutrophils, Ly lymphocytes, Mo monocytes. b Whole EDTA-blood from 11 to 13-week-old mice was analyzed by flow cytometry. Plots show
the representative gating strategy to identify live single cells for subsequent analysis. c Myeloid cells were identified as CD11b+B220− (Panel 1) then
separated by LY6C and SSC to identify granulocytes (LY6C+SSChi, panel 2). The LY6C+ and LY6Clo monocyte populations were then analyzed for CSF1R
expression (Panels 3 and 4, respectively). n= 7+/+, 5+/Δ, and 4 Δ/Δ from four experiments. For % of live cells P= 0.012 (*CD11b+) and 0.019 (*LY6C+
Mo). For median fluorescence intensity (MFI) of CSF1R P= 0.027 (*+/+ vs. +/Δ), and 0.022 (*+/+ vs. Δ/Δ). Grans. granulocytes, Mo monocyte. d F4/
80+B220− myeloid cells were analyzed for binding of CSF1 (pCSF1-FcAF647)11. n= 3 mice per genotype from four experiments. P= 0.033 (*). All source
data are provided within a Source Data excel file. Graphs show mean+ SEM and P values were determined by two-tailed t-tests
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However, there is a significant increase in LY6Clo monocyte-like
cells (CD11b+F4/80lo). The full gating strategy for liver flow
cytometry data is shown in Supplementary Fig. 4d.
The marginal zone is completely absent in the spleen of Csf1op/op
mice28 and in Csf1r−/− rats5. In Csf1rΔFIRE/ΔFIRE mice the overall
architecture and relative area of the marginal zone is
indistinguishable from the controls (Supplementary Fig. 4e and f).
As in the liver, there is no change in the spleen-to-body weight ratio
or the relative abundance of myeloid populations defined by
staining for F4/80+ or other markers (Supplementary Fig. 4g, h and
Fig. 4b). The full gating strategy for spleen flow cytometry data is
shown in Supplementary Fig. 4i.
Liver gated: CD45+Lin–a b














































































































































































































Fig. 4 Macrophage populations in liver, spleen, and lungs are unaffected in FIRE-deficient mice. a Leukocyte populations were analyzed from enzymatically
digested livers from mice aged between 8 and 10 weeks. Flow cytometry profiles show representative Csf1r+/+ (+/+) and Csf1rΔFIRE/ΔFIRE (Δ/Δ) mice
using the gating strategy described by Hawley et al.11. Kupffer cells (KC) were identified as CD45+, lineage− (Lin-; CD3−CD19−LY6G−) and F4/
80hiCD11blo (Panel 1). F4/80lo/CD11bhi and F4/80−/CD11b− populations were further separated on the basis of LY6C and MHCII expression (Panels 2
and 3). Mo monocyte, cDC conventional dendritic cell, pDC plasmacytoid dendritic cell. n= 7+/+ and 5 Δ/Δ from 3 repeat experiments. P= 0.0002
(***). b Leukocyte populations were analyzed from enzymatically digested spleens from mice aged between 8 and 10 weeks. The flow cytometry profiles
show representative Csf1r+/+ (+/+) and Csf1rΔFIRE/ΔFIRE (Δ/Δ) mice. Conventional dendritic cells (cDC) were identified as CD11b+B220−CD11c+LY6G−
and granulocytes as CD11b+B220−CD11c−LY6G+ (Panel 1). Red pulp macrophages were identified as CD11b+B220−F4/80+SSClo (Panel 2). n= 3–9 mice
per genotype from 4 repeat experiments. c Single cell suspensions of digested lungs were analyzed by flow cytometry as described above for the liver using
the same cohort of mice. Alveolar macrophages (AM) were defined as F480+CD11blo (Panel 1) and CD11c+SIGLECF+ (Panel 2). The CD11b+F4/80−/+
cells were further analyzed to define the monocytes (Mo, MHCII−LY6C−/+, Panel 3), interstitial macrophages (IM, MHCII+CD11c−/+CD64+) and
conventional dendritic cells subset 2 (cDC2, MHCII+CD11c+CD64−) in Panel 4. All source data are provided within a Source Data excel file. Graphs show
mean+ SEM and P values were determined by two-tailed t-tests
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Lung macrophage populations are primarily controlled by
CSF2 (also known as GM-CSF, encoded by Csf2), rather than
CSF129, but lung macrophages do express Csf1r and bind CSF111.
The Csf1r-EGFP macrophage-reporter transgene is highly
expressed in both alveolar (AM) and interstitial macrophage
populations in the lung10, which have distinct developmental
origins and renewal mechanisms during adulthood30. Further-
more, expression of Csf1r-EGFP in AM is dependent upon the
inclusion of FIRE in the transgene10. Macrophages of the lung are
partly depleted in Csf1op/op mice31 and double mutant Csf1op/op
and Csf2−/− mice develop severe alveolar proteinosis29. AM can
be identified based upon expression of SIGLECF30. Interstitial
myeloid populations have been classified as macrophage and
conventional dendritic cell subpopulations, based upon expres-
sion of CD64, CD11b, CD11c, and MHCII11. To assess the
impact of the FIRE deletion on these populations, lungs were
digested and analyzed by flow cytometry as previously
described11. The full gating strategy is shown in Supplementary
Fig. 5a. We also measured Csf1r mRNA in the lung of wild-type
and Csf1rΔFIRE/ΔFIRE mice (Supplementary Fig. 5b). FIRE
deletion has no effect on AM or any of the interstitial myeloid
populations of the lung (Fig. 4c). A marginal reduction in Csf1r
mRNA is likely attributable to the loss of expression in monocytes
in both blood and BM (Fig. 3c, d and Supplementary Fig. 3c, d).
F4/80 is barely detectable in either of the major lung macrophage
populations and is primarily associated with monocytes30.
Accordingly, the levels of total Adgre1 (encoding F4/80) and
Itgam (CD11b) mRNA in the lung are unaffected by the deletion
of FIRE. We conclude that FIRE is not required for expression of
Csf1r mRNA in lung macrophages nor for their development or
monocyte trafficking in the lung.
The large macrophage population of the intestine is constantly
renewed from recruited blood monocytes32. The Peyer’s patch
and surrounding mucosa contain several specialized mononuclear
phagocyte populations, distinguished by mRNA or protein
expression of the surface markers F4/80 (ADGRE1), CD4,
SIGLEC1, SIRPA, MERTK, TIM4, CX3CR1, and ITGAX
(CD11c)33, including a recently described long-lived
population34,35. All of these populations depend upon continuous
CSF1R signaling6,21. Monocytes enter the lamina propria
constantly and respond to the local environment with progressive
changes in surface phenotype and gene expression in a so-called
monocyte waterfall32. Supplementary Fig. 6 shows the compar-
ison of these populations in the Csf1r+/+ and Csf1rΔFIRE/ΔFIRE
mice. There is no detectable difference in distribution of
monocyte-like, DC-like, or macrophage populations in either
small or large intestine.
Macrophages are so abundant in the intestine that the level of
macrophage-specific transcripts can be reproducibly detected by
analysis of total mRNA. To complement the analysis of isolated
cells, we isolated mRNA from Peyer’s patches and surrounding
mucosa in the ileum of Csf1r+/+ and Csf1rΔFIRE/ΔFIRE mice and
profiled gene expression using microarrays. There is no
significant difference in Csf1r expression between Csf1r+/+ and
Csf1rΔFIRE/ΔFIRE mice nor in the level of mRNA encoding any of
the markers of intestinal macrophage subpopulations mentioned
above, including Itgam (CD11b) and Ly6c1, which are rapidly
down-regulated following extravasation into the intestine32
(Supplementary Data 1). These findings demonstrate that FIRE
is not required by intestinal macrophages for expression of Csf1r
and that the loss of CSF1R in monocytes has no impact on
intestinal macrophage homeostasis. In addition, the expression of
transcripts that mark cell types controlled indirectly by signals
from CSF1R-dependent macrophages, including markers of
Paneth cells (Lyz1), microfold cells (Spib, Ccl9, Tnfrsf11a) or
goblet cells (Muc2)21, are unaffected (Supplementary Data 1).
Loss of macrophage populations in Csf1rΔFIRE/ΔFIRE mice. The
resident macrophages of the peritoneal cavity may be subdivided
into two populations, based upon relative size and the level of
TIM4 and F4/80 antigen they express36. Both populations of
peritoneal macrophages (PM) are absent from Csf1op/op and
Csf1r−/− mice4,28 and from mice treated with anti-CSF1R anti-
body6. The major TIM4+F4/80hiCD11bhi large PM population is
almost entirely lost in Csf1rΔFIRE/ΔFIRE mice (Fig. 5a and Sup-
plementary Fig. 6a). The minor residual PM population consists
of the small PM that are TIM4−F4/80lo36. These cells were shown
previously to bind labeled CSF1 preferentially compared to large
PM11. Both anti-CSF1R (CD115) and CSF1-Fc binding to these
residual populations are absent in the Csf1rΔFIRE/ΔFIRE mice
(Fig. 5a). In Csf1rΔFIRE/+ mice the PM populations are retained
but as in blood and BM, there is a reduction in the level of surface
receptor detected with either labeled CSF1 or anti-CSF1R anti-
body, which is consistent with the lack of dosage compensation.
In summary, in the peritoneum, the Csf1rΔFIRE/ΔFIRE mutation
phenocopies the Csf1r-deficient mice.
The abundant interstitial F4/80hi macrophage populations of
the kidney have recognized roles in renal growth and
development37, homeostasis and immune surveillance38.
F4/80hi kidney macrophages were almost absent from both
Csf1op/op and Csf1r−/− mice4. To identify populations of renal
mononuclear phagocytes we enzymatically digested kidneys and
analyzed CD45+ myeloid cells by flow cytometry. The gating
strategy is shown in Supplementary Fig. 7b. Csf1rΔFIRE/ΔFIRE
mice have fewer total CD45+ cells and the F4/80hiCD11blo
resident kidney macrophages (KM)38 are undetectable (Fig. 5b).
In both control and mutant, a subset of the CD11bhi cells are F4/
80loMHCII− monocytes but the majority of cells in the F4/
80loCD11bhi (R1) gate are also MHCII+/CD64+. Their surface
phenotype is reminiscent of the monocyte-derived small PM
discussed above. As in the peritoneum, their abundance is
slightly increased by the FIRE mutation (Fig. 5b). Conventional
dendritic cells (cDC) in the kidney are difficult to separate from
macrophages based upon surface markers. A minor subpopula-
tion of cDC (F4/80−CD11b+MHCII+) is detected in both
control and Csf1rΔFIRE/ΔFIRE kidneys (R2 gate) (Fig. 5b).
Although exogenous CSF1 can promote mouse kidney morpho-
genesis in vitro and growth of the kidney in vivo37, there is no
change in the kidney-to-body weight ratio in Csf1rΔFIRE/ΔFIRE
mice (Supplementary Fig. 7c) and kidneys are histologically
normal (Supplementary Fig. 7d).
Macrophages of the heart can also be separated into
subpopulations attributed distinct roles in cardiac homeostasis
and repair following injury39–41. Supplementary Fig. 7e shows the
flow cytometry gating strategy for the heart and Fig. 5c
summarizes the analysis of digested cardiac macrophage popula-
tions from control and Csf1rΔFIRE/ΔFIRE mice. The total cardiac
CD45+ population is greatly reduced in the Csf1rΔFIRE/ΔFIRE
mice due to selective loss (70–80%) of both the F4/80hiCD64+
macrophage (MHCIIhi) and monocyte-like (MHCIIlo) popula-
tions previously described by others39–41. Interestingly, a recent
study proposed a link between resident macrophages of the
kidney and the heart in the generation of an adaptive response to
cardiac pressure overload40. However, as in the kidney, we detect
no change in the heart-to-body weight ratio in Csf1rΔFIRE/ΔFIRE
mice (Supplementary Fig. 7f) and the histology is indistinguish-
able from controls (Supplementary Fig. 7g).
There are two major macrophage populations in the skin, the
Langerhans cells of the epidermis and the dermal macrophages.
Both are CSF1R-dependent4,6 but Langerhans cells, like micro-
glia, depend specifically on the alternative CSF1R ligand, IL3442.
Langerhans cells are absent in epidermal sheets from tails of
Csf1rΔFIRE/ΔFIRE mice (Fig. 6a). The loss of this cell population
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has no effect on the morphology of the epidermis or the dermis
(Fig. 6b). Dermal macrophage populations accumulate melano-
somes from neighboring melanocytes and, like macrophages of
the gut, they turn over rapidly43. The stellate melanophagic
macrophage populations of the dermis are F4/80+ and are not
affected by the FIRE mutation (Fig. 6b).
Loss of microglia in Csf1rΔFIRE/ΔFIRE mice. Microglia, the
tissue-resident macrophage population of the brain, arise very
early in mouse embryonic development and depend upon CSF1R
signaling44. Microglia detected by localization of IBA1 or
P2RY12 in littermate controls are absent in the brain of
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Fig. 5 FIRE deletion results in loss of macrophages in the peritoneal cavity, kidney, and heart. a Flow cytometry profiles show peritoneal cells from
representative Csf1r+/+ and Csf1rΔFIRE/ΔFIRE mice using the gating strategy described by Bain et al.36. Small peritoneal macrophages (SPM) were identified
as F4/80loCD11b+ and large peritoneal macrophages (LPM) as F4/80hiCD11b+ (Panel 1). These populations were analyzed for CSF1R expression (Panel 2)
and binding of pCSF1-Fc (Panel 3). n= 8+/+, 6+/Δ and 9 Δ/Δ mice aged between 10 and 15 weeks, from five experiments. P= 0.012–0.048 (*),
0.002–0.006 (**), 0.001 (***) and <0.0001 (****). b Leukocyte populations were isolated from enzymatically digested kidneys and gated for CD45
expression. The flow cytometry profiles show analysis of representative Csf1r+/+ and Csf1rΔFIRE/ΔFIRE mice. Kidney macrophages (KM) were identified as
F4/80hiCD11blo (Panel 1), pooled LY6C−/+ monocytes (Mo) as F4/80loMHCII− (Panel 2), putative monocyte-derived macrophages as F4/80loMHCII+
(Panel 2), and conventional dendritic cells (cDC) as F4/80−CD11bloMHCII+ (Panel 3). n= 5 mice per genotype aged 8–10 weeks, from three experiments.
P= 0.015 (*) and 0.0001 (***). c Single cell suspensions of enzymatically digested hearts from the same cohort were analyzed by flow cytometry. Cells
were gated lineage− (Lin−= CD3/CD19/LY6G). n= 6+/+ and 5 Δ/Δ from three experiments. MΦ macrophage, Mo monocyte. P= 0.009 (**), 0.0003






































Csf1r +/+ Csf1r ΔFIRE/ΔFIRE
Fig. 6 The deletion of FIRE results in loss of Langerhans cells. a Whole-mount epidermal tail sheets were stained with antibodies against LANGERIN
(green) and MHCII (red). Nuclei were stained with DAPI (blue). Images are representative of four mice per genotype, aged between 8 and 10 weeks. Scale
bars= 50 µm. b Decalcified tails from the same cohort of mice above were stained with hematoxylin and eosin (H&E, upper panel) and an antibody against
F4/80 (lower panel). E epidermis, D dermis, H hair follicle. Scale bars= 50 µm
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brain and analysis by flow cytometry45 confirms the loss of
CD45low/CD11b+ microglia which persists up to 9 months of
age (Fig. 7c). The full flow cytometry gating strategy is shown in
Supplementary Fig. 8a. Heterozygous mutation (haploinsuffi-
ciency) of Csf1r has been proposed as a model for the human
neurodegenerative disease ALSP (adult onset leukoencephalo-
pathy with axonal spheroids and pigmented glia)46. However,
there is no detectable effect of the heterozygous mutation in mice
(Csf1rΔFIRE/+) on microglial numbers. The brain also contains
populations of CD45hi classical macrophages associated with
the vasculature, meninges, and choroid plexus with a distinct
transcriptional profile47,48. CD45hi cells are retained in
Csf1rΔFIRE/ΔFIRE brain digests (Fig. 7c) This was confirmed by
immunolocalization of CD169, shown recently to be a marker
alongside CD206 and LYVE1 for a perivascular macrophage
population in most tissues49 (Fig. 7d, e). The brain-to-body
weight ratios in adult male and female Csf1rΔFIRE/ΔFIRE mice




























































Fig. 7 FIRE deletion results in selective loss of microglia. a Cryosections of adult brains were stained with an antibody against IBA1. Boxed area shows an
IBA1+ perivascular macrophage in the Csf1rΔFIRE/ΔFIRE mouse brain. Scale bars= 100 µm, 50 µm in the upper and lower panels, respectively. Images are
representative of four mice per genotype. b Cryosections of adult brains were stained with an antibody against P2RY12. Scale bar= 40 µm. c Single cell
suspensions of myelin-depleted brains from males and females aged 10 weeks to 9 months were analyzed by flow cytometry for CD45 and CD11b
expression as per45. Microglia= CD45lowCD11b+. Macrophages= CD45+CD11b+. n= 8+/+, 5+/Δ, 8 Δ/Δ from five experiments. P < 0.0001 (****) Δ/Δ
compared to +/+. d Cryosections of adult brains stained with an antibody against IBA1 using the same cohort of mice in a and b. Upper panel shows the
choroid plexus (CP) and white arrows point to perivascular macrophages in the lower panel. Images are representative of three mice. Scale bars= 40 and
20 µm in the upper and lower panels, respectively. e Dissected meningeal dura mater was stained with antibodies against IBA1 and CD169. Images are
representative of two mice per genotype. Scale bars= 50 µm. All source data are provided within a Source Data excel file. Graphs show mean+ SEM and
P values were determined by two-tailed t-tests
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Microglia are so abundant in the brain that their gene
expression profile is readily detected in total mRNA. The
complete loss of microglia in Csf1r−/− rat brains was associated
with commensurate loss of known microglia-associated tran-
scripts in four brain regions5. To confirm the loss of microglia
we compared the gene expression profiles of Csf1rΔFIRE/ΔFIRE
and Csf1r+/+ hippocampi. The results, including ANOVA
analysis of significantly regulated transcripts, are contained
within Supplementary Data 2. Overall, 85 genes are significantly
downregulated in the Csf1rΔFIRE/ΔFIRE mouse hippocampus
and 77 genes from this group (including Csf1r) have been
previously shown to be expressed in human and mouse
microglia45,50,51. Of the top 35 transcripts found by Elmore
and colleagues to be down-regulated in the brains of adult mice
treated with a CSF1R kinase inhibitor52, 26 are also significantly
reduced in the hippocampus of Csf1rΔFIRE/ΔFIRE mice. The gene
set affected by the Csf1rΔFIRE/ΔFIRE mutation includes a small
set of novel genes that may be implicated in microglial biology.
Amongst these, the immune checkpoint protein, VISTA (Vsir),
was recently localized in both human and mouse and was
attributed functions in CNS pathologies53. In addition, HVCN1
was previously shown to regulate the production of microglial
reactive oxygen species54. Consistent with the retention of the,
CD45hiCD11b+CD169+ brain macrophage population in the
Csf1rΔFIRE/ΔFIRE mice (Fig. 7b–e), Ptprc (encoding CD45
antigen) and myeloid markers, such as Mrc1(Cd206), Siglec1,
Siglecf, Cd163, Csf2ra/b/b2, Fcgr2b, Tnfrfsf11a (RANK) that
have all been associated with these populations47,48 are not
significantly affected by the deletion of FIRE (Supplementary
Data 2). The complete loss of detectable Csf1r expression
implies that the perivascular and brain-associated macrophages,
like blood monocytes and the macrophages of the BM, have lost
Csf1r expression but are nevertheless produced normally.
Microglia have been implicated in oligodendrocyte maturation
and synaptic plasticity55. The loss or induced depletion of
microglia in other models leads to alterations in synaptic pruning,
hippocampal neurogenesis, myelination, oligodendrocyte matura-
tion, and astrocyte activation56. By contrast to phenotypes
reported in Csf1op/op and Csf1r−/− mice4, we observe no evidence
of auditory or visual abnormalities in the Csf1rΔFIRE/ΔFIRE mice.
Sensory neuronal deficits have been associated with deficient
hippocampal neurogenesis but in the Csf1rΔFIRE/ΔFIRE mice there
is no loss of expression of markers associated with neuronal
progenitor cells (such as doublecortin (Dcx), and Sox257)
(Supplementary Data 2). Nandi et al.58 claimed that Csf1r is
expressed in subsets of neuronal progenitors, and noted the
relative loss of excitatory neurons, expressing Cux1 or Ctip2
(BCll1b) in the Csf1r−/− mouse brain. CUX1 mRNA was also
reduced in the brain in a recently described human patient with a
homozygous CSF1R mutation59. Neither transcript is down-
regulated in the hippocampus of Csf1rΔFIRE/ΔFIRE mice (Supple-
mentary Data 2).
Zhang et al.60 used expression profiles of isolated cells to
identify a set of signatures of brain cell populations that can
support deconvolution of whole brain expression data. As
shown in Supplementary Fig. 8c, there is no significant effect
of the Csf1rΔFIRE/ΔFIRE mutation on any cell-type-specific
signature (neuron, astrocyte, oligodendrocyte, endothelium)
other than microglia. The lack of impact on astrocyte numbers
or morphology was confirmed by immunolocalization of the
specific markers GFAP and SOX9 in the hippocampus, as well
as the striatum, olfactory bulbs, and cerebellum (Supplemen-
tary Fig. 8d). Whereas microglia have been implicated as
major sources of trophic factors, mRNA expression of Bdnf,
Igf1, Tgfb1,2, and 3 is not affected by the absence of microglia
in Csf1rΔFIRE/ΔFIRE mice (Supplementary Data 2). Similarly,
macrophages and microglia selectively express very high levels
of lysosomal-associated genes (e.g. Lamp1, Ctsb, Atp6v0e) and
receptors for apoptotic cells (e.g. Mertk, Axl) compared to
whole brain regions (e.g. see biogps.org) but the loss of
microglia has no effect on the expression of any lysosome-
associated transcripts in the hippocampus of Csf1rΔFIRE/ΔFIRE
mice. This conclusion is consistent with the proposal that
astrocytes are potentially also engaged with apoptotic cell
clearance61 and might fill this role in the absence of microglia.
Embryonic macrophage development in Csf1rΔFIRE/ΔFIRE mice.
Many tissue resident macrophages are seeded during embryonic
development from the yolk sac and fetal liver
progenitors24,30,41,44,62,63. Csf1r−/− mice lack yolk sac-derived
macrophages and microglia but develop fetal monocytes44.
Treatment of a pregnant mouse with anti-CSF1R resulted in the
loss of embryonic macrophages derived from the yolk sac,
whereas circulating liver-derived monocytes were unaffected63.
As shown in Fig. 8a the Csf1rΔFIRE/ΔFIRE embryos develop nor-
mally but the overall density of IBA1+ macrophages throughout
the body is greatly reduced. In the critical window in which liver
hematopoiesis is established and the blood–brain barrier is closed
(embryonic day 12–13), IBA1+ ameboid microglia are prevalent
in controls but undetectable in Csf1rΔFIRE/ΔFIRE embryos
(Fig. 8b–d). Numerous macrophages expressing the CSF1R-ECFP
and CSF1R-EGFP reporter genes line the ventricular and external
surfaces of the developing brain from 9.5 dpc10,64. These cells are
absent in Csf1rΔFIRE/ΔFIRE embryos (Fig. 8b, c). Only occasional
monocyte-like cells associated with blood vessels are seen in the
brain parenchyma (Fig. 8b). By contrast, IBA1+ monocytes/
macrophages are detected in the meninges and choroid plexus in
both control and mutant embryos (Fig. 8c, d), consistent with our
findings in the adult brain (Fig. 7). There is also a reduction in the
IBA1+ macrophages in the fetal liver at the same stages of
development (Fig. 8e). We conclude that the Csf1rΔFIRE/ΔFIRE
mice recapitulate the phenotype of Csf1r−/− mice in early
hematopoiesis, producing a selective deficiency of yolk sac-
derived cells. The major macrophage populations that are
retained in the adult Csf1rΔFIRE/ΔFIRE mice (liver, lung, spleen,
intestine, dermis, etc.) are established late in gestation and post-
natally from monocytes derived from progenitors in the fetal
liver24,30,44,62,63. This conclusion is consistent with analysis of
expression of tissue macrophage-specific genes across an
embryonic gene expression time course65.
The chromatin landscape of Csf1r. Chromatin analysis and
ChIP-seq data identifies at least four other Csf1r enhancers that
are active in mouse BMDM. Each is bound by JUN, STAT1, PU.1,
and CEBPA, which also bind cooperatively to many other
macrophage-associated enhancers (reviewed in ref. 9). To extend
these findings to other macrophage populations, we explored data
from a previous study that compared the enhancer profiles of
monocytes, microglia, and macrophages isolated from lung, liver,
spleen, intestine, and peritoneal cavity66. Peaks of H3K4me1
methylation (indicative of poised enhancers) appear throughout
the Csf1r locus and extend upstream into the neighboring Pdgfrb
gene (Fig. 9a). This extended H3K4me1 signal is almost unde-
tectable in neutrophils, which express Csf1r mRNA and Csf1r
reporter genes at low levels but do not express surface CSF1R11.
These additional elements lie outside the 3.5 kb promoter region,
and intron containing FIRE, used in production of Csf1r-reporter
genes (Fig. 9a). The ATAC-seq data revealed heterogeneity
amongst monocyte–macrophage populations. FIRE is clearly a
major peak of open chromatin detected in microglia and peri-
toneal macrophages, consistent with the impact of deletion of this
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element (Fig. 9b). By contrast, the signal associated with FIRE is
barely detectable in isolated lung and intestinal macrophages.
Indeed, the promoter-associated ATAC-seq signal is barely
detectable, consistent with relatively low expression of Csf1r
mRNA in these cells35,67,68 and lack of phenotype observed in
these tissues in Csf1rΔFIRE/ΔFIRE mice21. The ATAC-seq data in
Fig. 9b reveals multiple additional elements in cells that clear the
majority of CSF1 from the circulation (notably in KC and splenic
macrophages), that likely contribute to the redundancy of FIRE
and to the high level of Csf1r expression in these cell types11. One
of these elements includes the distal promoter element (DPE).
Located 5′ of the macrophage transcription start site, the DPE
also has tissue-specific functions64. It includes a separate tran-
scription start site cluster used by osteoclasts69. Expression of an
amplified Csf1r-ECFP (MacBlue) reporter transgene, in which
the DPE was deleted from the promoter, was undetectable in
most tissue macrophages64. The exceptions that retained reporter
gene expression were those populations impacted in the
Csf1rΔFIRE/ΔFIRE mouse; embryonic macrophages, BM progeni-
tors and monocytes, microglia, Langerhans cells, and peritoneal
macrophages. Therefore, we conclude that FIRE and the DPE
interact to control expression of Csf1r in embryonic macrophages
and in some tissue-resident macrophage populations but that
both are partly redundant.
Discussion
We show that the regulatory element, FIRE, is not required to
support Csf1r transcription in all macrophage populations. FIRE
is essential for the generation or maintenance of specific CSF1R-
dependent tissue macrophages, including those of the embryo, the
brain (microglia), skin (Langerhans cells), peritoneum, heart, and
kidney but redundant for expression of Csf1r mRNA in adult
mononuclear phagocyte populations in the intestine and lung.
FIRE is not required for the development of CSF1R-dependent
macrophages in other locations (i.e. dermis, spleen, liver, and
bone). The microglial population of the brain is established early
in development from yolk sac-derived progenitors. Apart from a
transient postnatal monocyte influx, microglia are maintained
by self-renewal in a CSF1R-dependent manner70. The loss of







































Fig. 8 FIRE deletion results in a reduction of embryonic macrophages. a Formalin-fixed paraffin-embedded embryos (E13) were stained with antibodies
against IBA1. Images are representative of seven embryos per genotype at E12, E12.5, and E13 and four repeat experiments. CP choroid plexus, LV lateral
ventricle, S striatum, FL fetal liver. Black rectangle indicates the area magnified for panel d. Scale bar= 1 mm. b View of the striatum from E12.5 embryos
highlighting IBA1+ microglia and ventricular macrophages (MΦ) in the control embryo and a monocyte (Mo) in the FIRE deficient embryo. Dotted arrows
point to immature red blood cells in a blood vessel. Scale bar= 100 µm. c Images of the choroid plexus in the lateral ventricle (LV) of E12.5 embryos. CPM
choroid plexus macrophage, MΦ ventricular macrophages, CF choroidal fissure. Scale bar= 100 µm. d IBA1+ meningeal macrophages (MM) in the
forebrain (boxed area in panel a) of control and Csf1rΔFIRE/ΔFIRE embryos at E12.5. Scale bar= 50 µm. e IBA1+ fetal liver monocytes at E12 and E13 in upper
and lower panels, respectively. Scale bar= 100 µm
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microglial development fails early in embryogenesis. This is
consistent with the apparent failure of macrophage production
from Csf1rΔFIRE/ΔFIRE EB in the E14 ESC model (Fig. 1f).
The relative independence of the large majority of tissue-
resident macrophages on the enhancer activity of FIRE begs the
question of why this element is so highly conserved across evo-
lution. Enhancer redundancy (i.e. the presence of shadow
enhancers), is widespread in eukaryotic developmental systems71.
Nevertheless, redundancy is often incomplete and the non-
overlapping functions presumably explain why multiple enhan-
cers within a locus are conserved across evolution71. The core
element within FIRE, conserved from reptiles to humans, con-
tains binding sites for AP1 and PU.1 that are essential for
enhancer activity14. Colocalization of AP1 and PU.1 motifs is a
feature of many mouse macrophage-specific constitutive enhan-
cers72. The non-redundant role of FIRE in Csf1r transcription in
only a subset of macrophages may be a consequence of tissue-
specific expression of transcription factors that bind selectively to
this region of the Csf1r locus. Candidate regulators have been
identified in many CSF1R-dependent macrophage populations.
For example, microglia are uniquely dependent upon specific
transcriptional regulators encoded by Sall173 and Irf874. Whilst
multiple open chromatin sites are bound by PU.1, CEBPA, and
other transcription factors in BMDM, IRF8 bound strongly and
exclusively to FIRE (reviewed in ref. 9). Irf8 mRNA is co-
expressed with Csf1r in the earliest committed monocyte pro-
genitors75 and upregulated in erythro-myeloid progenitors in
parallel with Csf1r during early embryonic development67. Renal
macrophages, which are also lost in Csf1rΔFIRE/ΔFIRE mice, along
with blood monocytes, share high gene expression of Irf8 with
microglia67. RUNX1 is another transcription factor that interacts
with FIRE in both mouse and human macrophages and controls
CSF1-dependent macrophage growth76. Accordingly, Runx1
mRNA is expressed in the earliest progenitors of CSF1R-positive
microglia44 and is amongst the transcription factors down-
regulated in the hippocampus in Csf1rΔFIRE/ΔFIRE mice (Supple-
mentary Data 1).
CSF1R deficiency causes embryonic or perinatal death in most
mouse strains and the few surviving Csf1r mutant mice have
numerous developmental abnormalities77. The Csf1rΔFIRE/ΔFIRE
mice that are born survive and thrive. Aside from survival,
other major differences between the pleiotropic impacts of
Csf1rΔFIRE/ΔFIRE and Csf1r−/− mutations4,77 are clearly related to
the selective retention of most Csf1r-dependent macrophage
populations in mice with the FIRE deletion. The expression
profiling of the hippocampus supports the view that trophic and
phagocytic functions attributed to microglia can be compensated
in part by other cells. Notably, neuronal development, including
expression of markers such as Cux1, is unaffected by the complete
loss of Csf1r expression. This observation argues strongly against
a functional role for Csf1r in neuronal progenitors58 and instead
supports that Csf1r is expressed and functional only in micro-
glia19. So, we suggest that the reported developmental and
homeostatic roles of Csf1r-dependent macrophages, including
microglia and those of the epidermis, peritoneum, kidney, and
heart are at least partly redundant. By extension, the loss of most
peripheral macrophages and the associated systemic impacts of
that loss must contribute to the severe brain developmental
abnormality observed in Csf1r−/− mice19,78. Severe postnatal
growth retardation is a shared feature of Csf1 and Csf1r mutant
mice and rats4,5 and is a consequence of impacts on the growth
hormone (GH)/insulin-like growth factor 1 (IGF1) axis (reviewed
in ref. 79). By contrast to the Csf1r-deficient mice, liver macro-
phages develop normally in Csf1rΔFIRE/ΔFIRE animals (Fig. 4a and
Supplementary Fig. 4a) and somatic growth, as well as the
male–female sexual dimorphism in body weight gain, is unaf-
fected by the mutation. In Csf1 mutant rats, there was no post-
natal surge in circulating IGF179) and the Csf1r mutation in rats
reduced expression of both Ghr and Igf1 mRNA in the liver5.
Circulating IGF1 in turn crosses the blood brain barrier and
regulates many aspects of neuronal health (reviewed in ref. 80).
In overview, our objective in this study was to investigate the
role of a conserved enhancer in a key macrophage-expressed
gene. We have confirmed the functional importance of FIRE in
specific macrophage populations. In the process, we have gener-
ated a unique mouse model in which to identify non-redundant
functions of specific resident tissue macrophages, especially those
of the brain, heart, skin, kidney, and peritoneum, in mice that are
otherwise healthy and fertile.
Methods
CRISPR design and plasmid preparation. gRNAs were designed to complement
the flanking regions of the FIRE element of intron 2 (from 2646 to 3015 bp
downstream of the end of exon 2; NCBI Reference Sequence: NM_001037859.2)
using the online tool at http://crispr.mit.edu. Table 1 shows the guides designed,
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Fig. 9 Chromatin landscape of the mouse Csf1r locus. ChIP-seq and ATAC-
seq data for the 100 kb window surrounding mouse Csf1r for each of the
isolated myeloid cell populations shown was extracted from the primary
data generated in Lavin et al.66. a ChIP-seq data showing the location of
poised enhancers (H3K4me1). The boxed area indicates the 3.5 kb
promoter region used in the production of Csf1r reporter genes. b ATAC-
seq data showing the locations of open chromatin. The dotted lines
surround the double peak in the second intron; the more prominent peak
is FIRE
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BbSI-overhang sequences. Top and bottom oligonucleotides corresponding to each
gRNA were aligned, phosphorylated, and cloned into the pSpCas9(BB)-2A-GFP
(Px458) plasmid (Addgene), and transformed into competent DH5α E. coli. Fol-
lowing verification of gRNAs insertion by Sanger sequencing, plasmids were
purified using endotoxin-free MaxiPrep (QIAGEN).
Cell culture. RAW 264.7 macrophages (ATCC® TIB-71™) were cultured on
Sterilin-plastic dishes in RPMI 1640 medium (Sigma) supplemented with 10%
endotoxin-free FBS (GE Healthcare), 2 mM GlutaMAX (Invitrogen), 25 U/mL of
penicillin, and 25 µg/mL of streptomycin (Gibco). Cells were incubated at 37 °C in
a 5% CO2 humidified incubator. E14 (129P2/OlaHsd) mouse ESC (ATCC® CRL-
1821™) were cultured on porcine gelatin-coated (Sigma) flasks in GMEM (Invi-
trogen) supplemented with 10% ESC-tested FBS (Hyclone), 2 mM GlutaMAX
(Invitrogen), 1X MEM non-essential amino acids, 1 mM sodium pyruvate, 0.1 mM
2-mercaptoethanol (Gibco), and 100 U/mL leukemia inhibitory factor (LIF,
Merck), at 37 °C in a 5% CO2 humidified incubator.
Generation of CRISPR/Cas9 deletions in vitro. E14 cells were passaged twice
and plated at 8 × 104 cells/cm2 for 24 h prior to transfection. Cells were transfected
with a total of 2 µg DNA (i.e. pairs of Cas9-2A-EGFP vectors, each expressing
single gRNAs: US1+DS1 or DS2) using the Amaxa P3 Primary cell 4D-
Nucleofector X Kit (Lonza) and incubated with supplemented GMEM for 36 h.
Cells were then resuspended in Dulbecco’s phosphate buffered saline (DPBS,
Sigma), diluted in sterile Baxter water (TPS Healthcare/Baxter), supplemented with
2% FBS and kept at 4 °C. The GFP+ cells were collected with a FACS Aria IIIu cell
sorter (BD). To generate single cell clones of CRISPR-modified E14 cells, sorted
pools of GFP+ cells were plated on 0.1% gelatin-coated 100 mm culture dishes at a
density of 18 cells/cm2 and single colonies picked approximately 2 weeks later.
RAW 264.7 cells (5 × 106) were resuspended in 250 µL of culture medium con-
taining 10 µL of DPBS ± 20 µg DNA (as pairs of FIRE-targeting Cas9-2A-EGFP
vectors, as specified above) and incubated at RT for 10 min. Electroporation was
performed in 0.4 cm electroporation cuvettes (BioRad) using the BioRad Gene
Pulser II (BioRad), at 320 V and a capacitance of 950 µF. Cells were cultured for
36 h and GFP+ cells were single-cell sorted into polystyrene flat-bottom 96-well
plates, using a FACS Aria IIIu cell sorter (BD).
PCR analysis and sequencing of transfected E14 ESC and RAW 264.7 cells.
Isolation of DNA from sorted pools of GFP+ cells (either E14 ESC or RAW 264.7
cells), or from cells cultured in plates other than 96-well plates was performed with
the QIAGEN DNeasy Blood and Tissue Kit (QIAGEN), according to the manu-
facturer's instructions. Genomic DNA from single-cell-derived clones cultured in
96-well plates was isolated by adding a 1:1 mix of DirectPCR Lysis Reagent (Viagen)
and nuclease-free water (Invitrogen) supplemented with 20 µg of Proteinase K
(QIAGEN), per well. Cells were incubated in a heated orbital shaker at 200 rpm and
55 °C, for 12 h and Proteinase K was inactivated at 85 °C for 45min. Conventional
PCR was performed using 50 ng DNA per reaction, Taq DNA polymerase (Invi-
trogen) and the primers F-5′: GCTGCCCTGTCACTGTGTA and R-5′:
TCGTTTCCCATCCCAGGA, at an annealing temperature of 55 °C. PCR products
were run by electrophoresis to obtain a Csf1r+/+ of 925 bp, or Csf1r ΔFIRE/ΔFIRE
amplicons of either 485 bp (CRISPR pair: US1 and DS1) or 507 bp (CRISPR pair:
US1 and DS2). PCR amplicons were separated by standard electrophoresis, purified
with the QIAquick PCR purification kit (QIAGEN) and then sequenced using the
oligonucleotides listed in Supplementary Table 1.
DNA isolation and genotyping. Mouse ear biopsies were digested overnight at
50 °C, in mouse biopsy buffer containing 100 mM Tris–HCl (Sigma) pH 8.5, 0.2%
SDS (Ambion), 200 mM NaCl (Sigma), 5 mM EDTA (Ambion), and 160 µg Pro-
teinase K (QIAGEN). Digested tissues were centrifuged at 12,000×g for 15 min at
4 °C and DNA was precipitated through the isopropanol–ethanol method. DNA
pellets were dried at RT, resuspended in nuclease-free water and quantified using a
Nanodrop™ 1000 (Thermo Fisher Scientific). PCR amplification was performed as
described above and products were purified using the QIAquick PCR purification
kit (QIAGEN) and sequenced using the oligonucleotides listed in Supplementary
Table 1.
Phagocytosis assay. RAW 264.7 cells were cultured in high glucose DMEM
(Gibco) supplemented with 10% endotoxin-free FBS (GE Healthcare) and 1 mM
GlutaMAX (Life Technologies). Cells were incubated at 37 °C for 2 h in the pre-
sence of pHrodo® Red E. coli BioParticles® (Thermofisher) at a ratio of 100 µg/106
cells. Negative control samples were incubated on ice. Cells were analyzed using the
BD LSR Fortessa flow cytometer. Dead cells were identified and excluded based
upon DAPI uptake.
Flow cytometry. Cells were analyzed by flow cytometry using standard procedures.
Inhibition of non-specific binding was achieved by incubating the cells for 30 min
on ice in purified anti-CD16/32 (1 µg/mL, BioLegend, 101302) or hybridoma
2.4G2 supernatant. All antibodies are listed in Supplementary Table 2. Where
indicated, cells were fixed and permeabilized prior to staining using the Leuco-
permTM kit (BioRad). Blood was processed using the Uti-Lyse reagent (Agilent).
Data analysis was performed in FlowJo® v10.0 (Tree Star). Gates were determined
with isotype controls or FMO for all experiments.
Differentiation of ESC-derived macrophages. E14 ESCs were harvested and
plated at a density of 5 × 106 cells per 50 mm Sterilin-plastic dishes, using culture
medium without LIF. After 4 days, cell debris was removed using 70 µm cell
strainers. Fresh culture medium containing 50 ng/mL of rhCSF1 (a gift from
Chiron, USA) and 10 ng/mL of mouse recombinant interleukin 3 (IL3, Invitrogen)
was added. After 7 days the culture medium was replaced to contain 100 ng/mL of
rhCSF1 for 10 days, without IL3.
Generation of Csf1rΔFIRE/ΔFIRE mice. Ethical approval was obtained from The
Roslin Institute’s and The University of Edinburgh’s Protocols and Ethics Com-
mittees, under the authority of a UK Home Office Project License under the
regulations of the Animals (Scientific Procedures) Act 1986. Mice were bred and
housed under specific pathogen-free conditions. Csf1rΔFIRE/ΔFIRE mice were pro-
duced by pronuclear injection of oocytes with the plasmids encoding FIRE-
CRISPRs US1 and DS2 (10 µg of each) and Cas9 mRNA. Both donor and recipient
females were B6CBAF1/J (JAX™, stock number 100011). Founders were then
crossed to C57BL/6 mice and their offspring interbred.
Micro CT. Micro CT was performed on formalin-fixed, paraffin-embedded dec-
alcified femurs. Specimens were held in 1% agarose in a 20 mL universal tube
before mounting in a Skyscan 1172 desktop micro CT (Bruker). The tubes were
then scanned through 360° using a step of 0.28° between exposures. A voxel
resolution of 6.03 µm was obtained using the following control settings: 54 kV
source voltage, 185 µA source current with an exposure time of 1767 ms. A 0.5 mm
aluminum filter and two frame averaging were used to optimize the scan. After
scanning, the data was reconstructed using Skyscan software NRecon v1.6.9
(Bruker). The reconstruction thresholding window was optimized to encapsulate
the target image, with the same values used for all bones. Reconstructed bones were
oriented around their vertical axis using DataViewer v1.5.2.4 (Bruker). The tra-
becular region of bone 200 µm thick starting 100 µm proximal to the primary
spongiosa was identified, and volumetric analysis to determine the micro-
architecture of this region was performed using CTAn v1.16.4.
Histology and immunohistochemistry. Tissues were fixed in 10% neutral buf-
fered formalin and processed into paraffin using standard procedures. For exam-
ination of tissue architecture, sections were stained with hematoxylin and eosin
(H&E) or Luxol fast blue. Femurs and tails were decalcified in EDTA. Osteoclasts
were detected by staining sections with the tartrate-resistant acid phosphatase
(TRAP) kit (Sigma), according to instructions.
Goblet cells were stained by treating sections of small intestine with 1% periodic
acid for 7 min and incubating them in Schiff’s reagent for 15 min, with washes in
water between steps; followed by counterstaining for 15 s with Hematoxylin.
For immunohistochemistry, antigen retrieval was performed with Proteinase K
for 5 min at 37 °C prior to staining. Tissue-resident macrophages in spleen and
liver sections were detected by staining with the rat anti-mouse F4/80 monoclonal
antibody (1:600; AbD Serotec, MCA497G). For staining of adult brains, primary
antibodies were applied overnight at 4 °C in a humid chamber. These included
Table 1 CRISPR guide RNAs
Guide Top BbSI-flanking sequence Guide sequence Bottom BbSI-flanking sequence PAM
US1-top CACC 5' GAGTCCCTCAGTGTGTGAGA – AGG
US1-bottom – 3' TCTCACACACTGAGGGACTC CAAA –
DS1-top CACC 5' GGGATGACACAACGGTTTCC – TGG
DS1-bottom – 3' GGAAACCGTTGTGTCATCCC CAAA –
DS2-top CACC 5' CAATGAGTCTGTACTGGAGC – AGG
DS2-bottom – 3' GCTCCAGTACAGACTCATTG CAAA –
US upstream FIRE, DS downstream FIRE, PAM protospacer-adjacent motif
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chicken anti-GFAP (1:500; Cambridge Bioscience, 829401) and rabbit anti-SOX9
(1:500; Millipore, AB5535). Following three washes in PBS, fluorescently
conjugated secondary antibodies were applied (1:500; Life Technologies) for 2 h at
RT, then slides were counterstained with DAPI for 10 min and mounted with
Fluoromount G (Cambridge Bioscience). For isolation of epidermal sheets,
dissected tail skin was incubated in 2 mg/mL Dispase II (Sigma) at 37 °C for
20 min. Epidermal skin samples were fixed overnight in 4% PFA at 4 °C. After
washing with TBS, samples were incubated for 1 h at RT in permeabilization buffer
(PB)—TBS containing 0.25% gelatin from cold water fish skin (Sigma), 0.5% Triton
X100 (Sigma), and 5% heat-treated goat serum (Sigma). Epidermal samples were
then incubated in PB containing rat anti-mouse MHCII (Clone 2G9, 1:100, BD,
553621) and 1:30 goat anti-human Langerin (1:30, Thermo Fisher Scientific, PA5-
47250) overnight at 4 °C. Samples were washed five times for 1 h at RT in TBS
containing 0.02% Tween 20 (Fisher Scientific) (TBST) followed by incubation
overnight at RT with anti-goat and anti-rat Alexa Fluour secondary antibodies (Life
Technologies) diluted 1:500 in PB. After washing four times for 1 h in TBST,
epidermal sheets were counterstained with DAPI (Sigma) and mounted in Prolong
Gold (Life Technologies).
Frozen sections of 4% PFA perfused adult brains were processed and stained
with rabbit anti-IBA1 (1:500, Wako, 019-19741), rabbit anti-P2RY12 (Sigma, 1:125,
HPA013796), and Alexa Fluor® conjugated secondary antibodies using standard
procedures.
Dura mater were removed into ice-cold PBS, fixed for 1 h in 4% PFA, treated for
30 min at 37 °C in PBS containing 20 mM EDTA and then blocked in 3% BSA,
0.3% Triton X100 in PBS for 30 min. Whole mount staining steps were performed
in blocking buffer containing rabbit anti-IBA1 overnight (1:1000, Wako, 019-
19741), goat anti-rabbit Alexa Fluor® 594 1 h (1:400, Life Technologies, A-11012),
Alexa Fluor® 647 anti-mouse CD169 1 h (Clone Siglec-1, 1:200, BioLegend,
142408), with washes in buffer in between incubations. Stained tissues were then
mounted onto glass slides with mounting medium and cover-slipped. Slides were
imaged via a LSM710 confocal microscope (Zeiss) using Zen software.
Image acquisition and quantification. Whole-slide bright field images were
acquired using the NanoZoomer slide scanner. Image analysis was performed with
the NDP.view software v2.4.26 (Hamamatsu) and with ImageJ v1.46h. For spleen
and liver, 10 regions of interest (ROI) were exported per sample as jpg format from
the NDP.view files. Signal was quantified from the whole area corresponding to
each ROI (i.e. each jpg file). For analysis of small intestine, individual villi were set
as a ROI in the jpg file derived from PAS-staining. Villus perimeter, as well as the
area and the number of Goblet cells (PAS+ cells) were quantified. Measurement of
villus length was performed in H&E images where 30 villi were measured per
sample, from the mucosal base adjacent to the crypts to the apex, using the “ruler”
function of the NDP.view v2.4.26 software. Entire brain tissue sections were imaged
using a Zeiss AxioScan SlideScanner and visualized with Zen2 software. Epidermal
tail sheets were imaged with a Zeiss LSM 710 confocal microscope and ZEN
software. For astrocyte analysis the images were obtained by z-stacks using a Zeiss
Axio Scan.Z1 (10× objective) and an Olympus 3i Spinning Disk confocal micro-
scope (30× silicone objective) using SlideBook software. For astrocytes counts, tiff
files from max projections were imported to Image J, and the images were con-
verted to 8-bit fluorescence RGB tiff and thresholded. For nuclear counts, water-
shed segmentation on binary images was used to separate objects and then images
were analyzed. Two fields of view were quantified and then the mean was calcu-
lated and converted to mm2. To count the proportion of GFAP-positive cells, the
number of GFAP+ cells was divided by the number of SOX9+ nuclei.
Blood analysis. Blood was isolated through cardiac puncture, using syringe and
needle coated with 2% EDTA. Blood was collected into 2 mL EDTA tubes (BD
Vacutainer®) containing 1.8 mg of EDTA per mL of blood. Total blood cell counts
were performed using the ABX Pentra 60 hematology analyzer and differential
counts of WBC subsets were performed on blood smears.
BM isolation and cell culture. BM was isolated by flushing femurs with RPMI
containing 5 mM EDTA. For flow cytometry analysis, erythrocytes were not lysed
to prevent cleavage of CSF1R. For macrophage differentiation, erythrocytes were
lysed with RBC lysis buffer (BioLegend) and BM cells were cultured on Sterilin-
plastic dishes in the presence of rhCSF1 (at 100 ng/mL, a gift from Chiron) for
7 days. Fresh media containing rhCSF1 was added on Day 4.
Isolation of peritoneal cells. Cells for flow cytometry analysis were isolated from
mice by lavage of the peritoneal cavity with PBS. Cells were centrifuged at 400×g
for 5 min at 4 °C prior to resuspension in PBS containing 2% endotoxin-free FBS
(GE Healthcare).
Preparation of organs for flow cytometry. The spleen, liver, lung, heart, and
kidneys were prepared for flow cytometry from non-perfused mice. Organs were
removed, chopped finely, and digested in RPMI containing 0.625 mg/mL col-
lagenase D (Roche), 0.85 mg/mL collagenase V (Sigma), 1 mg/mL dispase (Life
Technologies), and 30 U/mL DNase (Roche) for 22 min (lung) or 45 min (other
organs) in a shaking incubator at 37 °C. Organ preparations were passed through
100 µm cell strainers and centrifuged at 300×g for 5 min at 4 °C prior to resus-
pension in PBS containing 2% endotoxin-free FBS. Erythrocytes were then lysed
using RBC lysis buffer (BioLegend).
Isolation of intestinal cells. Single cell suspensions of small and large intestines
(colon) from non-perfused mice were prepared for flow cytometry. Intestines were
opened longitudinally and cut into 2–3 cm segments in ice-cold PBS and intestinal
contents removed by gentle shaking. Tissue segments were incubated at 37 °C for
20 min whilst shaking in RPMI containing 3% endotoxin-free FBS (GE Health-
care), 20 mM HEPES (Gibco), 5 mM EDTA (Sigma), 1 mM DTT (Promega), and
100 U/mL polymyxin B (Sigma). Segments were transferred to RPMI containing
2 mM EDTA and 20mM HEPES and shaken by hand to ensure optimal dis-
sociation of epithelial cells and lamina propria leukocytes. Tissues were minced
with scissors and digested at 37 °C for 30 min, whilst shaking in RPMI containing
20 mM HEPES, 0.425 mg/mL Collagenase V (Sigma), 0.625 mg/mL Collagenase D
(Roche), 1 mg/mL Dispase (Gibco), and 30 µg/mL DNase (Roche). Cell suspen-
sions were passed through 70 µm then 40 µm cell strainers in RPMI containing
10% endotoxin-free FBS and 100 U/mL polymyxin B. After centrifugation at 400×g
at 4 °C for 5 min, including a wash step, cells were resuspended in PBS containing
2% FBS for flow cytometry.
Myelin depletion of brains and isolation of cells. Myelin-depleted brain sus-
pensions were prepared from saline perfused mice for flow cytometry. Whole
brains were finely minced with scissors in ice-cold Hank’s balanced salt solution
(HBSS, Sigma, without calcium or magnesium) and centrifuged at 400×g for 5 min
at 4 °C. Minced brains were then digested in HBSS containing 50 U/mL Col-
lagenase IV (Gibco), 100 µg/mL Nα-Tosyl-L-lysine chloromethyl ketone hydro-
chloride (Sigma), 5 U/mL DNase I (Roche) and 8.5 U/mL Dispase (Gibco) for 1 h
at 37 °C whilst shaking. The digested tissue was homogenized in a glass Dounce
tissue grinder for 20 passes and an equal volume of HBSS containing 10%
endotoxin-free FBS was then added. After centrifugation at 400×g for 5 min at 4 °C,
the cell pellet was resuspended in 16 mL 35% Percoll in HBSS, overlaid with 10 mL
HBSS and incubated on ice for 5 min. The gradient was centrifuged at 800×g for
45 min at 4 °C with no brake. The cell pellets were then resuspended in PBS
containing 2% FBS for flow cytometry.
RNA isolation and microarrays. For RNA isolation, tissues from saline perfused
mice were snap frozen, and subsequently disrupted in the Precellys24 Homo-
genizer® (Bertin Instruments). RNA isolation was performed using the RNeasy Plus
Mini kit (QIAGEN). Library preparation and hybridization to the Affymetrix
Mouse Gene 1.0 ST array was performed by Edinburgh Genomics, University of
Edinburgh. CEL files were RMA normalized and annotated in R/Bioconductor.
Analysis of differential expression was performed using the Affymetrix Tran-
scription Analysis Console (Thermo Fisher).
Analysis of hippocampi microarray data. These data were interrogated with sets
of genes whose expression is highly enriched in specific cell types of the brain
(astrocytes, oligodendrocytes, microglia, neurons, brain endothelial cells). These
sets were curated from published RNA-seq data (GEO, accession number
GSE73721) describing the transcriptome of astrocytes, oligodendrocytes, microglia,
neurons, and brain endothelial cells60. The inclusion criteria consisted of (a) being
expressed at least five-fold higher in the cell type of interest than all other cell types
and (b) being expressed at least 50 FPKM to enable robust detection in the mixed
cell type environment of a whole hippocampus.
cDNA synthesis and quantitative real-time PCR. Complementary DNA (cDNA)
was synthesized from RNA using the SuperScript III. First-Strand Synthesis System
and remaining template was removed by incubation with RNase H (Invitrogen).
Oligonucleotides were designed in Primer3 v4.0.0 (available at http://bioinfo.ut.ee/
primer3/). Real-time qPCR reactions were performed using the Fast SYBR green
master mix and the 7500 Fast System (Applied Biosystems). Analysis was per-
formed with 7500 software v2.0.6 (Applied Biosystems, Life Technologies Cor-
poration). For analysis of relative changes in gene expression, data were normalized
according to the 2−ΔΔCT method. Hypoxanthine guanine phosphoribosyl trans-
ferase (Hprt) was used as a loading control/housekeeping gene. Oligonucleotide
sequences are listed in Supplementary Table 3.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors declare that all data supporting the findings in this study are available within
the article and its Supplementary Information files or from the corresponding authors on
reasonable request. The RNA expression datasets are publicly available in the gene
expression omnibus (GEO; https://www.ncbi.nlm.nih.gov/gds) via the accession number
GSE108207. Published ATAC-seq and ChIP-seq data used in this manuscript is available
via GEO accession number GSE63341. The RNA-seq data used to curate cell type specific
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genes in the brain is available via GEO accession number GSE73721. The data used to
identify microglia-enriched genes versus macrophage genes is available via GEO
accession number GSE48579. All other data contained within this manuscript is located
in the Source Data excel file.
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A B S T R A C T
Astrocytes are known to play critical roles in central nervous system development, homeostasis, and response to
injury. In addition to well-defined functions in synaptic signalling and blood-brain barrier control, astrocytes are
now emerging as important contributors to white matter health. Here, we review the roles of astrocytes in
myelin formation and regeneration (remyelination), focusing on both direct interactions with oligodendrocyte
lineage cells, and indirect influences via crosstalk with central nervous system resident macrophages, microglia.
1. Introduction
In the central nervous system (CNS), the ensheathment of axons
with myelin membrane by oligodendrocytes provides insulation for
efficient electrical impulse conduction and trophic/ metabolic support
[1,2]. Lack of myelination (as seen in leukodystrophies) or destruction
of myelin, termed demyelination (as seen in multiple sclerosis (MS),
Alzheimer’s disease, and motor neuron disease) contributes to axonal
dysfunction and/or loss and, consequently, clinical impairments.
However, myelin can be regenerated in a process termed remyelination,
which restores axonal health and function [3,4]. Lineage tracing and
human neuropathological tissue analysis have demonstrated that dif-
ferentiation of oligodendrocyte precursor cells (OPCs) into new myeli-
nating oligodendrocytes leads to remyelination [5,6]. In addition, re-
cent studies suggest a potential contribution of existing mature
oligodendrocytes to this process [7–9].
Both myelination and remyelination are guided in part by interac-
tion of oligodendrocyte lineage cells with other cell types: microglia
and astrocytes. Microglia are required for normal developmental mye-
lination (in the brain), and support remyelination via phagocytosis of
myelin debris and secretion of regenerative factors that drive OPC re-
cruitment/proliferation and differentiation [10]. Much less is known
regarding the contribution of the astrocyte to these processes, however,
despite being the most abundant glial cell type in the CNS and its
known interactions with microglia. A specific type of astrocyte is found
in the white matter (termed ‘fibrous’), distinct from protoplasmic as-
trocytes in the grey matter, Müller glia in the retina, and Bergmann glia
in the cerebellum [11]. As astrocytes are considered to adapt their
functions to the requirements of cells in their surroundings [12], as
demonstrated by well-defined roles in regulation of synaptogenesis/
synaptic signalling [13–15], the blood-brain barrier (BBB) [16], cere-
bral blood flow [17,18], energy supply and metabolism [19], ion and
pH homeostasis [20], and antioxidant responses and inflammation
[21], it is likely that they also play significant roles in the development,
homeostasis, and regeneration of white matter. Here, we review the
evidence for the function of astrocytes in developmental myelination
and remyelination.
2. Astrocytes in development
The investigation of astrocytes in development has in the past been
challenging due to the lack of specific markers [22]. Glial fibrillary
acidic protein (GFAP) has been the most widely used, however it should
be noted that it only labels 30% of all astrocytes, with a very low ex-
pression in grey matter [23]. In addition, other cells such as neuronal
progenitors can also express GFAP [24]. Other markers such as S100
calcium-binding protein B (S100B), aquaporin-4 (AQP4), glutamate
transporter-1 (GLT-1) and glutamate aspartate transporter-1 (GLAST-1)
have been used to investigate astrocytes, yet some of these can also be
expressed by OPCs and ependymal cells [25]. Nonetheless, the recently
identified aldehyde dehydrogenase 1 family member L1 (Aldh1l1) and
Sox9 are considered to be more specific pan-astrocytic markers, the
latter outside neurogenic regions [26,27].
2.1. Astrocyte origins
Astrocytes are derived from neuroepithelium, together with oligo-
dendrocytes and neurons. Neural precursor cells in the ventricular zone
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(VZ) differentiate into radial glia which give rise to neurons and mac-
roglia. Neurogenesis and gliogenesis take place within a tightly regu-
lated time-window. The switch from neurogenesis to gliogenesis is
controlled by upregulation of nuclear factor I A (NFIA) and Sox9
[28–30]. Astrogenesis in the mouse brain initiates at embryonic day (E)
12.5 in the spinal cord and E16-18 in the brain [28,31], and astrocyte
fate is defined by the upregulation of the transcription factor Zinc
finger- and BTB domain-containing protein 20 (Zbtb20). These cells
migrate throughout the CNS with support from radial glia then mature,
involving changes in gene expression, morphology, connectivity and
electrophysiological characteristics that in turn define their function
[22,28]. Recent studies have revealed heterogeneity in the astrocyte
population, with different subtypes of astrocytes seen throughout the
brain [32]. These arise from distinct progenitors with specific molecular
identities and localization within the neuroepithelium [33,34].
2.2. Astrocytes in developmental myelination
White matter astrocytes have small cell bodies and an elongated
morphology that aligns with myelinated axons [35]. These astrocytes
express higher levels of GFAP compared to protoplasmic astrocytes
[36]. Further regional specialisation is present within the white matter,
with spinal cord and brain astrocytes showing differential marker ex-
pression during development and in adulthood [37]. Although the
functions of astrocytes in the white matter are still being defined, there
is evidence that they play important roles during developmental mye-
lination.
The capacity of astrocytes to support myelination may depend on
their reactivity. Astrocytes which are activated (by treatment with
ciliary neurotrophic factor; CNTF) promote in vitro myelination of dis-
sociated rat spinal cord cultures, whereas quiescent astrocytes (treated
with tenascin-C) inhibit myelination [38]. Astrocytes communicate
with oligodendrocytes via secretion of factors that promote the onset of
myelination. For instance, culturing rat optic nerve oligodendrocyte
lineage cells with astrocytes promotes oligodendrocyte differentiation
and extension of processes along axons, which is not observed in the
absence of astrocytes [39]. Additionally, conditioned media generated
from human induced pluripotent stem cell (iPSC)-derived immature
astrocytes increases OPC differentiation into mature oligodendrocytes,
in part via expression of tissue inhibitor metalloproteinase-1 (TIMP-1)
[40]. Astrocytes also secrete CNTF, which supports in vitro oligoden-
drocyte differentiation [41] and survival [42]. Furthermore, astrocytic
release of chemokine (C-X-C motif) ligand 1 (CXCL1) acts on C-X-C
chemokine receptor type 2 (CXCR2) on oligodendrocyte lineage cells to
promote differentiation and myelination in vivo [43]. Lastly, astrocytes
contribute to biosynthesis and supply of lipids to oligodendrocytes
during developmental myelination [44]; although postulated to occur
via horizontal transfer, the mechanisms underpinning lipid transfer
during myelination are still unclear.
Astrocytes directly provide oligodendrocytes with nutrients and
substrates to support the metabolically-demanding process of myelin
sheath formation and maintenance, via gap junctions [45]. Oligoden-
drocytes and astrocytes can form two different types of heterodimeric
connections involved in ion/water homeostasis and energy supply,
through connexin 30 (Cx30) and connexin 43 (Cx43) in astrocytes,
binding to connexin 32 (Cx32) and connexin 47 (Cx47) in oligoden-
drocytes, respectively [45–47]. Mice lacking both Cx47 and Cx30 fail to
couple oligodendrocytes to astrocytes, leading to decreased survival,
reduced number of oligodendrocytes, vacuolated and thinner myelin,
and severe astro- and micro-gliosis [48].
The importance of the communication between astrocytes and oli-
godendrocytes is further demonstrated by the disruption of this inter-
action leading to myelin disorders. For instance, Pelizaeus-Merzbacher-
like disease is an autosomal recessive hypomyelinating condition
caused by a mutation in the gene encoding Cx47, GJC2 [49], and
mutations in Cx47 prevent formation of functional channels [50]. Ad-
ditionally, leukodystrophies can arise from mutations in genes pre-
dominantly expressed by astrocytes, such as GFAP, leading to Alex-
ander’s disease [51] and NPC-1 (intracellular cholesterol transported-
1), causing failure in cholesterol storage and metabolism leading to
Niemann-Pick type C disease [52–54]. Another example is where hy-
pomyelination is caused by deficiency of pyruvate carboxylase, an en-
zyme which in the CNS is mainly found in the mitochondria of astro-
cytes and controls glucogenesis, lipogenesis and insulin secretion
[55–57]. Astrocytes also regulate the outcome of white matter devel-
opment after perinatal insult. Transplantation of human iPSC-derived
Fig. 1. Astrocytes regulate developmental myelination.
Astrocytes support developmental myelination by expression
of supportive factors such as C-X-C motif ligand 1, CXCL1,
tissue inhibitor of metalloproteinase 1 (TIMP1), and ciliary
neurotrophic factor (CNTF), transfer of cholesterol, and
channels with oligodendrocytes via connexins (Cx) which
allow flow of ions (K+ ), water and metabolites.
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immature astrocytes into a model of neonatal hypoxic-ischemic injury
rescues hypomyelination and promotes behavioural recovery [40], and
conditional ablation of STAT3 signalling in reactive astrocytes ag-
gravates white matter injury in a model of infection-induced myelin
pathology [59].
In summary, astrocytes have a vital role in communicating with
oligodendrocyte lineage cells during developmental myelination, and
disruption of this communication underpins myelin pathology in sev-
eral neurodevelopmental disorders (Fig. 1). There are still open ques-
tions that need to be answered to fully understand the role of astrocytes
in myelination, relating to potentially distinct roles of astrocytes in
different white matter tracts [37], the importance of the direction of
ion/ water flow through gap junctions between astrocytes and oligo-
dendrocytes [59], and whether manipulation or transplant of astrocytes
can restore healthy myelination in the context of developmental disease
[60].
3. Astrocytes in remyelination
Astrocytes are also important for myelin health in the adult brain.
Varela-Echevarria and colleagues (2017) observed that astrocyte pro-
cesses are in contact with myelinated fibres. When opposed to areas of
disrupted myelin in normal adult animals (e.g. myelin collapse or loss
of myelin), these show accumulation of lysosomes containing lipid
droplets or membrane-like debris [61], suggesting a role for oligoden-
drocyte-astrocyte contacts in myelin turnover and maintenance. In
addition, reduction of exocytosis in astrocytes is associated with para-
nodal loop detachment, increased nodal gap length, and thinning of
myelin in the optic nerve, pointing to the importance of astrocytes in
maintaining myelin in homeostasis [62]. An example of this function is
illustrated by the demyelination incurred from damage to astrocytes,
observed in Neuromyelitis Optica (NMO) where auto-antibodies target
acquaporin4 (AQP4) ̶ expressed in astrocyte end-feet at the BBB ̶
causing astrocyte cytotoxicity, BBB disruption, inflammation, periph-
eral immune cell recruitment, and demyelination [63–66]. One of the
first studies to suggest a role for astrocytes in remyelination came from
their transplantation into focally demyelinated spinal cord lesions,
which revealed that astrocytes encourage remyelination mediated by
oligodendrocytes over that by Schwann cells [67]. Subsequent studies
have suggested both beneficial and deleterious functions of astrocytes
following white matter injury (Fig. 2).
3.1. Pro-remyelination functions of astrocytes
In the cuprizone toxin diet model, in which widespread demyeli-
nation occurs, ablation of GFAP-expressing astrocytes impairs re-
myelination [68], and overexpression of GFAP reduces neuronal da-
mage and demyelination [69]. Astrocytes may support remyelination
by secreting regenerative factors, as they express CNTF [70] and os-
teopontin [71] during remyelination following viral- or cuprizone-in-
duced demyelination, respectively, and these factors support oligo-
dendrocyte lineage cell responses in vitro [41,42,71]. Astrocytes may
also regulate remyelination through cholesterol metabolism. Dietary
cholesterol promotes remyelination [72], suggested to function in part
by influencing astrocyte phenotype or by encouraging their secretion of
the pro-remyelination factor fibroblast growth factor 2 (FGF2) [72]. In
adulthood, astrocytes are the main producers of cholesterol in the CNS.
Downregulation of cholesterol biosynthesis genes in astrocytes has been
observed in the context of chronic demyelination: in the autoimmune-
mediated demyelination model experimental autoimmune en-
cephalomyelitis (EAE) and in the optic chiasm in MS [73]. Cholesterol
transport occurs via apolipoprotein E (ApoE) [74]; increasing choles-
terol efflux to extracellular ApoE in EAE increases cholesterol synthesis
gene expression and, consequently, decreases EAE severity [73]. Im-
portantly, the upstream molecular signals that control these pro-re-
myelination functions of astrocytes remain unknown.
3.2. Damaging functions of astrocytes
Astrocytes have also been suggested to impair remyelination, as it
was observed that their ablation after chronic cuprizone administration
(which prevents remyelination) increased the number of oligoden-
drocyte lineage cells [75]. However, it was not shown whether these
were mature oligodendrocytes, nor whether remyelination was en-
hanced after astrocyte depletion. Another study demonstrated that,
following focal demyelination and subsequent elimination of all en-
dogenous OPCs and astrocytes by irradiation, co-transplant of OPCs
with astrocytes reduced remyelination compared to that seen following
injection of OPCs alone [76].
Astrocytes may inhibit remyelination through the production of
factors that inhibit oligodendrocyte lineage cell responses. For instance,
astrocytic expression of the extracellular matrix component fibronectin
is correlated with disease severity in EAE [77] and inhibits re-
myelination [78]. Additionally, reactive astrocytes express high levels
of endothelin-1 (ET-1) after demyelination, which impairs remyelina-
tion [79] by induction of Jagged1 expression in reactive astrocytes,
leading to blockade of OPC differentiation through Notch signalling
[80]. Furthermore, astrocytes may encourage demyelination by pro-
moting a pro- inflammatory response. Transcriptomic analysis of as-
trocytes in EAE reveals upregulation of genes associated with in-
flammation [73]. Detachment of astrocyte end feet from the vasculature
coincides with areas of inflammation and T lymphocyte infiltration
[80]. Astrocytes can facilitate recruitment of peripheral immune cells
through the release of chemokines (e.g. CCL2) [81], and expression of
adhesion molecules (e.g. VCAM-1) at the BBB [82]. Recruitment of
immune cells by astrocytes may be controlled by phagocytosis of
myelin debris early after injury, which leads to NFκB signalling and
chemokine secretion [83,84]. Additionally, astrocytes may directly
regulate T lymphocyte activation by acting as antigen presenting cells
[85].
Recent studies have suggested that damaging versus beneficial
functions of astrocytes are regulated by distinct phenotypes. Akin to the
simplified classification of microglia into ‘M1′ (pro-inflammatory) and
‘M2′ (pro-repair) microglia/ macrophages, astrocytes have been cate-
gorized as ‘A1′ and ‘A2′. The A1 phenotype results from exposure to
bacterial peptide lipopolysaccharide (LPS), which induces a pro-in-
flammatory gene expression profile. The ‘A2′ phenotype is found in an
ischemia model, where inflammation resolves, and gene expression
relates to extracellular matrix and neurotrophic support [86]. However,
recent work has revealed that markers associated with the A1 pheno-
type do not necessarily identify a damaging astrocyte, as inhibiting the
appearance of A1 astrocytes in a model of prion disease leads to a mixed
A1/A2 astrocyte phenotype associated with accelerated disease course
and severity [87]. Therefore, astrocyte gene expression and activation
may be highly context-dependent, and how these control their dama-
ging versus regenerative functions in white matter injury remains to be
fully elucidated.
3.3. Astrocytes in multiple sclerosis
MS is the prime example of a neurological disorder with extensive
demyelination and, in early phases of disease, remyelination. Astrocytes
can form a ‘glial scar’ that is a hallmark of demyelinating conditions
like MS, and can have either beneficial or detrimental consequences.
For instance, the glial scar may limit the migration of oligodendroglial
cells into demyelinated areas, thereby impeding remyelination [88].
However, the glial scar may be beneficial for limiting inflammation
within MS lesions [89]. It is required for axonal regrowth in a model of
severe spinal cord injury, via secretion of repair-supporting molecules
[90]. More recently, it was observed that in remyelinating lesions of rat
EAE, astrocytes in the glial scar express factors known to have the ca-
pacity to induce oligodendrocyte differentiation [91].
In the normal-appearing white matter (NAWM) in MS, several
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studies have suggested that astrocytes have supportive functions. Here,
astrocytes upregulate genes involved in the control of iron homeostasis
and neurotrophic support, indicating a neuroprotective role [92]. The
regulation of iron metabolism by astrocytes is also important for re-
myelination; Conditional deletion of the iron efflux transporter ferro-
portin in all astrocytes decreases OPC proliferation and causes re-
myelination failure [93]. NAWM astrocytes in MS also upregulate genes
that regulate oxidative responses [92]. Astrocytes have antioxidant
functions mediated through the activation of the transcription factor
nuclear factor E2-related factor 2 (Nrf2), which regulates the tran-
scription of genes with antioxidant response elements (ARE) [94,95].
Nrf2 activation is neuroprotective in some neurological disorders [96].
In the cuprizone model, hyperactivation of Nrf2 in reactive astrocytes
(driven by a GFAP promoter) prevents oligodendrocyte loss and de-
myelination [97]. However, the effects of Nrf2 signalling in re-
myelination have not been investigated. In the periplaque area in MS,
transcriptomic analysis revealed transforming growth factor beta-1
(TGFβ1)-driven gene expression in astrocytes that may limit in-
flammation, yet induce astrocytosis and inhibit oligodendrocyte dif-
ferentiation [98].
Within MS lesions, astrocytic responses may be lesion type-specific.
For instance, astrocytes in remyelinated lesions express TGFβ-R2, but
this is downregulated in chronic active lesions [99] which have poor
remyelination at their core. Remyelination may also be impacted by
disruption of astrocyte-oligodendrocyte connections via gap junctions
[100]; In lesions in MS and NMO, a reduction of Cx43 was observed,
associated with loss of astrocyte-to-oligodendrocyte connections via
Cx43/Cx47 [101]. The loss of Cx43 was linked with actively pro-
gressive disease, oligodendrocyte pathology, and degenerating
astrocytes, and was more often seen in patients with a rapid disease
progression [101]. Remyelination may also be inhibited in MS by as-
trocytic expression of extracellular matrix components (such as fi-
bronectin, chondroitin sulfate proteoglycans, and hyaluronic acid) that
inhibit oligodendrocyte differentiation and impair remyelination
[78,102–105]. In addition, reactive astrocytes in chronic MS lesions
with poor remyelination (termed ‘chronic inactive’), upregulate bone
morphogenic protein (BMP)-4 [106,107], whose overexpression is
known to decrease oligodendrocyte numbers in development [108].
Conversely, the BMP4 antagonist Noggin is upregulated in astrocytes in
remyelinated MS lesions [106] and promotes oligodendrocyte differ-
entiation and remyelination in the cuprizone model [107].
Astrocyte markers have been proposed as potential biomarkers for
MS. For instance, CHI3L1has been suggested as an indicator for pro-
gressive MS [109], as it is expressed by astrocytes at the rim of chronic
active lesions and downregulated in all other lesion types [99]. GFAP is
a potential biomarker of highly active inflammation in relapse-remit-
ting MS (RRMS) and in clinically isolated syndrome (CIS) [110]; GFAP
levels are also elevated in the cerebrospinal fluid in primary progressive
MS [111].
Therefore, astrocytes have been associated with both beneficial and
detrimental functions in MS. Although their activation is being in-
vestigated as potential biomarkers for disease progression, a clearer
indication of the roles of astrocytes at distinct stages of myelin damage
and repair is needed in order to understand the biological processes
associated with this activation, and how to potentially target this to
enhance remyelination.
Fig. 2. Astrocytes regulate remyelination and demyelination.
A) Astrocytes support remyelination by cholesterol transfer (via ApoE) and secretion of regenerative factors such as fibroblast growth factor 2 (FGF2), ciliary
neurotrophic factor (CNTF), and osteopontin. These regenerative astrocytes have increased expression of glial acidic fibrillary protein (GFAP) and transforming
growth factor receptor beta 2 (TGFRβ2).
B) Astrocytes induce neural damage/ prevent repair by secretion of inhibitory factors like endothelin-1 (ET-1), transforming growth factor beta-1 (TGFβ1), and bone
morphogenic protein-4 (BMP-4), facilitating recruitment of peripheral immune cells via chemokine secretion or expression of vascular cell adhesion protein
1(VCAM1), and release of inhibitory extracellular matrix components. These inhibitory astrocytes have increased expression of GFAP, chitinase 3 like 1 (CHI3L1),
and increase signalling via nuclear factor kappa-light-chain enhancer or activated B cells (NFκB).
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4. Astrocyte-microglia crosstalk following white matter injury
One cell type with which astrocytes communicate to regulate white
matter health is the microglia (Fig. 3). The beneficial roles of microglia
in myelination [112–114] and remyelination [68,115–117] have re-
cently been uncovered [10]. Microglia-astrocyte interactions occur as
early as in development, when microglia regulate astrocyte numbers in
the retina by engulfment, which is critical for proper retinal network
formation [118].
4.1. Astrocytes influencing microglia
Several studies have shown how astrocytes can regulate microglia
function. First, they influence phagocytosis by microglia. Astrocytes can
attract microglia through the release of CXCL10 [68,69,75], which is
required for clearance of myelin debris and remyelination in the cu-
prizone model [68]. In a model of Alzheimer’s disease, acute release of
complement-3 (C3) by astrocytes promotes microglia phagocytosis,
whereas chronic C3 release impairs phagocytosis and increases amy-
loid-beta (Aβ) pathology [119]. Astrocytes can also directly influence
myelin debris clearance by microglia via expression of angiopoietin-like
4 (ANGLP4), an inhibitor of lipoprotein-lipase; reducing ANGLPL4 in-
duces myelin debris clearance by microglia/ macrophages to enable
remyelination [120].
Second, astrocytes can influence microglia activation. In EAE,
transcriptomic analysis of astrocytes in the progressive phase revealed
regulation of pathways that control expression of granulocyte-macro-
phage colony-stimulating factor (GM-CSF), which in turn modulates
microglial activation [121]. In EAE, knockout of Cx30 (expressed by
astrocytes) is associated with appearance of microglia with a protective
phenotype (Arg-1+ , brain-derived neurotrophic factor (BDNF)+, re-
duced inducible nitric oxide synthase), associated with decreased
neuronal death in the chronic phase [122]. On the contrary, mice
lacking Cx47 have worse clinical outcome during EAE, associated with
increased pro-inflammatory cytokine production by microglia and loss
of myelin and axons [123]. This suggests that microglia phenotypes can
be regulated by the coupling between astrocytes and oligodendrocytes.
Astrocytes in MS release advanced glycation end-products, whose re-
ceptors are expressed by microglia and induce NFκB activation and pro-
inflammatory cytokine release [124].
Third, astrocytes can regulate secretion of factors from microglia. In
a developmental brain injury model induced by peripheral LPS injec-
tion, astrocytes restrict the production of TGFβ-1 by microglia through
the activation of STAT3 signalling, which in turn regulates oligoden-
drocyte differentiation [58]. Additionally, iron transport regulation by
astrocytes could influence microglia function, as a decrease in iron re-
duces microglial secretion of pro-inflammatory cytokines tumor ne-
crosis factor alpha (TNFα) and interleukin-1 beta (IL1β) [93].
4.2. Microglia influencing astrocytes
On the other hand, microglia can influence astrocyte function. in
vitro studies demonstrated that treatment of microglia with LPS
increases secretion of IL-1α, TNFα, and complement 1q (C1q), which in
turn alters astrocyte gene expression (e.g. upregulation of C3) and
function such that they are less phagocytic, do not promote synapse
formation, and are toxic to neurons and oligodendrocytes [125]. The
gene expression associated with this astrocyte phenotype could be
largely reproduced by LPS treatment of wildtype mice, but not in mice
lacking microglia (Csf1r−/−). This indicates the requirement of mi-
croglia-astrocyte crosstalk for these changes to take place [125].
Microglia can also induce a protective astrocyte phenotype in a
traumatic brain injury model via purinergic signalling [126]. Ad-
ditionally, Rothhammer and colleagues (2018) demonstrated that mi-
croglia can regulate damaging and protective astrocyte properties in
EAE, where microglia-derived TGFα acting on the ErbB1 receptor on
astrocytes reduces pathogenesis, whereas microglial VEGFβ triggers
FLT1 signalling in astrocytes to worsen disease [127]. Microglia can
also control astrocyte survival; in a model of spinal cord injury, pro-
inflammatory microglia mediate astrocyte death, which is considered to
be detrimental for repair [128] yet protective in dampening excessive
astrogliosis [129].
5. Conclusions
In summary, astrocytes have both supportive and detrimental
functions in myelination and remyelination, and their interaction with
microglia may be important for controlling these processes. Future
work could reveal how astrocyte heterogeneity regulates their roles in
myelination and remyelination. Single-cell RNA sequencing has de-
monstrated subpopulations exist within specific regions [32], and after
demyelination, differing levels of GFAP expression in astrocytes in
brain versus spinal cord might indicate region-specific responses [37].
Furthermore, depletion of astrocytes in spinal cord cannot be rescued
by astrocytes from neighbouring areas [14]. In addition, elucidating the
interaction of astrocytes with other cell types, such as oligodendrocyte
lineage cells and microglia, is needed prior to development of cell-type
specific drugs aimed at enhancing myelin health in disease. In-
vestigating how astrocytes can counteract damaging responses by mi-
croglia, for example via Nrf2 signalling to oppose oxidative stress ̶ is of
particular interest for the MS field due to existing drugs targeting this
pathway. Given the emerging evidence for critical roles of astrocytes in
white matter, further understanding of their contribution to myelin
development and regeneration is pivotal for the identification of novel
therapies for neurological disorders with impaired white matter in-
tegrity.
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Fig. 3. Astrocyte-microglia crosstalk in white matter. Astrocytes
can signal to microglia to regulate their phagocytic potential (via
complement 3 (C3) and angiopoietin-like 4 (ANGLP4), activation
[via granulocyte macrophage stimulating factor (GM-CSF), con-
nexins, and glycation end products], and modulation of signalling
(via STAT3 and iron pathways in astrocytes). Microglia can signal
to astrocytes to alter their gene expression, induce damaging
function [via secretion of interleukin-1 alpha (IL1-α), tumor ne-
crosis factor alpha (TNFα), complement 1q (C1q), and vascular
endothelial growth factor beta (VEGF-β)], induce beneficial
function [via secretion of transforming growth factor alpha (TGF-
α) or purinergic signalling], and induce death of astrocytes.
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